Devi, S.
09/489711



17oct01 13:05:42 User219783 Session D1751.2

SYSTEM:OS - DIALOG OneSearch
File 35:Dissertation Abs Online 1861-2001/Oct
(c) 2001 ProQuest Info&Learning
File 65:Inside Conferences 1993-2001/Oct W2
(c) 2001 BLDSC all rts. reserv.
*File 65: For variance in UDs please see Help News65.
File 77:Conference Papers Index 1973-2001/Sep
(c) 2001 Cambridge Sci Abs
File 144:Pascal 1973-2001/Oct W2
(c) 2001 INIST/CNRS
File 266:FEDRIP 2001/Sep
Comp & dist by NTIS, Intl Copyright All Rights Res
File 440:Current Contents Search(R) 1990-2001/Oct W3
(c) 2001 Inst for Sci Info
File 348:EUROPEAN PATENTS 1978-2001/Oct W01
(c) 2001 European Patent Office
File 357:Derwent Biotechnology Abs 1982-2001/Dec B1
(c) 2001 Derwent Publ Ltd
*File 357: Price changes as of 1/1/01. Please see HELP RATES 357.
File 113:European R&D Database 1997
(c)1997 Reed-Elsevier(UK)Ltd All rts reserv
*File 113: This file is closed (no updates)

Set Items Description
--- ----- -----------

- key terms

Set Items Description
S1 372713 STABILIS? OR STABILIZ? OR (METAL OR AL OR ALUMIN??? OR AL - OR CALCIUM OR CA OR ZINC OR ZN)(W)(OH OR HYDROXIDE) OR ALOH OR CAOH OR ZNOH
S2 37806 (METAL OR ALUMIN??? OR AL OR CALCIUM OR AL OR CA)(W)(PO? ? OR PHOSPHATE) OR CAPO? ? OR ALPO? ? OR ALUM
S3 402384 S1 OR S2
S4 20 S3 AND RHUSIOPATH?
S5 19 RD (unique items)
>>>No matching display code(s) found in file(s): 65, 113

5/3,AB/1 (Item 1 from file: 35)
DIALOG(R)File 35:Dissertation Abs Online
(c) 2001 ProQuest Info&Learning. All rts. reserv.

213713 AAD5802369
A PARTIAL AND COMPARATIVE EVALUATION IN MICE OF AN *ALUMINUM"** *PHOSPHATE"** ADSORBED ANTI-SWINE ERYSIPELAS BACTERIN PREPARED BY THE SONIC BACTERIOCLASIS OF ERYSIPELOTHRIX *RHUSIOPATHIAE"**
Author: TIFFANY, LOYD WAYNE
Degree: PH.D.
Year: 1955
Corporate Source/Institution: MICHIGAN STATE UNIVERSITY (0128)
Source: VOLUME 19/01 OF DISSERTATION ABSTRACTS INTERNATIONAL.
PAGE 23. 47 PAGES

5/3,AB/2 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

01276120
Oil-based adjuvant vaccine
Oladjuvierter Impfstoff
Adjuvant pour vaccin a base d'huile
PATENT ASSIGNEE:
NOF CORPORATION, (1558205), 20-3, Ebisu 4-chome, Shibuya-ku, Tokyo 150-6019, (JP), (Applicant designated States: all)
Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute, (283933), 6-1, Okubo 1-chome, Kumamoto-shi, Kumamoto 860-8568, (JP), (Applicant designated States: all)
INVENTOR:
Saito, Koichi, 2-20-8-101, Minamitsukaguchi-cho, Amagasaki-shi, Hyogo 661-0012, (JP)
Kishimoto, Yoko, 1-7-8, Nishikigaoka, Uozumi-cho, Akashi-shi, Hyogo 674-0081, (JP)
Miyahara, Tokuji, 1866-1445, Kikudomi, Koushi-machi, Kikuchi-gun, Kumamoto 861-1112, (JP)
Takase, Kouzou, 3410-30, Sugimizu, Ohzu-machi, Kikuchi-gun, Kumamoto 869-1236, (JP)
LEGAL REPRESENTATIVE:
von Kreisler, Alek, Dipl.-Chem. et al (12437), Patentanwalte, von Kreisler-Selting-Werner, Bahnhofsvorplatz 1 (Deichmannhaus), 50667 Koln, (DE)
PATENT (CC, No, Kind, Date): EP 1097721 A2 010509 (Basic)
EP 1097721 A3 010523
APPLICATION (CC, No, Date): EP 2000123909 001103;
PRIORITY (CC, No, Date): JP 99316121 991105
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; TR
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: A61K-009/113

ABSTRACT EP 1097721 A3
The present invention provides a W/O/W type oil adjuvant vaccine containing an outer aqueous phase containing 0.5 wt% - 20 wt% of a polyethylene glycol derivative having a molecular weight of 400 - 20,000, and an inner aqueous phase containing a biologically acceptable and effective amount of an antigen. The constitution of the present invention that a polyethylene glycol derivative having a specific molecular weight is contained in the outer aqueous phase enables preparation of a W/O/W type oil adjuvant vaccine showing a high adjuvant effect, reduced side effects such as topical response, superior preparation stability and superior workability to allow a person to give an injection easily due to the lowered viscosity.
ABSTRACT WORD COUNT: 114

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | 200119 | 457 |
| SPEC A | (English) | 200119 | 7301 |
| Total word count - document A | | | 7758 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 7758 |

5/3,AB/3 (Item 2 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01270274
Lawsonia intracellularis proteins, and related methods and materials
Lawsonia intracellularis Proteine sowie Methoden und Materialien die diese verwenden
Proteines de Lawsonia intracellularis et procedes et materiaux relatifs a ces proteines
PATENT ASSIGNEE:
Pfizer Products Inc., (2434221), Eastern Point Road, Groton, Connecticut 06340, (US), (Applicant designated States: all)
INVENTOR:
Rosey, Everett Lee, Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, (US)
LEGAL REPRESENTATIVE:
Eddowes, Simon et al (87482), Urquhart-Dykes & Lord, 30 Welbeck Street, London W1G 8ER, (GB)
PATENT (CC, No, Kind, Date): EP 1094070 A2 010425 (Basic)
APPLICATION (CC, No, Date): EP 309125 001017;
PRIORITY (CC, No, Date): US 160922 991022
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C07K-014/205; C12N-015/31

ABSTRACT EP 1094070 A2
Isolated polynucleotide molecules contain a nucleotide sequence that encodes a L. intracellularis HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein, a substantial portion of the sequences, or a homologous sequence. Related polypeptides, immunogenic compositions and assays are described.
ABSTRACT WORD COUNT: 40
NOTE:
Figure number on first page: 1

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | 200117 | 864 |
| SPEC A | (English) | 200117 | 25111 |
| Total word count - document A | | | 25975 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 25975 |

5/3,AB/4 (Item 3 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


01179843
Erysipelothrix *rhusiopathiae"** antigens and vaccine compositions
Erysipelothrix *rhusiopathiae"** Antigene und Impfstoff-Zusammensetzungen
Antigenes de Erysipelothrix *rhusiopathiae"** et compositions vaccinales
PATENT ASSIGNEE:
Pfizer Products Inc., (2434221), Eastern Point Road, Groton, Connecticut 06340, (US), (Applicant designated States: all)
INVENTOR:
Roberts, David Stewart, 604 Washington Square South, Philadelphia,

Pennsylvania 19106, (US)
Suiter, Brian Thomas, 7425 Plum Creek Drive, Lincoln, Nebraska 68516, (US)
Swearingin, Leroy Allen, 653 Vauxhall Street Extension, Waterford, Connecticut 06385, (US)
LEGAL REPRESENTATIVE:
Simpson, Alison Elizabeth Fraser et al (77401), Urquhart-Dykes & Lord, 30 Welbeck Street, London W1G 8ER, (GB)
PATENT (CC, No, Kind, Date): EP 1027895 A2 000816 (Basic)
EP 1027895 A3 010718
APPLICATION (CC, No, Date): EP 99309202 991118;
PRIORITY (CC, No, Date): US 117704 P 990129
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: A61K-039/08; A61K-039/39

ABSTRACT EP 1027895 A2
The invention relates to *stabilized"** antigen compositions of Erysipelothrix *rhusiopathiae"** and vaccine formulations containing such antigen compositions. Antigens of the invention are effective in providing long-term protection against erysipelas in animals.
ABSTRACT WORD COUNT: 32

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | 200033 | 236 |
| SPEC A | (English) | 200033 | 7050 |
| Total word count - document A | | | 7286 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 7286 |

5/3,AB/5 (Item 4 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


01159829
PREVENTIVES/REMEDIES FOR INFECTION, ANTI-ENDOTOXIN AGENTS, VACCINE ADJUVANTS AND GROWTH PROMOTERS
PRAVENTIVA/MITTEL FUR INFEKTION, ANTI-ENDOTOXIN MITTEL, IMPFSTOFF-ADJUVANZIEN SOWIE WACHSTUMSPROMOTOREN
PROPHYLACTIQUES/MEDICAMENTS POUR L'INFECTION, AGENTS ANTI-ENDOTOXINE, ADJUVANTS DE VACCIN ET PROMOTEURS DE CROISSANCE
PATENT ASSIGNEE:
Shin Mitsui Sugar Co., Ltd., (1427013), 8-2, Nihonbashi Honcho 2-chome, Chuo-ku, Tokyo 103-8423, (JP), (Applicant designated States: all)
INVENTOR:
MIZUTANI, Takeo, 1194-33, Hazawa-cho, Kanagawa-ku, Yokohama-shi, Kanagawa 221-0863, (JP)
KOGE, Kenji, 12-9-201, Dai 4-chome, Kamakura-shi, Kanagawa 247-0061, (JP)
NAGAI, Yukie, 5-44, Enzo 1-chome, Chigasaki-shi, Kanagawa 253-0084, (JP)
MURAKAMI, Hiroshi, 5-1-305, Kobukuroya 2-chome, Kamakura-shi, Kanagawa 247-0055, (JP)
KAWAI, Toshikazu, 5-1-304, Kobukuroya 2-chome, Kamakura-shi, Kanagawa 247-0055, (JP)
KASHIMURA, Jun, 22-3, Shinkamata 2-chome, Ota-ku, Tokyo 144-0054, (JP)

SHIMIZU, Takeo, Fujinodai-danchi 2-27-501, 3549-3, Honmachida, Machida-shi, Tokyo 194-0032, (JP)
ARAKI, Seiichi, 1-35, Nagakunidai, Tsuchiura-shi, Ibabaki 300-0810, (JP)
SUZUKI, Mamoru, 30-2-A101, Matsushiro 1-chome, Tsukuba-shi, Ibaraki 305-0035, (JP)
LEGAL REPRESENTATIVE:
Prins, Adrianus Willem et al (20903), Vereenigde, Nieuwe Parklaan 97, 2587 BN Den Haag, (NL)
PATENT (CC, No, Kind, Date): EP 1120118 A1 010801 (Basic)
WO 200021546 000420
APPLICATION (CC, No, Date): EP 99970325 991008; WO 99JP5583 991008
PRIORITY (CC, No, Date): JP 98301745 981009; JP 9935047 990212
DESIGNATED STATES: DE; ES; FR; GB; IT; NL
INTERNATIONAL PATENT CLASS: A61K-035/78; A61K-039/39; A23L-001/214; A23L-001/30; A23K-001/16

ABSTRACT EP 1120118 A1
A preventive or remedy for infection, an anti-endotoxin agents, a vaccine adjuvants and a growth promoter each comprising a sugar cane-derived extract as an active ingredient which agent is safe to man and animals . Also presented are foods and feeds comprising these agents.
ABSTRACT WORD COUNT: 45
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; Japanese
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | 200131 | 1674 |
| SPEC A | (English) | 200131 | 13040 |
| Total word count - document A | | | 14714 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 14714 |

5/3,AB/6 (Item 5 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


01148679
Outer membrane proteins from actinobacillus pleuropneumoniae
Hauptproteine der Aussenmembran von actinobacillus pleuropneumoniae
Proteines principales de la membrane externe de actinobacillus pleuropneumoniae
PATENT ASSIGNEE:
Pfizer Products Inc., (2434221), Eastern Point Road, Groton, Connecticut 06340, (US), (Applicant designated States: all)
INVENTOR:
Ankenbauer, Robert Gerard, Pfizer Inc., Central Research Division, Eastern Point Road, Groton, Connecticut 06340, (US)
Baarsch, Mary Jo, Pfizer Inc., Central Research Division, Eastern Point Road, Groton, Connecticut 06340, (US)
Campos, Manuel, Pfizer Inc., Central Research Division, Eastern Point Road, Groton, Connecticut 06340, (US)
Keich, Robin Lee, Pfizer Inc., Central Research Division, Eastern Point Road, Groton, Connecticut 06340, (US)
Rosey, Everett Lee, Pfizer Inc., Central Research Division, Eastern Point Road, Groton, Connecticut 06340, (US)

Warren-Stewart, Lynn Marie, Pfizer Inc., Central Research Division, Eastern Point Road, Groton, Connecticut 06340, (US)
Suiter, Brian Thomas, Pfizer Inc., Central Research Division, Eastern Point Road, Groton, Connecticut 06340, (US)
LEGAL REPRESENTATIVE:
Simpson, Alison Elizabeth Fraser et al (77401), Urquhart-Dykes & Lord, 91 Wimpole Street, London W1M 8AH, (GB)
PATENT (CC, No, Kind, Date): EP 1001025 A2 000517 (Basic)
APPLICATION (CC, No, Date): EP 99308262 991020;
PRIORITY (CC, No, Date): US 105285 981022
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C12N-015/12; C12N-015/62; C07K-014/285; A61K-039/07; G01N-033/68

ABSTRACT EP 1001025 A2
The present invention is directed to five novel, low molecular weight proteins from Actinobacillus pleuropneumoniae (APP), which are capable of inducing, or contributing to the induction of, a protective immune response in swine against APP. The present invention is further directed to polynucleotide molecules having nucleotide sequences that encode the proteins, as well as vaccines comprising the proteins or polynucleotide molecules, and methods of making and using the same.
ABSTRACT WORD COUNT: 70
NOTE:
Figure number on first page: 1

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | 200020 | 3435 |
| SPEC A | (English) | 200020 | 24943 |
| Total word count - document A | | | 28378 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 28378 |

5/3,AB/7 (Item 6 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00985690
Clostridium perfringens vaccine
Clostridium perfringens Impfstoff
Vaccine contre clostridium perfringens
PATENT ASSIGNEE:
Akzo Nobel N.V., (200754), Velperweg 76, 6824 BM Arnhem, (NL),
(applicant designated states:
AT;BE;CH;CY;DE;DK;ES;FI;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)
INVENTOR:
Sergers, Ruud Philip Antoon Maria, Groenling 3, 5831 MZ Boxmeer, (NL)
Waterfield, Nicolas Robin, 20 Lucerne Close, Cherry Hinton, Cambridge CB1 4YR, (GB)
Frandsen, Peer Lyng, 56 Borgmester Schneiders Vej, 2840 Holte, (DK)
Wells, Jeremy Mark, The Cottage Old House RD, Balsham, Cambridge CB1 GEF, (GB)
LEGAL REPRESENTATIVE:

Ogilvie-Emanuelson, Claudia Maria et al (80441), Patent Department Pharma N.V. Organon P.O. Box 20, 5340 BH Oss, (NL)
PATENT (CC, No, Kind, Date): EP 892054 A1 990120 (Basic)
APPLICATION (CC, No, Date): EP 98202032 980617;
PRIORITY (CC, No, Date): EP 97201888 970620
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
INTERNATIONAL PATENT CLASS: C12N-015/31; A61K-039/08; C07K-014/33; C12N-001/21;

ABSTRACT EP 892054 A1
The present invention relates to detoxified immunogenic derivatives of Clostridium perfringens (beta)-toxin or an immunogenic fragment thereof that have as a characteristic that they carry a mutation in the (beta)-toxin amino acid sequence, not found in the wild-type (beta)-toxin amino acid sequence. The invention also relates to genes encoding such (beta)-toxins, as well as to expression systems expressing such (beta)-toxins. Moreover, the invention relates to bacterial expression systems expressing a native (beta)-toxin. Finally, the invention relates to vaccines based upon detoxified immunogenic derivatives of Clostridium perfringens (beta)-toxin, and methods for the preparation of such vaccines.
ABSTRACT WORD COUNT: 96

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | 9903 | 583 |
| SPEC A | (English) | 9903 | 7428 |
| Total word count - document A | | | 8011 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 8011 |

5/3,AB/8 (Item 7 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00964612
Live attenuated bacteria of the species Actinobacillus pleuropneumoniae
Lebende attenuierte Bakterien der Spezies Actinobacillus pleuropneumoniae
Bacteries attenuees vivantes de l'espece Actinobacillus pleuropneumoniae
PATENT ASSIGNEE:
Akzo Nobel N.V., (200754), Velperweg 76, 6824 BM Arnhem, (NL), (Applicant designated States: all)
INVENTOR:
Segers, Ruud, P.A.M., Groenling 3, 5831 MZ Boxmeer, (NL)
Frey, Joachim, Hoheweg 53, 3054 Schupfen, (CH)
LEGAL REPRESENTATIVE:
Mestrom, Joannes Jozef Louis et al (74851), P.O. Box 20, 5340 BH Oss, (NL)
PATENT (CC, No, Kind, Date): EP 875574 A2 981104 (Basic)
EP 875574 A3 000322
APPLICATION (CC, No, Date): EP 98201115 980408;
PRIORITY (CC, No, Date): EP 97201032 970410
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI

INTERNATIONAL PATENT CLASS: C12N-015/31; A61K-039/102; A61K-039/295; G01N-033/569; G01N-033/68; C12N-001/20; C12N-001/21

ABSTRACT EP 875574 A2
The present invention relates to live attenuated bacteria of the genus Actinobacillus pleuropneumoniae that have a mutation in an apxIV gene such that no functional ApxIV toxin can be produced. The invention also relates to methods for the production of such bacteria. Also vaccines comprising such bacteria and methods for the production of such vaccines are part of the invention. The invention further relates to subunit vaccines comprising an ApxIV toxin, to methods for the production of such vaccines and to methods for the protection of animals against infection with bacteria of the genus Actinobacillus pleuropneumoniae. In addition, the invention relates to the promotor of the apxIV gene. Finally, the invention relates to diagnostic tests for the selective diagnosis of Actinobacillus pleuropneumoniae infections and to diagnostic tests discriminating between Actinobacillus pleuropneumoniae field strains and vaccine strains.
ABSTRACT WORD COUNT: 137
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | 9845 | 580 |
| SPEC A | (English) | 9845 | 8249 |
| Total word count - document A | | | 8829 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 8829 |

5/3,AB/9 (Item 8 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00916244
European vaccine strains of the porcine reproductive and respiratory syndrome virus (PRRSV)
Europaische Vakzinstamme des Fortplanzungs-Atmungs-Syndromsvirus des Sweins (PRRSV)
Souches vaccinales Europeennes du virus du syndrome respiratoire reproducteur porcin (PRRSV)
PATENT ASSIGNEE:
Akzo Nobel N.V., (200754), Velperweg 76, 6824 BM Arnhem, (NL), (Proprietor designated states: all)
INVENTOR:
van Woensel, Petrus A.M., Krekelzanger 49, 5831 NL Boxmeer, (NL)
Demaret, Jean G.J., Spoorstraat 7, 5831 CH Boxmeer, (NL)
LEGAL REPRESENTATIVE:
Mestrom, Joannes Jozef Louis et al (74855), N.V. Organon, Postbus 20, 5340 BH Oss, (NL)
PATENT (CC, No, Kind, Date): EP 835930 A1 980415 (Basic)
EP 835930 B1 010131
APPLICATION (CC, No, Date): EP 97203111 971007;
PRIORITY (CC, No, Date): EP 96202804 961009
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE

INTERNATIONAL PATENT CLASS: C12N-007/00; A61K-039/12; A61K-039/295

ABSTRACT EP 835930 A1
The present invention is concerned with European strains of the Porcine Reproductive Respiratory Syndrome (PRRS) virus, having as a unique feature that they are non-infectious to macrophages, and to methods for the production of such strains. The invention also provides vaccines for the protection of pigs against PRRS, based on these strains, as well as methods for the production of such vaccines.
ABSTRACT WORD COUNT: 63

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS B | (English) | 200105 | 365 |
| CLAIMS B | (German) | 200105 | 377 |
| CLAIMS B | (French) | 200105 | 404 |
| SPEC B | (English) | 200105 | 4570 |
| Total word count - document A | | | 0 |
| Total word count - document B | | | 5716 |
| Total word count - documents A + B | | | 5716 |

5/3,AB/10 (Item 9 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00885807
Live attenuated RTX-procucing bacteria of the family Pasteurellaceae
Lebende attenuierte RTX-produzierende Bakterien aus der Familie pasteurellaceae
Bacteries vivantes attenuees de la Famille Pateurellaceae produisant des RTX
PATENT ASSIGNEE:
Akzo Nobel N.V., (200754), Velperweg 76, 6824 BM Arnhem, (NL),
(applicant designated states:
AT;BE;CH;DE;DK;ES;FI;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)
INVENTOR:
Segers, Ruud Philip Antoon Maria, Groenling 3, 5831 MZ Boxmeer, (NL)
van den Bosch, Johannes Franciscus, Spoorstraat 9, 5831 CH Boxmeer, (NL)
Frey, Joachim, Hoheweg 53, 3054 Schupfen, (CH)
LEGAL REPRESENTATIVE:
Mestrom, Joannes Jozef Louis et al (74855), N.V. Organon, Postbus 20, 5340 BH Oss, (NL)
PATENT (CC, No, Kind, Date): EP 810283 A2 971203 (Basic)
EP 810283 A3 971210
APPLICATION (CC, No, Date): EP 97201613 970530;
PRIORITY (CC, No, Date): EP 96201557 960531
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
INTERNATIONAL PATENT CLASS: C12N-001/21;

ABSTRACT EP 810283 A3
The present invention relates to live attenuated RTX-toxin producing bacteria of the family Pasteurellaceae, of which the attenuation is due to the fact that they produce RTX toxin in a non-activated form. The invention also relates to vaccines for the protection of mammals against infection with RTX-toxin producing bacteria of the family

Pasteurellaceae, and to methods for the preparation of said live attenuated bacteria and vaccines.
ABSTRACT WORD COUNT: 67

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | 9711W4 | 477 |
| SPEC A | (English) | 9711W4 | 6497 |
| Total word count - document A | | | 6974 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 6974 |

5/3,AB/11 (Item 10 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00786496
T CELL STIMULATING PROTEIN OF PESTIVIRUS
T-ZELLEN STIMULIERENDES PROTEIN VON PESTIVIRUS
PROTEINE DE VIRUS DE LA PESTE STIMULANT LES CELLULES T
PATENT ASSIGNEE:
Akzo Nobel N.V., (200754), Velperweg 76, 6824 BM Arnhem, (NL),
(Proprietor designated states: all)
INVENTOR:
THIEL, Heinz-Jurgen, Sandfeld 15, D-35396 Giessen, (DE)
ELBERS, Knut, Gosstrasse 33, D-72070 Tubingen, (DE)
PAULY, Thomas, Vischerstrasse 18, D-72072 Tubingen, (DE)
LEGAL REPRESENTATIVE:
Mestrom, Joannes Jozef Louis (74851), P.O. Box 20, 5340 BH Oss, (NL)
PATENT (CC, No, Kind, Date): EP 772632 A2 970514 (Basic)
EP 772632 B1 011004
WO 9619498 960627
APPLICATION (CC, No, Date): EP 95943175 951220; WO 95EP5066 951220
PRIORITY (CC, No, Date): EP 94203696 941220
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
INTERNATIONAL PATENT CLASS: C12N-015/40; C07K-014/185; A61K-039/187
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS B | (English) | 200140 | 105 |
| CLAIMS B | (German) | 200140 | 109 |
| CLAIMS B | (French) | 200140 | 130 |
| SPEC B | (English) | 200140 | 7627 |
| Total word count - document A | | | 0 |
| Total word count - document B | | | 7971 |
| Total word count - documents A + B | | | 7971 |

5/3,AB/12 (Item 11 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00742869

RECOMBINANT PRRS PROTEINS, DIAGNOSTIC KITS AND VACCINES CONTAINING SAID RECOMBINANT PROTEINS
Recombinante PRRS Viren -Proteine und dieselben Diagnosesatze und Impfstoffe enthaltenden
PROTEINES RECOMBINANTES DU PRRSV, KITS DE DIAGNOSTIC ET VACCINS CONTENANT LESDITES PROTEINES RECOMBINANTES

PATENT ASSIGNEE:
CYANAMID IBERICA, SA, (1998690), Cristobal Bordiu, 35, E-28003 Madrid, (ES), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;NL;PT;SE)
INVENTOR:
PLANA DURAN, Juan, Carretera Camprodon, "La Riba", E-17813 Vall de Bianya , (ES)
CASAL ALVAREZ, Jose Ignacio, Hermanos Garcia Noblejas, 41-2, E-28037 Madrid, (ES)
CLIMENT SANCHEZ, Isabel, Carretera Camprodon, "La Riba", E-17813 Vall de Bianya, (ES)
LEGAL REPRESENTATIVE:
Walters, Philip Bernard William (73282), Wyeth Laboratories, Patents & Trade Marks Department, Huntercombe Lane South, Taplow, Maidenhead, Berkshire SL6 0PH, (GB)

PATENT (CC, No, Kind, Date): EP 717108 A1 960619 (Basic)
WO 9531550 951123
APPLICATION (CC, No, Date): EP 95917990 950510; WO 95ES53 950510
PRIORITY (CC, No, Date): ES 94102 940513; ES 9581 950427
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
INTERNATIONAL PATENT CLASS: C12N-015/40; C07K-014/08; C12N-007/01; A61K-039/12; G01N-033/569;

ABSTRACT EP 717108 A1
The present invention discloses the production of recombinant proteins of the virus causing the porcine respiratory and reproductive syndrome (PRRS), corresponding to the ORFs 2-7 of the PRRSV isolated in Spain, (PRRS-Olot), in a system of expression of recombinant baculoviruses multiplided in a cell culture of a permissive host. Said recombinant proteins are appropriate to formulate vaccines capable of efficiently protecting pigs against PRRS as well as to prepare diagnotic kits appropriate to detect both the presence of antibodies which recognize PRRSV and the presence of PRRSV in a porcine biological sample. This invention applies to veterinary.
ABSTRACT WORD COUNT: 108

LANGUAGE (Publication,Procedural,Application): English; English; Spanish
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | EPAB96 | 1498 |
| SPEC A | (English) | EPAB96 | 11142 |
| Total word count - document A | | | 12640 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 12640 |

5/3,AB/13 (Item 12 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00714272

European vaccine strains of the porcine reproductive respiratory syndrome virus (PRRSV)
Europaische Vakzinstamme des Fortplanzungs-Atmungs-Syndromsvirus des Schweins
Souches vaccinales Europeennes du virus du syndrome respiratoire reproducteur porcin (PRRSV)
PATENT ASSIGNEE:
Akzo Nobel N.V., (200754), Velperweg 76, 6824 BM Arnhem, (NL),
(Proprietor designated states: all)
INVENTOR:
Visser, Nicolaas, De Sering 26, NL-5831 RV Boxmeer, (NL)
van Woensel, Petrus Alphonsus Maria, Krekelzanger 49, NL-5831 NL Boxmeer, (NL)
Ohlinger, Volker, Pieperfeldweg 131, D-48239 Havixbeck, (DE)
Weiland, Emilie, Panoramastrasse 15, D-72119 Ammerbuch, (DE)
LEGAL REPRESENTATIVE:
Mestrom, Joannes Jozef Louis et al (74853), Akzo Nobel Pharma B.V., Postbus 20, 5340 BH Oss, (NL)
PATENT (CC, No, Kind, Date): EP 676467 A2 951011 (Basic)
EP 676467 A3 990929
EP 676467 B1 011004
APPLICATION (CC, No, Date): EP 95200877 950407;
PRIORITY (CC, No, Date): EP 94200964 940411
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
INTERNATIONAL PATENT CLASS: C12N-007/00; A61K-039/12; C07K-016/10

ABSTRACT EP 676467 A2
The present invention is concerned with European strains of the Porcine Reproductive Respiratory Syndrome (PRRS) virus, which are attenuated, and show a characteristic reaction pattern with two monoclonal antibodies against wild-type PRRSV.
The invention also relates to vaccines for the protection of pigs against PRRS, to monoclonal antibodies reactive with PRRS virus and monoclonal antibodies specifically non-reactive with the attenuated strains.
ABSTRACT WORD COUNT: 63
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS B | (English) | 200140 | 295 |
| CLAIMS B | (German) | 200140 | 310 |
| CLAIMS B | (French) | 200140 | 309 |
| SPEC B | (English) | 200140 | 4299 |
| Total word count - document A | | | 0 |
| Total word count - document B | | | 5213 |
| Total word count - documents A + B | | | 5213 |

5/3,AB/14 (Item 13 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00681732
PASTEURELLA MULTOCIDA TOXOID VACCINES

PASTEURELLA MULTOCIDA TOXOID ENTHALTENDE IMPFSTOFFE
VACCINS CONTRE L'ANATOXINE PASTEURELLA MULTOCIDA
PATENT ASSIGNEE:
PFIZER INC., (200962), 235 East 42nd Street, New York, N.Y. 10017-5755, (US), (Proprietor designated states: all)
INVENTOR:
FRANTZ, Joseph, C., 3027 Browning Road, Lincoln, NB 68506, (US)
ROBERTS, David, S., 6420 Meeker Circle, Lincoln, NB 68506, (US)
SWEARINGIN, Leroy, A., 934 South 33rd, Lincoln, NB 68510, (US)
KEMMY, Richard, J., 437 Brentwood Drive, Gretne, NB 68028, (US)
LEGAL REPRESENTATIVE:
Simpson, Alison Elizabeth Fraser et al (77401), Urquhart-Dykes & Lord, 91 Wimpole Street, London W1M 8AH, (GB)
PATENT (CC, No, Kind, Date): EP 651609 A1 950510 (Basic)
EP 651609 B1 990811
WO 9119419 911226
APPLICATION (CC, No, Date): EP 91913518 910610; WO 91US4092 910610
PRIORITY (CC, No, Date): US 537454 900613
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: C07K-014/285; A61K-039/102; A61K-039/116
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS B | (English) | 9932 | 1426 |
| CLAIMS B | (German) | 9932 | 1278 |
| CLAIMS B | (French) | 9932 | 1472 |
| SPEC B | (English) | 9932 | 8885 |
| Total word count - document A | | | 0 |
| Total word count - document B | | | 13061 |
| Total word count - documents A + B | | | 13061 |

5/3,AB/15 (Item 14 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00649588
Vaccine against Streptococcus suis infection
Impstoff gegen Streptococcus suis-Infektion
Vaccin contre une infection par streptococcus suis
PATENT ASSIGNEE:
Akzo Nobel N.V., (200754), Velperweg 76, 6824 BM Arnhem, (NL), (Proprietor designated states: all)
INVENTOR:
Jacobs, Antonius Arnoldus Christiaan, Ondersteweg 2, NL-5995 PS Kessel, (NL)
LEGAL REPRESENTATIVE:
Mestrom, Joannes Jozef Louis et al (74851), P.O. Box 20, 5340 BH Oss, (NL)
PATENT (CC, No, Kind, Date): EP 626452 A1 941130 (Basic)
EP 626452 B1 990811
APPLICATION (CC, No, Date): EP 94201295 940509;
PRIORITY (CC, No, Date): EP 93201401 930517
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
INTERNATIONAL PATENT CLASS: C12P-021/02; C07K-014/315; A61K-039/09

ABSTRACT EP 626452 A1

The present invention relates to a polypeptide of the bacterium Streptococcus suis with a molecular weight of about 54 kD, capable of inducing neutralising antibodies against Streptococcus suis. The invention also relates to a vaccine against Streptococcus suis infection, and a method for the preparation of such a vaccine.

ABSTRACT WORD COUNT: 51

NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS B | (English) | 9932 | 258 |
| CLAIMS B | (German) | 9932 | 251 |
| CLAIMS B | (French) | 9932 | 288 |
| SPEC B | (English) | 9932 | 6142 |
| Total word count - document A | | | 0 |
| Total word count - document B | | | 6939 |
| Total word count - documents A + B | | | 6939 |

5/3,AB/16 (Item 15 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00625751
PORCINE REPRODUCTIVE RESPIRATORY SYNDROME (PRRS) VACCINE AND DIAGNOSTIC.
Impfstoff gegen das Fortpflanzungs- und Atmungssyndrom bei Schweinen (PRRS) und Diagnose.
VACCIN CONTRE LE SYNDROME RESPIRATOIRE REPRODUCTIF PORCIN (PRRS).
PATENT ASSIGNEE:
Akzo Nobel N.V., (200754), Velperweg 76, NL-6824 BM Arnhem, (NL),
(applicant designated states:
AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;SE)
INVENTOR:
VISSER, Nicolaas, De Sering 26, NL-5831 RV Boxmeer, (NL)
OHLINGER, Volker, Hagellocher Weg 38/1, D-7400 Tubingen, (DE)
LEGAL REPRESENTATIVE:
Mestrom, Joannes Jozef Louis et al (74851), P.O. Box 20, NL-5340 BH Oss, (NL)
PATENT (CC, No, Kind, Date): EP 610250 A1 940817 (Basic)
EP 610250 B1 951206
WO 9307898 930429
APPLICATION (CC, No, Date): EP 92920950 921009; WO 92EP2331 921009
PRIORITY (CC, No, Date): EP 91202646 911014
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/12; G01N-033/569; C12N-007/00;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS B | (English) | EPAB95 | 2393 |
| CLAIMS B | (German) | EPAB95 | 2737 |
| CLAIMS B | (French) | EPAB95 | 1856 |
| SPEC B | (English) | EPAB95 | 6408 |

Total word count - document A 0
Total word count - document B 13394
Total word count - documents A + B 13394

5/3,AB/17 (Item 16 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00577676
SWINE PNEUMONIA VACCINE AND METHOD FOR THE PREPARATION THEREOF
IMPFSTOFF GEGEN DIE PNEUMONIE BEI SCHWEINEN UND VERFAHREN ZU SEINER HERSTELLUNG
VACCIN CONTRE LA PNEUMONIE PORCINE ET PROCEDE DE PREPARATION DUDIT VACCIN
PATENT ASSIGNEE:
AMERICAN CYANAMID COMPANY, (212593), Five Giralda Farms, Madison, New Jersey 07940, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
DAYALU, Krishnaswamy, I., 2336 S. 75th Street, Lincoln, NB 68506, (US)
PEETZ, Richard, H., 3818 Dudley Street, Lincoln, NB 68503, (US)
FRANTZ, Joseph, C., 3027 Browning, Lincoln, NB 68516, (US)
ROBERTS, David, S., 6420 Meeker Circle, Lincoln, NB 68506, (US)
SWEARINGIN, Leroy, A., 934 South 33rd, Lincoln, NB 68510, (US)
KEMMY, Richard, J., 437 Brentwood Drive, Gretna, NB 68028, (US)
LEGAL REPRESENTATIVE:
VOSSIUS & PARTNER (100311), Postfach 86 07 67, 81634 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 597852 A1 940525 (Basic)
EP 597852 B1 971203
WO 9118627 911212
APPLICATION (CC, No, Date): EP 91911598 910524; WO 91US3689 910524
PRIORITY (CC, No, Date): US 530669 900529; US 575921 900831; US 634237 901226
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/02;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS B | (English) | 9711W4 | 1245 |
| CLAIMS B | (German) | 9711W4 | 1213 |
| CLAIMS B | (French) | 9711W4 | 1432 |
| SPEC B | (English) | 9711W4 | 4869 |

Total word count - document A 0
Total word count - document B 8759
Total word count - documents A + B 8759

5/3,AB/18 (Item 17 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00476975
Actinobacillus pleuropneumoniae subunit vaccine.
Untereinheit-Impfstoff gegen Actinobacillus Pleuropneumoniae.
Vaccin de sous-unites d'actinobacillus pleuropneumoniae.
PATENT ASSIGNEE:

Akzo Nobel N.V., (200754), Velperweg 76, NL-6824 BM Arnhem, (NL), (applicant designated states: BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;NL;SE)
INVENTOR:
van den Bosch, Johannes Franciscus, Spoorstraat 9, NL-5831 CH Boxmeer, (NL)
LEGAL REPRESENTATIVE:
Hermans, Franciscus G.M. et al (20111), Patent Department AKZO NOBEL N.V. Pharma Division P.O. Box 20, NL-5340 BH Oss, (NL)
PATENT (CC, No, Kind, Date): EP 453024 A1 911023 (Basic)
EP 453024 B1 950531
APPLICATION (CC, No, Date): EP 91200849 910411;
PRIORITY (CC, No, Date): EP 90200989 900420
DESIGNATED STATES: BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/102;

ABSTRACT EP 453024 A1
The present invention is concerned with vaccines effective in protecting pigs against porcine pleuropneumonia. Said vaccines comprising a hemolysin and/or macrophage toxin and a 42 kD OMP preparation derived from Actinobacillus pleuropneumoniae (App) cells induce a complete and heterologous protection against App infection.
ABSTRACT WORD COUNT: 45

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | EPABF1 | 343 |
| CLAIMS B | (English) | EPAB95 | 695 |
| CLAIMS B | (German) | EPAB95 | 693 |
| CLAIMS B | (French) | EPAB95 | 827 |
| SPEC A | (English) | EPABF1 | 7944 |
| SPEC B | (English) | EPAB95 | 7993 |
| Total word count - document A | | | 8288 |
| Total word count - document B | | | 10208 |
| Total word count - documents A + B | | | 18496 |

5/3,AB/19 (Item 18 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00361231
Preparation of a recombinant subunit vaccine against pseudorabies infection.
Verfahren zur Herstellung von Rekombinat-Impfstoffen gegen Pseudorabische Infektionen.
Preparation d'un vaccin recombinant contre les infections pseudorabiques.
PATENT ASSIGNEE:
SMITHKLINE BECKMAN CORPORATION, (201242), One Franklin Plaza P O Box 7929 , Philadelphia Pennsylvania 19103, (US), (applicant designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
Jones, Elaine Verne, 1217 Andover Road Green Hill Farms, Wynnwood, PA 19151, (US)
Mellencamp, Mark William, 5394 Leafback Drive, West Chester, OH 45069, (US)
Miller, Timothy Joe, 102 Crestside Way, Malvern, PA 19355, (US)
LEGAL REPRESENTATIVE:

Wood, David John et al (37881), PFIZER LIMITED, Ramsgate Road, Sandwich, Kent CT13 9NJ, (GB)
PATENT (CC, No, Kind, Date): EP 327305 A2 890809 (Basic)
EP 327305 A3 901205
APPLICATION (CC, No, Date): EP 89300913 890131;
PRIORITY (CC, No, Date): US 151736 880203
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/245; A61K-039/225; C12N-015/38;

ABSTRACT EP 327305 A2
A method of preparation of a vaccine for use in immunizing animals against pseudorabies virus (PRV) infection which comprises inactivated recombinant PRV subunit antigens. Also described is a diagnostic kit for detection of PRV infection which distinguishes vaccinated animals from naturally exposed animals.
ABSTRACT WORD COUNT: 47

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | EPABF1 | 1277 |
| SPEC A | (English) | EPABF1 | 9456 |
| Total word count - document A | | | 10733 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 10733 |

| Set | Items | Description |
|---|---|---|
| S6 | 4818 | LECITHIN AND OIL? ? |
| S7 | 282 | S6 AND (AMPHIPHIL?(3N)(SURFACTANT? ? OR SURFACE(W)ACTIVE) OR (TWEEN OR SPAN)(W)80) |
| S8 | 4 | S7 AND RHUSIOPATH? |
| S9 | 182 | S3 AND S7 |
| S10 | 156 | S9 AND (ANTIGEN? ? OR FILTRATE? ? OR SUPERNATANT? ? OR PROTEIN? ? OR POLYPROTEIN? ? OR POLYPEPTIDE? ? OR PEPTIDE? ? OR CARBOHYDRATE? ? OR POLYSACCHARIDE? ? OR POLY(W)SACCHARIDE? ?) |
| S11 | 108 | S9 AND (GLYCOPROTEIN? ? OR (GLYCO OR LIPO)(W)PROTEIN? ? OR LIPOPROTEIN? ? OR LIPID? ?) |
| S12 | 76 | (S10 OR S11) AND (ADJUVANT? ? OR VACCIN? OR IMMUNIS? OR IMMUNIS?) |
| S15 | 20 | S12/TI,DE,MAJ |
| S17 | 16 | (S8 OR S15) NOT S4 |
| S18 | 16 | RD (unique items) |

>>>No matching display code(s) found in file(s): 65, 113

18/3,AB/1 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


01088669
Methods of increasing lean tissue mass using ob *protein"** compositions
Verfahren zur Erhogung der mageren Fleischmasse mit *Fettleibigkeitsprotein"** (OB) Zusammensetzungen
Procedes permettant d'accroitre la masse tissulaire maigre a l'aide de compositions a base de *proteine"** ob
PATENT ASSIGNEE:
AMGEN INC., (923234), 1840 DeHavilland Drive, Thousand Oaks California

91320 -1789, (US), (Applicant designated States: all)
INVENTOR:
Pelleymounter, Mary Ann, 3806 Fallon Circle, San Dieg, CA 92130-1867, (US)
Toombs, Christopher Francis, 5076 Ladera Vista Drive, Camarillo, CA 93012, (US)
Mann, Michael Benjamin, 1506 Rugby Circle, Thousand Oaks, CA 91360, (US)
LEGAL REPRESENTATIVE:
Brown, John David et al (28811), FORRESTER & BOEHMERT
Franz-Joseph-Strasse 38, 80801 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 956862 A1 991117 (Basic)
APPLICATION (CC, No, Date): EP 98119160 961104;
PRIORITY (CC, No, Date): US 561732 951122
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; RO; SI
RELATED PARENT NUMBER(S) - PN (AN):
EP 866720 (EP 96938773)
INTERNATIONAL PATENT CLASS: A61K-038/22; C07K-014/575

ABSTRACT EP 956862 A1
Methods of using OB protein compositions for increasing lean tissue mass are provided. Also provided are methods of using OB protein compositions for increasing insulin sensitivity, as well as increasing overall body strength and decreasing bone resorption. Furthermore fusion proteins comprising a Fc protein and an OB protein are provided.
ABSTRACT WORD COUNT: 51

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | 9946 | 460 |
| SPEC A | (English) | 9946 | 9623 |
| Total word count - document A | | | 10083 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 10083 |

18/3,AB/2 (Item 2 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


01085200
Polynucleotide molecules encoding neospora *proteins"**
Fur Neospora *Proteine"** kodierende polynukleotid Molekule
Molecules nucleotidiques encodant des proteines de Neospora
PATENT ASSIGNEE:
Pfizer Products Inc., (2434221), Eastern Point Road, Groton, Connecticut 06340, (US), (Applicant designated States: all)
INVENTOR:
Brake, David Alan, 196 Upper Plattagansett Road, East Lyme, Connecticut 06333, (US)
Madura (nee Coleman), Rebecca Anne, 43 Beach Street, Westerly, Rhode Island 02891, (US)
Durtschi, Becky Ann, 4 Barton Lane, Ledyard, Connecticut 06339, (US)
Krishnan, Balakrishnan Rajendra, 81 Charter Oak Drive, East Lyme, Connecticut 06333, (US)
Yoder, Susan Christine, 163 Music Vale Road, Salem, Connecticut 06340,

(US)
LEGAL REPRESENTATIVE:
Simpson, Alison Elizabeth Fraser et al (77401), Urquhart-Dykes & Lord, 91 Wimpole Street, London W1M 8AH, (GB)
PATENT (CC, No, Kind, Date): EP 953641 A2 991103 (Basic)
APPLICATION (CC, No, Date): EP 99301746 990309;
PRIORITY (CC, No, Date): US 79389 980326; US 112282 981215
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: C12N-015/30; C07K-014/44; C07K-016/20; C12N-005/16; A61K-039/002

ABSTRACT EP 953641 A2
The present invention provides isolated polynucleotide molecules comprising nucleotide sequences encoding GRA1, GRA2, SAG1, MIC1 and MAG1 proteins from Neospora caninum, as well as recombinant vectors, transformed host cells, and recombinantly-expressed proteins. The present invention further provides a polynucleotide molecule comprising the nucleotide sequence of the bidirectional GRA1/MAG1 promoter of N. caninum. The present invention further provides genetic constructs based on the polynucleotide molecules of the present invention that are useful in preparing modified strains of Neospora cells for use in vaccines against neosporosis.
ABSTRACT WORD COUNT: 85

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | 9944 | 1947 |
| SPEC A | (English) | 9944 | 21082 |
| Total word count - document A | | | 23029 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 23029 |

18/3,AB/3 (Item 3 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00995337
Neospora *vaccine"**
Neospora Impstoff
*Vaccin"** Neospora
PATENT ASSIGNEE:
Pfizer Products Inc., (2434220), Eastern Point Road, Groton, CT 06340-5146, (US), (Applicant designated States: all)
INVENTOR:
Brake, David Alan, 196 Upper Pattagansett Road, East Lyme, Connecticut 06333, (US)
Campos, Manuel, 106 Stonybrook Road, Stonington, Connecticut 06378, (US)
LEGAL REPRESENTATIVE:
Hayles, James Richard et al (75142), Pfizer Limited, Patents Department, Ramsgate Road, Sandwich Kent CT13 9NJ, (GB)
PATENT (CC, No, Kind, Date): EP 898969 A2 990303 (Basic)
EP 898969 A3 010207
APPLICATION (CC, No, Date): EP 98306431 980812;
PRIORITY (CC, No, Date): US 56956 970826

DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: A61K-039/002; A61K-039/002; A61K-39:02; A61K-039/002; A61K-39:12

ABSTRACT EP 898969 A2
The present invention provides an homogenate prepared from cells of Neospora, and vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals.
ABSTRACT WORD COUNT: 31
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | 9909 | 766 |
| SPEC A | (English) | 9909 | 8302 |
| Total word count - document A | | | 9068 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 9068 |

18/3,AB/4 (Item 4 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00958718
*Vaccines"**
Impffstoffe
*Vaccins"**
PATENT ASSIGNEE:
SMITHKLINE BEECHAM BIOLOGICALS S.A., (1311860), 89 rue de l'Institut, 1330 Rixensart, (BE), (Applicant designated States: all)
INVENTOR:
Momin, Patricia Marie, Smithkline Beecham Biologicals s.a., 89, Rue de l' , Institut, 1330 Rixensart, (BE)
Garcon, Marie-Josephe, Smithkline Beecham Biologicals s.a., 89, Rue de l' , Institut, 1330 Rixensart, (BE)
LEGAL REPRESENTATIVE:
Dalton, Marcus Jonathan William (60102), SmithKline Beecham plc Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP, (GB)
PATENT (CC, No, Kind, Date): EP 868918 A2 981007 (Basic)
EP 868918 A3 000426
APPLICATION (CC, No, Date): EP 98201308 941220;
PRIORITY (CC, No, Date): GB 9326253 931223
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: SI
RELATED PARENT NUMBER(S) - PN (AN):
EP 735898 (EP 95904511)
INTERNATIONAL PATENT CLASS: A61K-039/39

ABSTRACT EP 868918 A2
The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl

lipid A and QS21. The vaccines compositions are potent inducers of a range of immune responses.
ABSTRACT WORD COUNT: 32
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | 9841 | 346 |
| SPEC A | (English) | 9841 | 3629 |
| Total word count - document A | | | 3975 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 3975 |

18/3,AB/5 (Item 5 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00938127
FUNGAL *ANTIGENS"** AND PROCESS FOR PRODUCING THE SAME
PILZLICHE *ANTIGENE"** UND VERFAHREN ZU DEREN HERSTELLUNG
ANTIGENES FONGIQUES ET PROCESSUS DE FABRICATION
PATENT ASSIGNEE:
TAKARA SHUZO CO. LTD., (710324), 609 Takenaka-cho Fushimi-ku, Kyoto-shi, Kyoto 612, (JP), (Applicant designated States: all)
INVENTOR:
TAKESAKO, Kazutoh, 4-20-208, Akibadai, Otsu-shi, Shiga 520, (JP)
MIZUTANI, Shigetoshi, 1-86, Miyazu, Azuchi-cho, Gamo-gun, Shiga 521-13, (JP)
ENDO, Masahiro, Hamoparesu-Kusatsu 405, 12-1, Nishishibukawa 2-chome, Kusatsu-shi, Shiga 525, (JP)
KATO, Ikunoshin, 1-1-150, Nanryo-cho, Uji-shi, Kyoto 611, (JP)
LEGAL REPRESENTATIVE:
VOSSIUS & PARTNER (100314), Siebertstrasse 4, 81675 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 970966 A1 000112 (Basic)
WO 9809990 980312
APPLICATION (CC, No, Date): EP 97937856 970829; WO 97JP3041 970829
PRIORITY (CC, No, Date): JP 96255400 960904; JP 9799775 970331
DESIGNATED STATES: DE; FR; GB; IT; NL
INTERNATIONAL PATENT CLASS: C07K-014/37; C12N-015/31; A61K-039/00; A61K-039/35; C12N-015/31; C12R-1:725

ABSTRACT EP 970966 A1
There can be provided a fungal antigen which is an insoluble fraction obtainable from fungal cells of which cell wall has been substantially removed or at least partially removed; a process for producing the same; a nucleic acid encoding the fungal antigen; a biologic product containing the fungal antigen; a method of stimulating immunological responses by using the biologic product; a method of suppressing allergic reaction to fungi in a vertebrate; and a method for diagnosing a disease caused by fungi in a vertebrate.
ABSTRACT WORD COUNT: 85
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; Japanese

FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | 200002 | 1918 |
| SPEC A | (English) | 200002 | 22461 |
| Total word count - document A | | | 24379 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 24379 |

18/3,AB/6 (Item 6 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00852251
*Vaccines"** and diagnostic assays for Haemophilus influenzae
Impfstoffe und Diagnosetest fur Haemophilus influenzae
*Vaccins"** et analyses diagnostiques pour l'haemophilus influenzae
PATENT ASSIGNEE:
PRAXIS BIOLOGICS, INC., (693522), 30 Corporate Woods, Rochester NY 14623-1493, (US), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
Deich, Robert A., 10 Fallbrook Circle, Rochester, NY 14625, (US)
Green, Bruce, 49 Northfield Gate, Pittsford, NY 14534, (US)
Zlotnick, Gary, 17 Redwood Drive, Penfield, NY 14526, (US)
LEGAL REPRESENTATIVE:
Warcoin, Jacques (19071), Cabinet Regimbeau, 26, avenue Kleber, 75116 Paris, (FR)
PATENT (CC, No, Kind, Date): EP 786472 A1 970730 (Basic)
APPLICATION (CC, No, Date): EP 96119698 871223;
PRIORITY (CC, No, Date): US 948364 861231; US 20849 870302; US 132073 871211
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
RELATED PARENT NUMBER(S) - PN (AN):
EP 294469 (EP 889009270)
INTERNATIONAL PATENT CLASS: C07K-014/285; C07K-016/12; C12Q-001/68; C12N-015/62;

ABSTRACT EP 786472 A1
Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae. The peptides and proteins can be prepared by methods including novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP-1 related peptides and proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of PBOMP-1 related peptides and proteins in appropriate host cells. The peptides, proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections. The peptides and proteins are also used as reagents in immunoassays as well as to prepare immunoglobulins for passage immunization. Use of the nucleotide sequences encoding the PBOMP related peptides and proteins in hybridization assays is also described.
ABSTRACT WORD COUNT: 151

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | 9707W5 | 762 |
| SPEC A | (English) | 9707W5 | 19520 |
| Total word count - document A | | | 20282 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 20282 |

18/3,AB/7 (Item 7 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00802353
Mammalian *vaccines"** composition comprising squalene or squalane, *phospholipid"** and a surfactant as *adjuvant"**
Impfstoffzusammensetzung fur Saugetiere enthaltend Squalen oder Squalan, *Phospholipid"** und ein Tensid als Adjuvans
Composition de *vaccin"** pour mammiferes comprenant du squalene ou du squalane, des phospholipides et un agent tensio-actif comme *adjuvant"**
PATENT ASSIGNEE:
AMERICAN HOME PRODUCTS CORPORATION, (201462), Five Giralda Farms, Madison, New Jersey 07940-0874, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FI;FR;GB;GR;IE;IT;LI;LU;NL;PT;SE)
INVENTOR:
Hjorth, Richard Norman, 570 West DeKalb Pike, no. 209, King of Prussia, Pennsylvania 19406, (US)
LEGAL REPRESENTATIVE:
Walters, Philip Bernard William et al (73282), Wyeth Laboratories, Patents & Trade Marks Department, Huntercombe Lane South, Taplow, Maidenhead, Berkshire SL6 0PH, (GB)
PATENT (CC, No, Kind, Date): EP 745388 A1 961204 (Basic)
APPLICATION (CC, No, Date): EP 96303930 960531;
PRIORITY (CC, No, Date): US 459602 950602
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
INTERNATIONAL PATENT CLASS: A61K-039/39;

ABSTRACT EP 745388 A1
The present invention discloses mammalian vaccine compositions having an effective amount of an adjuvant, the adjuvant comprising squalene or squlane, one or more phospholipids and a surfactant. These compositions also optionally contain an aluminium salt and one or more pharmaceutically acceptable buffers.
ABSTRACT WORD COUNT: 52

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | EPAB96 | 563 |
| SPEC A | (English) | EPAB96 | 2591 |
| Total word count - document A | | | 3154 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 3154 |

18/3,AB/8 (Item 8 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS


00802307
*Adjuvants"** for viral *vaccines"**
Adjuvans fur vitale Impfstoffe
*Adjuvants"** pour *vaccins"** viraux
PATENT ASSIGNEE:
AMERICAN HOME PRODUCTS CORPORATION, (201462), Five Giralda Farms, Madison, New Jersey 07940-0874, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FI;FR;GB;GR;IE;IT;LI;LU;NL;PT;SE)
INVENTOR:
Hjorth, Richard Norman, 570 West DeKalb Pike, no. 209, King of Prussia, Pennsylvania, 19406, (US)
LEGAL REPRESENTATIVE:
Walters, Philip Bernard William et al (73282), Wyeth Laboratories, Patents & Trade Marks Department, Huntercombe Lane South, Taplow, Maidenhead, Berkshire SL6 0PH, (GB)
PATENT (CC, No, Kind, Date): EP 745387 A2 961204 (Basic)
EP 745387 A3 980311
APPLICATION (CC, No, Date): EP 96303835 960529;
PRIORITY (CC, No, Date): US 459600 950602
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
INTERNATIONAL PATENT CLASS: A61K-039/39;

ABSTRACT EP 745387 A2
The present invention discloses mammalian vaccine compositions having an effective amount of an adjuvant, the adjuvant comprising squalene or squlane, glycerol and a surfactant. These compositions also optionally contain an aluminium salt and one or more pharmaceutically acceptable buffers.
ABSTRACT WORD COUNT: 49

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | EPAB96 | 551 |
| SPEC A | (English) | EPAB96 | 2667 |
| Total word count - document A | | | 3218 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 3218 |

18/3,AB/9 (Item 9 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00710359
*VACCINES"**
IMPFSTOFFE
*VACCINS"**
PATENT ASSIGNEE:
SMITHKLINE BEECHAM BIOLOGICALS S.A., (1311860), 89 rue de l'Institut, 1330 Rixensart, (BE), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)
INVENTOR:
MOMIN, P.M., SmithKline Beecham Bio.(S.A.), 89, rcue de l'Institut,

B-1330 Rixensart, (BE)
GARCON, N. Marie-J., SmithKline Beecham Bio.(S.A.), 89, rue de l'Institut , B-1330 Rixensart, (BE)
LEGAL REPRESENTATIVE:
Dalton, Marcus Jonathan William (60102), SmithKline Beecham plc Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP, (GB)
PATENT (CC, No, Kind, Date): EP 735898 A1 961009 (Basic)
EP 735898 B1 990310
WO 9517210 950629
APPLICATION (CC, No, Date): EP 95904511 941220; WO 94EP4246 941220
PRIORITY (CC, No, Date): GB 9326253 931223
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
INTERNATIONAL PATENT CLASS: A61K-039/39;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS B | (English) | 9910 | 270 |
| CLAIMS B | (German) | 9910 | 257 |
| CLAIMS B | (French) | 9910 | 284 |
| SPEC B | (English) | 9910 | 3624 |
| Total word count - document A | | | 0 |
| Total word count - document B | | | 4435 |
| Total word count - documents A + B | | | 4435 |

18/3,AB/10 (Item 10 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00598055
The use of tyloxapol as a nanoparticle *stabilizer"** and dispersant
Anwendung von Tyloxapol als Nanopartikelstabilisator und Dipergiermittel
Utilisation du tyloxapol comme *stabilisateur"** de nanoparticules et agent dispersant
PATENT ASSIGNEE:
NanoSystems L.L.C., (2106910), 1250 South Collegeville Road, Bldg. 1, Collegeville, Pennsylvania 19426, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)
INVENTOR:
June, Siegfied K., c/o STERLING WINTHROP INC., 90 Park Avenue, New York, New York 10016, (US)
LEGAL REPRESENTATIVE:
Baillie, Iain Cameron et al (27951), Ladas & Parry, Dachauerstrasse 37, 80335 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 602702 A1 940622 (Basic)
EP 602702 B1 990414
APPLICATION (CC, No, Date): EP 93203365 931201;
PRIORITY (CC, No, Date): US 990874 921215
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
INTERNATIONAL PATENT CLASS: A61K-009/14; A61K-009/51; A61K-049/04;

ABSTRACT EP 602702 A1
A composition comprising nanoparticles having tyloxapol adsorbed on the

surface thereof, preferably containing a diagnostic or therapeutic agent, and most preferably including a further surface modifier associated therewith is described.

A method of making such nanoparticles and a method of diagnosis comprising administering to a mammal of a contrast effective amount of particles of nanoparticles having tyloxapol adsorbed on the surface thereof is also described.

ABSTRACT WORD COUNT: 67

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS B | (English) | 9915 | 132 |
| CLAIMS B | (German) | 9915 | 139 |
| CLAIMS B | (French) | 9915 | 147 |
| SPEC B | (English) | 9915 | 3329 |
| Total word count - document A | | | 0 |
| Total word count - document B | | | 3747 |
| Total word count - documents A + B | | | 3747 |

18/3,AB/11 (Item 11 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00524051
*Vaccine"** *adjuvant"** comprising a tetra-polyol
Einen Tetra-Polyol enthaltendes Impfstoff-Adjuvans
*Adjuvant"** pour *vaccin"** comprenant un tetra-polyol
PATENT ASSIGNEE:
SYNTEX (U.S.A.) INC., (200863), 3401 Hillview Avenue, Palo Alto California 94304, (US), (applicant designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
Allison, Anthony Clifford, 2513 Hastings Dr., Belmont, CA 94002, (US)
Byars, Noelene Elva, 1092 Syracuse Dr., Sunnyvale, CA 94087, (US)
Fu, Cherng-Chyi, 14050 Shadow Oaks Way, Saratoga, CA 95070, (US)
Lidgate, Deborah Marilyn, 325 Arboleda Drive, Los Altos, CA 94022, (US)
Felgner, Philip Lewis, P.O. Box 3302, Rancho Sante Fe, CA 92067, (US)
Foster, Linda Cheryl, 733 Carolina Avenue, Sunnyvale, CA 94086, (US)
Lee, William Alfred, 749 Anderson Drive, Los Altos, CA 94022, (US)
LEGAL REPRESENTATIVE:
Witte, Hubert et al (78221), F.Hoffmann-La Roche AG Patent Department (PLP), 124 Grenzacherstrasse, 4070 Basel, (CH)
PATENT (CC, No, Kind, Date): EP 513861 A1 921119 (Basic)
EP 513861 B1 970226
APPLICATION (CC, No, Date): EP 92113037 881102;
PRIORITY (CC, No, Date): US 116425 871103
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE
RELATED PARENT NUMBER(S) - PN (AN):
EP 315153 (EP 881182638)
INTERNATIONAL PATENT CLASS: A61K-039/39;

ABSTRACT EP 513861 A1
An adjuvant for potentiating the immunogenicity of an antigen, suitable for manufacture on a commercial scale, is an emulsion having oily particles dispersed in a continuous aqueous phase, which emulsion comprises: an emulsion-forming amount of a non-toxic tetra-polyol;

optionally, an emulsion-forming amount of a non-toxic metabolizable oil; optionally, an emulsion-stabilizing amount of a glycol ether-based surfactant; and an immunopotentiating amount of a glycopeptide.
ABSTRACT WORD COUNT: 65

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | EPABF1 | 859 |
| CLAIMS B | (English) | EPAB97 | 847 |
| CLAIMS B | (German) | EPAB97 | 822 |
| CLAIMS B | (French) | EPAB97 | 972 |
| SPEC A | (English) | EPABF1 | 6064 |
| SPEC B | (English) | EPAB97 | 5609 |
| Total word count - document A | | | 6923 |
| Total word count - document B | | | 8250 |
| Total word count - documents A + B | | | 15173 |

18/3,AB/12 (Item 12 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00449812
FLUORINE AND PHOSPHOROUS-CONTAINING *AMPHIPHILIC"** MOLECULES WITH *SURFACTANT"** PROPERTIES.
FLUOR- UND PHOSPHORHALTIGE AMPHIPHILISCHE MOLEKULE MIT OBERFLACHENAKTIVEN EIGENSCHAFTEN.
MOLECULES AMPHIPHILIQUES CONTENANT DU FLUOR ET DU PHOSPHORE, PRESENTANT DES PROPRIETES TENSIO-ACTIVES.
PATENT ASSIGNEE:
APPLICATIONS ET TRANSFERTS DE TECHNOLOGIES AVANCEES ATTA, (889381), 47, Corniche des Oliviers, F-06000 Nice, (FR), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
RIESS, Jean, Les Giaines, F-06950 Falicon, (FR)
JEANNEAUX, Francois, 135, avenue Saint-Lambert, F-06100 Nice, (FR)
KRAFFT, Marie-Pierre, 34, rue Vernier, F-06100 Nice, (FR)
SANTAELLA, Catherine, 74, avenue Saint-Barthelemy, F-06100 Nice, (FR)
VIERLING, Pierre, Les Giaines, F-06950 Falicon, (FR)
LEGAL REPRESENTATIVE:
Kedinger, Jean-Paul et al (16351), c/o Cabinet Malemont 42, avenue du President Wilson, F-75116 Paris, (FR)
PATENT (CC, No, Kind, Date): EP 478686 A1 920408 (Basic)
EP 478686 B1 930811
WO 9015807 901227
APPLICATION (CC, No, Date): EP 90910640 900621; WO 90EP991 900621
PRIORITY (CC, No, Date): EP 89401777 890622
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: C07F-009/10; A61K-031/675; C07F-009/09; C07F-009/6533;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS B | (English) | EPBBF1 | 1333 |
| CLAIMS B | (German) | EPBBF1 | 1250 |

| | | | |
|---|---|---|---|
| CLAIMS B | (French) | EPBBF1 | 1490 |
| SPEC B | (English) | EPBBF1 | 7814 |
| Total word count - document A | | | 0 |
| Total word count - document B | | | 11887 |
| Total word count - documents A + B | | | 11887 |

18/3,AB/13 (Item 13 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00361147
*Vaccines"** for the protection of animals against hypodermosis.
Vakzine zum Schutz von Tieren gegen Hypodermosis.
*Vaccins"** pour la protection des animaux contre l'hypodermose.
PATENT ASSIGNEE:
THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF AGRICULTURE, (834250), United States Department of Agriculture, Washington, DC 20250, (US), (applicant designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)
CODON, (601482), 213 East Grand Avenue, South San Fransisco CA 94080, (US), (applicant designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
Pruett, John H. ,Jr., 212 Stephanie, Herrville Texas 87028, (US)
Files, James G., 1911 Lyon Avenue, Belmont California 94002, (US)
Kuhn, Irene, 24A Cumberland Street, San Francisco California 78257, (US)
Temeyer, Kevin B., 25115, Danna Marie Drive, San Antonio Texas 78257, (US)
LEGAL REPRESENTATIVE:
Thomson, Paul Anthony et al (36701), Potts, Kerr & Co. 15, Hamilton Square, Birkenhead Merseyside L41 6BR, (GB)
PATENT (CC, No, Kind, Date): EP 326419 A2 890802 (Basic)
EP 326419 A3 910925
APPLICATION (CC, No, Date): EP 89300829 890127;
PRIORITY (CC, No, Date): US 148749 880127
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: C12N-015/00; C12N-001/20; C12N-001/18; C12N-005/00; A61K-037/547; C12N-009/64;

ABSTRACT EP 326419 A2
This invention relates to the development of a vaccine against hypodermosis, a disease resulting from a maggot invasion by an insect taxonomically classified within the genus Hypoderma. The effective ingredients of the disclosed vaccines are hypodermins A, B, and C. Hypodermins A, B and C are serine proteases. Hypodermin C is generally known as collagenase. The hypodermins are produced naturally by the larvae of the insect. Methods for producing the hypodermins by recombinant genetics are disclosed as well as vaccines containing pure hypodermins and selected mixtures. Methods for immunoprotecting animals from Hypoderma species, especially Hypoderma lineatum are also provided. The precursor sequence of Hypodermin A and B is also disclosed for use as a general purpose signal sequence for the secretion of heterologous proteins expressed by recombinant insect cells.
ABSTRACT WORD COUNT: 133

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | EPABF1 | 549 |
| SPEC A | (English) | EPABF1 | 9201 |
| Total word count - document A | | | 9750 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 9750 |

18/3,AB/14 (Item 14 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00332096
*LIPID"** MICROEMULSIONS FOR CULTURE MEDIA
*LIPIDMIKROEMULSIONEN"** FUR WACHSTUMSMEDIEN
MICRO-EMULSIONS DE LIPIDES POUR DES MILIEUX DE CULTURE
PATENT ASSIGNEE:
CHIRON CORPORATION, (572530), 4560 Horton Street, Emeryville, California 94608, (US), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
INLOW, Duane, 630 Mariposa, Apt. 310, Oakland, CA 94610, (US)
LEGAL REPRESENTATIVE:
Bizley, Richard Edward et al (28352), Hepworth, Lawrence, Bryer & Bizley Merlin House Falconry Court Baker's Lane, Epping Essex CM16 5DQ, (GB)
PATENT (CC, No, Kind, Date): EP 377582 A1 900718 (Basic)
EP 377582 B1 971015
WO 8901027 890209
APPLICATION (CC, No, Date): EP 88906679 880720; WO 88US2440 880720
PRIORITY (CC, No, Date): US 77189 870724
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: C12N-005/00;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS B | (English) | 9710W2 | 592 |
| CLAIMS B | (German) | 9710W2 | 524 |
| CLAIMS B | (French) | 9710W2 | 710 |
| SPEC B | (English) | 9710W2 | 7687 |
| Total word count - document A | | | 0 |
| Total word count - document B | | | 9513 |
| Total word count - documents A + B | | | 9513 |

18/3,AB/15 (Item 15 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00329638
PAUCILAMELLAR *LIPID"** VESICLES.
PAUCILAMELLARE *LIPIDVESIKEL"**.
VESICULES DE LIPIDES PAUCILAMELLAIRES.
PATENT ASSIGNEE:
MICRO VESICULAR SYSTEMS, INC., (1024770), 20 Cotton Road Birch Pond Business Center Suite 230, Nashua New Hampshire 03063, (US), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:
  WALLACH, Donald, F., H., 45 Marshall Street, Brookline, MA 02146, (US)
LEGAL REPRESENTATIVE:
  Price, Vincent Andrew et al (79513), FRY HEATH & SPENCE The Old College
    53 High Street, Horley Surrey RH6 7BN, (GB)
PATENT (CC, No, Kind, Date): EP 352282 A1 900131 (Basic)
                             EP 352282 B1 920108
                             WO 8806883 880922
APPLICATION (CC, No, Date): EP 88903062 880308; WO 88US723 880308
PRIORITY (CC, No, Date): US 25525 870313; US 157571 880303
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-009/127;
NOTE:
  No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS B | (English) | EPBBF1 | 1557 |
| CLAIMS B | (German) | EPBBF1 | 1452 |
| CLAIMS B | (French) | EPBBF1 | 1819 |
| SPEC B | (English) | EPBBF1 | 7076 |
| Total word count - document A | | | 0 |
| Total word count - document B | | | 11904 |
| Total word count - documents A + B | | | 11904 |

18/3,AB/16 (Item 16 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00301600
*Vaccine"** *adjuvant"**.
Impfstoff-Adjuvans.
*Adjuvant"** pour *vaccin"**.
PATENT ASSIGNEE:
  SYNTEX (U.S.A.) INC., (200860), 3401 Hillview Avenue, Palo Alto
    California 94303, (US), (applicant designated states:
    AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
  Allison, Anthony Clifford, 2513 Hastings Drive, Belmont, CA 94002, (US)
  Byars, Noelene Elva, 1092 Syracuse Drive, Sunnyvale, CA 94087, (US)
  Fu, Cherng-Chyi, 14050 Shadow Oaks Way, Saratoga, CA 95070, (US)
  Lidgate, Deborah Marilyn, 325 Arboleda Drive, Los Altos, CA 94022, (US)
  Felgner, Philip Lewis, P.O. Box 3392, Rancho Santa Fe, CA 92067, (US)
  Foster, Linda Cheryl, 733 Carolina Avenue, Sunnyvale, CA 94086, (US)
  Lee, William Alfred, 749 Anderson Drive, Los Altos, CA 94022, (US)
LEGAL REPRESENTATIVE:
  Barz, Peter, Dr. et al (1461), Patentanwalte Dipl.-Ing. G. Dannenberg Dr.
    P. Weinhold, Dr. D. Gudel Dipl.-Ing. S. Schubert, Dr. P. Barz
    Siegfriedstrasse 8, D-80803 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 315153 A2 890510 (Basic)
                             EP 315153 A3 890809
                             EP 315153 B1 940511
APPLICATION (CC, No, Date): EP 88118263 881102;
PRIORITY (CC, No, Date): US 116425 871103
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/39;

ABSTRACT EP 315153 A2

An adjuvant for potentiating the immunogenicity of an antigen, suitable for manufacture on a commercial scale, is an emulsion having oily particles dispersed in a continuous aqueous phase, which emulsion comprises: an emulsion-forming amount of a non-toxic tetra-polyol or polyoxyethylene-polyoxypropylene (POP-POE) block polymer; optionally, an emulsion-forming amount of a non-toxic metabolizable oil; optionally, an emulsion-stabilizing amount of a glycol ether-based surfactant; and an immunopotentiating amount of a glycopeptide;
wherein substantially all of said oily particles have a diameter less than about 800 nm if a POP-POE block polymer is present.

ABSTRACT WORD COUNT: 94

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS B | (English) | EPBBF1 | 2479 |
| CLAIMS B | (German) | EPBBF1 | 2354 |
| CLAIMS B | (French) | EPBBF1 | 2924 |
| SPEC B | (English) | EPBBF1 | 8557 |
| Total word count - document A | | | 0 |
| Total word count - document B | | | 16314 |
| Total word count - documents A + B | | | 16314 |

- Author(s)

| Set | Items | Description |
|---|---|---|
| S19 | 8267 | AU=(ROBERTS, D? OR ROBERTS D?) |
| S20 | 8 | AU=(SWEARINGIN, L? OR SWEARINGIN L?) |
| S21 | 10 | AU=(SUITER, B? OR SUITER B?) |
| S22 | 1 | S19 AND S20 AND S21 |
| S23 | 7 | S19 AND (S20 OR S21) |
| S24 | 1 | S20 AND S21 |
| S25 | 8277 | S19 OR S20 OR S21 |
| S26 | 6 | S25 AND RHUSIOPATH? |
| S27 | 5 | (S22 OR S23 OR S24 OR S26) NOT (S17 OR S4) |
| S28 | 4 | RD (unique items) |

>>>No matching display code(s) found in file(s): 65, 113

28/3,AB/1 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


01175011
Adjuvants for use in vaccines
Adjuvanzien zur Verwendung in Impfstoffen
Adjuvants pour utilisation dans des vaccins
PATENT ASSIGNEE:
Pfizer Products Inc., (2434221), Eastern Point Road, Groton, Connecticut 06340, (US), (Applicant designated States: all)
INVENTOR:
Dearwester, Don Alan, Pfizer Inc., Central Res. Div., Eastern Point Road, Groton, Connecticut 06340, (US)
*Swearingin, Leroy Allen, Pfizer Inc."**, Central Res. Div., Eastern Point Road, Groton, Connecticut 06340, (US)
*Roberts, David Stewart"**, 604 Washington Square South, Apt. 303, Philidelphia, Pennsylvania 19106, (US
LEGAL REPRESENTATIVE:
Simpson, Alison Elizabeth Fraser et al (77401), Urquhart-Dykes & Lord, 30 Welbeck Street, London W1M 7PG, (GB)

PATENT (CC, No, Kind, Date): EP 1023904 A2 000802 (Basic
APPLICATION (CC, No, Date): EP 99310514 991223;
PRIORITY (CC, No, Date): US 117705 990129; US 121760 990226
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR
LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS: A61K-039/39; A61K-039/02; A61K-039/
A61K-039/10; A61K-039/40; A61P-031/04

ABSTRACT EP 1023904 A2
The invention relates to adjuvants that contain a lecithin, a
an amphiphilic surfactant and that are capable of forming a stab
oil-in-water emulsion vaccine so as to minimize local reactions t the
vaccine in the injected animal.
ABSTRACT WORD COUNT: 40
NOTE:
Figure number on first page: 1

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|---|---|---|---|
| CLAIMS A | (English) | 200031 | 541 |
| SPEC A | (English) | 200031 | 6736 |
| Total word count - document A | | | 7277 |
| Total word count - document B | | | 0 |
| Total word count - documents A + B | | | 7277 |

28/3,AB/2 (Item 2 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00705427
GRAM-NEGATIVE BACTERIAL VACCINES.
GRAM-NEGATIVE BAKTERIELLE VAKZINE.
VACCINS BACTERIENS GRAM-NEGATIFS.
PATENT ASSIGNEE:
SMITHKLINE BEECHAM CORPORATION, (201243), P.O. Box 7929 1 Franklin Plaza, Philadelphia Pennsylvania 19101, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;SE)
INVENTOR:
DEARWESTER, Donald, A., 7640 Davies Drive, Lincoln, NB 68506, (US)
*ROBERTS, David, S."**, 1020 Rockhurst Drive, Lincoln, NB 68510, (US)
*SWEARINGIN, Leroy, A."**, 934 South 33rd Street, Lincoln, NB 68510, (US
LEGAL REPRESENTATIVE:
Simpson, Alison Elizabeth Fraser et al (77401), Urquhart-Dykes & Lord, 91 Wimpole Street, London W1M 8AH, (GB)
PATENT (CC, No, Kind, Date): EP 669971 A1 950906 (Basic)
WO 9310216 930527
APPLICATION (CC, No, Date): EP 92925307 921113; WO 92US9944 921113
PRIORITY (CC, No, Date): US 792488 911115
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; SE
INTERNATIONAL PATENT CLASS: C12N-001/36; A61K-039/02;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English

28/3,AB/3 (Item 3 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS


00632408
PASTEURELLA MULTOCIDA TOXOID VACCINES.
Pasteurella multocida Toxoid-Vakzine.
VACCINS A BASE D'ANATOXINES DE PASTEURELLA MULTOCIDA.
PATENT ASSIGNEE:
SMITHKLINE BEECHAM CORPORATION, (201243), P.O. Box 7929 1 Franklin Plaza, Philadelphia Pennsylvania 19101, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;SE)
INVENTOR:
FRANTZ, Joseph, C., 3027 Browning, Lincoln, NB 68506, (US)
KEMMY, Richard, J., 437 Brentwood Drive, Gretna, NB 68028, (US)
*ROBERTS, David, S."**, 1020 Rockhurst Drive, Lincoln, NB 68510, (US)
*SWEARINGIN, Leroy, A."**, 934 South 33rd, Lincoln, NB 68510, (US
LEGAL REPRESENTATIVE:
Russell, Brian John et al (45993), SmithKline Beecham plc Corporate Intellectual Property SB House Great West Road, Brentford, Middlesex TW8 9BD, (GB)
PATENT (CC, No, Kind, Date): EP 614371 A1 940914 (Basic)
EP 614371 A1 950607
WO 9309809 930527
APPLICATION (CC, No, Date): EP 92925340 921113; WO 92US10008 921113
PRIORITY (CC, No, Date): US 792490 911115
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/00; A61K-039/02;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English

28/3,AB/4 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs


0258641 DBA Accession No.: 2000-13131 PATENT
Vaccine containing lecithin, oil and surfactant as adjuvant, useful for protection against bacterial or viral pathogens, particularly in pigs, does not cause significant local reactions - Bordetella bronchiseptica, Pasteurella multocida culture and antigen use in vaccine for pig protection from infection
AUTHOR: Dearwester D A; *Swearingin L A"**; *Roberts D S"**
CORPORATE SOURCE: Groton, CT, USA.
PATENT ASSIGNEE: Pfizer 2000
PATENT NUMBER: EP 1023904 PATENT DATE: 20000802 WPI ACCESSION NO.: 2000-516029 (2047)
PRIORITY APPLIC. NO.: US 121760 APPLIC. DATE: 19990226
NATIONAL APPLIC. NO.: EP 99310514 APPLIC. DATE: 19991223
LANGUAGE: English
ABSTRACT: A vaccine composition (A) comprises 0.25-12.5 vol% lecithin (I), 1-23 vol% oil (II), 1.5-3.5 vol% at least one amphipathic surfactant (III) plus an antigen (Ag). Also claimed are: an adjuvant composition (B) of (I)-(III); preparation of vaccines by adding (B) to a Ag composition; an Ag composition (C) comprising a Bordetella

bronchiseptica culture inactivated by adding formalin and then glutaraldehyde; a vaccine composition (D) of (C) plus an adjuvant; inactivating a B. bronchiseptica culture by adding formalin and glutaraldehyde; a vaccine for protection against B. bronchiseptica infection comprising cells from a culture inactivated by the claimed method plus a carrier; and a method for protecting a piglet against atrophic rhinitis. (A) can be formulated with Ag from any bacterial or viral pathogen, especially for protection of animals, piglets against B. bronchiseptica and/or Pasteurella multocida. The antigen is from Pasteurella multocida, Bordetella bronchiseptica, Erysipelothrix *rhusiopathiae"**, Escherichia coli, Actinobacillus pleuropneumoniae or Pasteurella hemolytica culture. In an example, B. bronchiseptica 2-9NADL was cultured. (12pp)

? log y
17oct01 13:30:56 User219783 Session D1751.3

Applicants
Devi, S.
09/489711



FILE 'REGISTRY' ENTERED AT 12:16:56 ON 17 OCT 2001
E ALUMINUM HYDROXIDE/CN 5
L1 7 SEA ABB=ON PLU=ON ("ALUMINUM HYDROXIDE"/CN OR "ALUMINUM HYDROXIDE (AL(18OH)3)"/CN OR "ALUMINUM HYDROXIDE (AL(OD))"/CN OR "ALUMINUM HYDROXIDE (AL(OD)2)"/CN OR "ALUMINUM HYDROXIDE (AL(OD)3)"/CN OR "ALUMINUM HYDROXIDE (AL(OH))"/CN OR "ALUMINUM HYDROXIDE (AL(OH)2)"/CN OR "ALUMINUM HYDROXIDE (AL(OH)3)"/CN)
E CALCIUM HYDROXIDE/CN 5
L2 6 SEA ABB=ON PLU=ON ("CALCIUM HYDROXIDE"/CN OR "CALCIUM HYDROXIDE (40CA(OH))"/CN OR "CALCIUM HYDROXIDE (CA(OD))"/CN OR "CALCIUM HYDROXIDE (CA(OD)2)"/CN OR "CALCIUM HYDROXIDE (CA(OH)(OT))"/CN OR "CALCIUM HYDROXIDE (CA(OH))"/CN OR "CALCIUM HYDROXIDE (CA(OH)2)"/CN)
E ZINC HYDROXIDE/CN 5
L3 4 SEA ABB=ON PLU=ON ("ZINC HYDROXIDE"/CN OR "ZINC HYDROXIDE (65ZN(OH)2)"/CN OR "ZINC HYDROXIDE (ZN(OD))"/CN ) OR "ZINC HYDROXIDE (ZNOH)"/CN
E ALUMINUM PHOSPHATE/CN
L4 13 SEA ABB=ON PLU=ON ("ALUMINUM PHOSPHATE"/CN OR "ALUMINUM PHOSPHATE (1:1)"/CN) OR ("ALUMINUM PHOSPHATE (AL(PO4))"/CN OR "ALUMINUM PHOSPHATE (AL0.5(PO4)0.5)"/CN OR "ALUMINUM PHOSPHATE (AL2(HPO4)3)"/CN OR "ALUMINUM PHOSPHATE (AL2(OH)3(PO4))"/CN OR "ALUMINUM PHOSPHATE (AL2O3(P2O5)5)"/CN OR "ALUMINUM PHOSPHATE (AL2P6O18)"/CN OR "ALUMINUM PHOSPHATE (AL3(OH)3(PO4)2)"/CN OR "ALUMINUM PHOSPHATE (AL3(PO4)(OH)6)"/CN OR "ALUMINUM PHOSPHATE (AL4(P4O12)3)"/CN OR "ALUMINUM PHOSPHATE (AL4P10O31)"/CN OR "ALUMINUM PHOSPHATE (ALH2P3O10)"/CN) OR "ALUMINUM PHOSPHATE (ALP3O9)"/CN
E CALCIUM PHOSPHATE/CN 5
L5 6 SEA ABB=ON PLU=ON ("CALCIUM PHOSPHATE"/CN OR "CALCIUM PHOSPHATE (1:1)"/CN OR "CALCIUM PHOSPHATE (1:2)"/CN OR "CALCIUM PHOSPHATE (3:2)"/CN OR "CALCIUM PHOSPHATE (CA(H2PO4)2)"/CN) OR "CALCIUM PHOSPHATE (CA(PO3)2)"/CN OR "CALCIUM PHOSPHATE (CA2P2O7)"/CN
E ALUM/CN
L6 2 SEA ABB=ON PLU=ON ALUM/CN
L7 38 SEA ABB=ON PLU=ON L1 OR L2 OR L3 OR L4 OR L5 OR L6

FILE 'CAPLUS' ENTERED AT 12:24:42 ON 17 OCT 2001
L8 156919 SEA ABB=ON PLU=ON L7 OR (STABILIS? OR STABILIZ?)(3A)AGENT OR (METAL OR AL OR ALUMIN? OR CALCIUM OR CA OR ZINC OR ZN)(W)(OH OR HYDROXIDE) OR CAOH OR ALOH OR ZNOH OR (METAL OR ALUMIN? OR CALCIUM OR AL OR CA)(W)(PO# OR PHOSPHATE) OR ALPO# OR CAPO# OR ALUM
L9 2 SEA ABB=ON PLU=ON L8 AND (ERYSIPEL? OR E)(W)RHUSIOPATH?

L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:544802 CAPLUS
DOCUMENT NUMBER: 133:155383
TITLE: **Erysipelothrix rhusiopathiae** antigen compositions and their vaccine compositions for prevention and treatment of swine erysipelas
INVENTOR(S): Roberts, David Stewart; Swearingin, Leroy Alan; Suiter, Brian Thomas
PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 2000219637 | A2 | 20000808 | JP 2000-17930 | 20000124 |
| AU 9959445 | A1 | 20000803 | AU 1999-59445 | 19991116 |
| EP 1027895 | A2 | 20000816 | EP 1999-309202 | 19991118 |
| EP 1027895 | A3 | 20010718 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| CN 1262129 | A | 20000809 | CN 1999-126163 | 19991215 |
| BR 9905853 | A | 20001114 | BR 1999-5853 | 19991215 |

PRIORITY APPLN. INFO.: US 1999-117704 P 19990129

AB The antigen compns. contain fluid fraction of cultured **E. rhusiopathiae**, and stabilizers, e.g. **metal hydroxides** or phosphates. Rehydragel [**Al(OH)**3 gel] prevented loss of activity of formalin- or .beta.-propiolactone-inactivated **E. rhusiopathiae** antigen.

IT **1305-62-0, Calcium hydroxide**, biological studies **7784-30-7, Aluminum phosphate** **10103-46-5, Calcium phosphate** **20427-58-1, Zinc hydroxide** **21645-51-2**, Rehydragel, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gel, stabilizer; vaccines contg. **erysipelothrix rhusiopathiae** antigen for treatment of swine erysipelas)

IT **10043-67-1, Alum**
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilizer; vaccines contg. **erysipelothrix rhusiopathiae** antigen for treatment of swine erysipelas)

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1999:451503 CAPLUS
DOCUMENT NUMBER: 131:92494
TITLE: Adjuvant combination for vaccines
INVENTOR(S): Neubert, Andreas; Reuter, Torsten
PATENT ASSIGNEE(S): Impfstoffwerk Dessau-Tornau G.m.b.H., Germany
SOURCE: Ger. Offen., 4 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| DE 19801834 | A1 | 19990715 | DE 1998-19801834 | 19980114 |

AB Vaccine adjuvants made of mineral oil and **Al(OH)**3 gel as oil-in-water emulsion combinations and process of their prepn. are described. The mineral oil-**Al(OH)**3

ratios may be 1:0.1 to 0.1:1. The adjuvant can be used for the prepn. of vaccines against swine parvovirus, influenza virus, or **Erysipelthrix rhusiopathiae**. The antigen is first mixed with **Al(OH)**3 gel for 12 at 4-8.degree.C and then emulsified with mineral oil. A vaccine against swine parvovirus was prepd. and tested in pigs and guinea pigs. The vaccine with mineral oil and **Al(OH)**3 adjuvant had superior immunizing properties compared to vaccines with **Al(OH)**3 only or with **Al(OH**)3-saponin adjuvant.

IT **21645-51-2, Aluminum hydroxide,**
biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**aluminum hydroxide** and mineral oil emulsions as adjuvants for swine vaccines)

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, JICST-EPLUS, JAPIO, CABA, AGRICOLA, VETU, VETB, PHIC, PHIN, TOXLIT, TOXLINE' ENTERED AT 12:29:05 ON 17 OCT 2001)

L10 23 S L9
L11 23 DUP REM L10 (0 DUPLICATES REMOVED)

L11 ANSWER 1 OF 23 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 2001-381498 [40] WPIDS
DOC. NO. CPI: C2001-116878
TITLE: Composition for enhancing immunogenic effect of a vaccine comprises an extract of a ginseng plant and an aluminum salt.
DERWENT CLASS: B01 B04
INVENTOR(S): RIVERA VEGA, E
PATENT ASSIGNEE(S): (STAT-N) STATENS VETERINAERMEDICINSKA ANSTALT
COUNTRY COUNT: 94
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---|---|---|---|---|---|
| WO 2001041802 | A1 | 20010614 | (200140)* | EN | 50 |

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|---|---|---|---|
| WO 2001041802 | A1 | WO 2000-SE2478 | 20001208 |

PRIORITY APPLN. INFO: US 1999-169613 19991208; SE 1999-4480 19991208
AN 2001-381498 [40] WPIDS
AB WO 200141802 A UPAB: 20010719
NOVELTY - Composition for enhancing immunogenic effect of a vaccine

comprising an extract of a ginseng plant and an aluminum salt, is prepared by providing an extract of a ginseng plant comprising at least one ginsenoside; and adding the aluminum salt to the extract.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(i) a kit comprising a composition as above; and

(ii) a preparation comprising a composition as above, and optionally an immunogenic substance.

ACTIVITY - Immunostimulant.

Mice were vaccinated with either: diluted **Erysipelothrix rhusiopathiae** and NaCl solution (vaccine 1); diluted virus and 3 % **Al**(**OH**)3 (Vaccine 2); vaccine 1 + Ginseng; or vaccine 2 + Ginseng (no amounts given). After vaccination mean group antibody titers were calculated. Vaccine 1 gave 10.0 plus or minus 0.0, vaccine 1 + ginseng gave 13.3 plus or minus 4.7, vaccine 2 gave 13.3 plus or minus 4.7 and vaccine 2 + ginseng gave 13.3 plus or minus 4.7. After 2 boosters vaccine 1 gave 80.0 plus or minus 0.0, vaccine 1 + ginseng gave 320.0 plus or minus 0.0, vaccine 2 gave 66.6 plus or minus 18.9 and vaccine 2 + ginseng gave 173.3 plus or minus 14.6.

MECHANISM OF ACTION - Vaccine.

USE - The composition is used for enhancing the immunogenic effect of a vaccine.

ADVANTAGE - The amount of aluminum salt required is reduced compared to prior art. The composition has a strong adjuvant effect, and is safe and effective with no local or general side-effects.

Dwg.0/2

L11 ANSWER 2 OF 23 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 2000-484844 [43] WPIDS
DOC. NO. CPI: C2000-145992
TITLE: Novel antigen comprising fluid function from an **Erysipelothrix rhusiopathiae** culture, useful as a vaccine.
DERWENT CLASS: B04 C06 D16
INVENTOR(S): ROBERTS, D S; SUITER, B T; SWEARINGEN, L A; SWEARINGIN, L A
PATENT ASSIGNEE(S): (PFIZ) PFIZER PROD INC
COUNTRY COUNT: 31
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---|---|---|---|---|---|
| EP 1027895 | A2 | 20000816 | (200043)* | EN | 13 |
| R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI | | | | | |
| JP 2000219637 | A | 20000808 | (200043) | | 12 |
| AU 9959445 | A | 20000803 | (200046) | | |
| CA 2290078 | A1 | 20000729 | (200051) | EN | |
| CN 1262129 | A | 20000809 | (200055) | | |
| BR 9905853 | A | 20001114 | (200064) | | |
| ZA 9907138 | A | 20010627 | (200140) | | 23 |

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|---|---|---|---|
| EP 1027895 | A2 | EP 1999-309202 | 19991118 |

| | | | |
|---|---|---|---|
| JP 2000219637 | A | JP 2000-17930 | 20000124 |
| AU 9959445 | A | AU 1999-59445 | 19991116 |
| CA 2290078 | A1 | CA 1999-2290078 | 19991116 |
| CN 1262129 | A | CN 1999-126163 | 19991215 |
| BR 9905853 | A | BR 1999-5853 | 19991215 |
| ZA 9907138 | A | ZA 1999-7138 | 19991116 |

PRIORITY APPLN. INFO: US 1999-117704 19990129
AN 2000-484844 [43] WPIDS
AB EP 1027895 A UPAB: 20000907
NOVELTY - Antigen (I) comprising a fluid function from an **Erysipelothrix rhusiopathiae** culture and a **stabilizing agent**, is new.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
(1) a vaccine comprising an antigen as in (I) and an adjuvant; and
(2) making an antigen comprising adding a **stabilizing agent** to a fluid fraction from an **E. rhusiopathiae** culture.
ACTIVITY - Antibacterial.
MECHANISM OF ACTION - Vaccine.
Pigs were vaccinated intramuscularly with two 2 ml doses of vaccine with Al gel (3 and 6 weeks). Immunity was tested at 9 weeks with intramuscular injections of **E. rhusiopathiae** . Protection due to vaccine was 100 %.
USE - The antigen composition of (I) and a vaccine comprising it are used to vaccinate an animal, especially a pig against **E. rhusiopathiae** infection and erysipelas (claimed).
ADVANTAGE - The vaccine provides long term protection from **E. rhusiopathiae**.
Dwg.0/0

L11 ANSWER 3 OF 23 TOXLIT
ACCESSION NUMBER: 2000:54719 TOXLIT
DOCUMENT NUMBER: CA-133-155383R
TITLE: **Erysipelothrix rhusiopathiae** antigen compositions and their vaccine compositions for prevention and treatment of swine erysipelas.
AUTHOR: Roberts DS; Swearingin LA; Suiter BT
SOURCE: (2000). Jpn. Kokai Tokkyo Koho PATENT NO. 2000219637 08/08/2000 (Pfizer Products Inc.). CODEN: JKXXAF.
PUB. COUNTRY: UNITED STATES
DOCUMENT TYPE: Patent
FILE SEGMENT: CA
LANGUAGE: Japanese
OTHER SOURCE: CA 133:155383
ENTRY MONTH: 200009
AB The antigen compns. contain fluid fraction of cultured **E. rhusiopathiae**, and stabilizers, e.g. **metal hydroxides** or phosphates. Rehydragel [**Al(OH)**3 gel] prevented loss of activity of formalin- or .beta.-propiolactone-inactivated **E. rhusiopathiae** antigen.

L11 ANSWER 4 OF 23 TOXLIT
ACCESSION NUMBER: 1999:44980 TOXLIT
DOCUMENT NUMBER: CA-131-092494P
TITLE: Adjuvant combination for vaccines.
AUTHOR: Neubert A; Reuter T
SOURCE: (1999). Ger. Offen. PATENT NO. 19801834 07/15/1999 (Impfstoffwerk Dessau-Tornau G.m.b.H.). CODEN: GWXXBX.
PUB. COUNTRY: GERMANY, FEDERAL REPUBLIC OF
DOCUMENT TYPE: Patent
FILE SEGMENT: CA
LANGUAGE: German
OTHER SOURCE: CA 131:92494
ENTRY MONTH: 199908
AB Vaccine adjuvants made of mineral oil and **Al(OH)3** gel as oil-in-water emulsion combinations and process of their prepn. are described. The mineral oil-**Al(OH)3** ratios may be 1:0.1 to 0.1:1. The adjuvant can be used for the prepn. of vaccines against swine parvovirus, influenza virus, or **Erysipelthrix rhusiopathiae**. The antigen is first mixed with **Al(OH)3** gel for 12 at 4-8.degree.C and then emulsified with mineral oil. A vaccine against swine parvovirus was prepd. and tested in pigs and guinea pigs. The vaccine with mineral oil and **Al(OH)3** adjuvant had superior immunizing properties compared to vaccines with **Al(OH)3** only or with **Al(OH)3**-saponin adjuvant.

L11 ANSWER 5 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1999-60845 VETU
TITLE: Protective activity of the purified protein antigen of **Erysipelothrix rhusiopathiae**.
AUTHOR: Yamazaki Y; Sato H; Sakakura H; Shigeto K; Nakano K; Saito H
CORPORATE SOURCE: Univ.Kitasato
LOCATION: Aomori, Jap.
SOURCE: J.Vet.Med.Ser.B (46, No. 1, 47-55, 1999) 5 Fig. 2 Tab. 16 Ref. CODEN: JVMBE9
AVAIL. OF DOC.: Department of Veterinary Microbiology, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori 034, Japan. (7 authors).
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
AN 1999-60845 VETU
AB The protein antigen (P64), which contains 66 and 64 kDa proteins, was purified from the alkaline extract (AE) of whole cells of **Erysipelothrix rhusiopathiae** strain Agata (serovar 5) to determine the protective activity of the antigen against **E. rhusiopathiae** infection in pigs. S.c. immunization with P64 antigen or live cell erysipelas vaccine resulted in a rapid increase in the serum antibody titer against P64. Pigs vaccinated with P64 antigen or live cell vaccine were protected from challenge 3 wk after 1st immunization. The results indicate that a specific antibody against the 64 kDa protein was raised in pigs immunized with P64 or a live cell vaccine and that this anti-P64 antibody has a strong protective effect against

**E. rhusiopathiae** infection in pigs.

ABEX 20 Mixed breed pigs (2-mth-old) were divided into 5 grou 4 and immunized s.c. with 500, 100 or 20 ug of P64 mixed in **aluminum phosphate** gel or live erysipelas vaccine, or acted as nonimmunized controls. 2 Wk after 1st immunization, each of 4 pigs immunized with P64 was re-immun[redacted] with the above doses of P64. Pigs possessing a high serum antibody titer were challenged s.c. with **E. rhusiopathiae** strain Fujisawa (serotype 1a) 3 wk after 1st immunization. The serum antibody titer against P64 rapidly increased in pigs immunized with 500 and 100 ug P64 and attained peak values at 3 wk after 1st immunization. However, the serum antibody titers were not increased in pigs immunized with 20 ug P64 and in nonimmunized controls. In pigs immunized with the live cell vaccine, serum titers against P64 also increased at 1-2 wk postimmunization. On challenge, all nonimmunized pigs showed typical clinical signs of swine erysipelas, while all pigs immunized with 500 and 100 ug of P64 and live cell vaccine showed no clinical signs of disease. In Western blot analysis, sera from pigs immunized with P64 and live cell vaccine strongly reacted with the 64 kDa protein. In contrast, the serum from nonimmunized pigs did not react with any proteins.

L11 ANSWER 6 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1996-63321 VETU
TITLE: Reliable protection of pigs against parvovirosis and erysipelas by vaccination with the combination vaccine Erysorb Parvo ad us. vet.
(Zuverlaessiger Schutz von Schweinen vor Parvovirose und Rotlau)
AUTHOR: Klein N; Goddard R; Pugh C
CORPORATE SOURCE: Hoechst; Cent.Vet.Lab.U.K.
LOCATION: Marburg, Ger.; Weybridge; Milton Keynes, U.K.
SOURCE: Prakt.Tierarzt (77, No. 9, 838, 841-44, 1996) 1 Fig. 4 Tab. 19 Ref.
CODEN: PRTIAV
AVAIL. OF DOC.: Behringwerke AG, Veterinaer Unit, Postfach 11 40, 35001 Marburg.
LANGUAGE: German
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
AN 1996-63321 VETU
AB The efficacy of a combined vaccine, Erysorb Parvo (Hoechst) for s.c. immunization against porcine parvovirus (PPV) and erysipelas (ERY) was evaluated in pregnant gilts, which received 2 injections, 3 wk apart. The vaccine contained inactivated **Erysipelothrix rhusiopathiae** serotypes 1 (strain P) and 2 (strain CN 3342) and inactivated PPV with **aluminum hydroxide** and Quil A as adjuvants. The combined vaccine was very well tolerated by the pigs without apparent side-effects. Following experimental infection of the gilts with PPV, none of the fetuses in the vaccinated animals showed evidence of infection. The vaccine also protected against experimental ERY infection with all the vaccinated pigs remaining healthy. The combined vaccine demonstrated comparable efficacy against both infections to those of the individual monovalent products.
ABEX 8 Gilts (5.6-7 mth-old) were vaccinated with Erysorb Parvo as 2 doses given 3 wk apart, while 6 similar sows remained

unvaccinated to serve as controls. All animals were covered after vaccination and then experimentally infected with PPV strain CVL 1243 between days 40-43 of pregnancy. Fetuses from the slaughtered sows were examined clinically and anatomically and infection detected by ELISA assay of fetal organ samples and hemagglutination inhibition (HI) antibody titers in fetal sera. 5 Gilts (aged 10 wk) were vaccinated as above, while 5 similar animals served as controls with all being experimentally infected 2 wk later with ERY serotypes 1 and 2 by i.d. injection. In the 1st vaccination study, 101 fetuses were produced by the vaccinated gilts of which 91 fetuses survived. No infection was detected by immunoassays in any of these fetuses. The control pigs produced 71 fetuses of which 30 survived (41 were mummified) and PPV infection was detected in 57/71 (80.3%) fetuses. At 1 wk after the 2nd vaccination, all the pigs had seroconverted with HI titers of 1:64 to 1:512. Infection resulted in a marked booster effect and at slaughter, the mean titer was 1:1722. In controls, all the animals at slaughter had high titers with most being above 1:4096. In the 2nd study, all unvaccinated pigs experimentally infected with ERY displayed the typical severe clinical signs (temperature above 40 deg, lethargy) and skin lesions of the disease. In contrast, none of these were observed in the vaccinated pigs subsequently infected with ERY.

L11 ANSWER 7 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1997-63620 VETU
TITLE: The prevention of atrophic rhinitis in swine by vaccination with Rhinogen CTE 5000.
AUTHOR: Udovicic I; Bilic V; Valpotic I; Vrbanac I; Lausin M
CORPORATE SOURCE: Croatian-Vet.Inst.; Univ.Zagreb
LOCATION: Zagreb, Croatia
SOURCE: Proc.Int.Pig Vet.Soc.Congress (14 Meet., 255, 1996) 1 Tab. 3 Ref.
AVAIL. OF DOC.: Croatian Veterinary Institute, Zagreb, Croatia.
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
AN 1997-63620 VETU
AB In an intensive rearing pig farm in Croatia during an outbreak of atrophic rhinitis (AR) for which enrofloxacin (Enroxil, Krka) had been given, vaccination of sows i.m. and offspring s.c. with AR vaccine (Rhinogen CTE 5000, Upjohn) effectively prevented symptoms. There were no side effects of the vaccine. The vaccine contained Bordetella bronchiseptica, **Erysipelothrix rhusiopathiae** and Pasteurella multocida serotypes D bacterin-toxoid adsorbed on **aluminum hydroxide** gel adjuvant. Enroxil given at the beginning of the outbreak prevented and controlled AR on the farm; Rhinogen, along with chemotherapy, seems to be an effective means of control of AR in pigs. (conference abstract).
ABEX In 1995 the farm (360 sows/gilts) had 20% of pigs with clinical AR and was treated with Enroxil. 10 Sows received 2 ml Rhinogen at and 2 wk after farrowing; their 67 suckling offspring received 2 ml vaccine at 7 and 28 days-old. 10 Sows and their offspring served as unvaccinated controls. No adverse reactions were seen at the injection site or systemically. Weight gain, farrowed, liveborn, stillborn, weaned and prefattener pigs/litter did not differ between treated and control groups. From birth to 115 days-old, 3.65% control vs. 0 treated pigs showed sneezing,

snuffling, serous nasal discharge and copious shed of tears, and 1.2% vs. 0 showed deformed nasal bones and marked brachygnathia. .

L11 ANSWER 8 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1996-60759 VETU
TITLE: Growth ability and immunological properties of **Erysipelothrix rhusiopathiae** serotype 2.
AUTHOR: Zarkasie K; Sawada T; Yoshida T; Takahashi I; Takahashi T
CORPORATE SOURCE: Univ.Nippon-Vet.+Anim.Sci.
LOCATION: Tokyo, Jap.
SOURCE: J.Vet.Med.Sci. (58, No. 1, 87-90, 1996) 3 Fig. 2 Tab. 24 Ref.
AVAIL. OF DOC.: Department of Veterinary Microbiology, Nippon Veterinary and Animal Science University, Musashino, Tokyo 180, Japan.
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
AN 1996-60759 VETU
AB The growth ability and immunogenicity of **Erysipelothrix rhusiopathiae** serotype 2 strains are reported. The strains grew better in tryptose phosphate broth (TPB) than Feist medium. After 20 hr culture, the strains were inactivated with formalin (Wako-Pure-Chem.) and emulsified with **aluminum hydroxide** gel (Nippon). In mice vaccinated s.c. and then challenged, the most effective strain was Tama-96 followed by Shizuoka-63, 82-510, 82-527 and strain 44. Tama-96 prepared from brain heart infusion (BHI) with 10% horse serum was more immunogenic than vaccines prepared in BHI plus Tween 80 or Feist medium. Western blots revealed no quantitative or qualitative differences between strains and that the 66 to 64 kDa proteins predominated.
ABEX **E. rhusiopathiae** strains 82-510, 82-527, 44, Shizuoka-63 and Tama-96 and 2 reference strains (Kg-2, SE-9) were grown in modified Feist medium or tryptose phosphate broth (TPB, plus Tween-80) at 37 deg for 23 hr. SDS-PAGE and immunoblotting were performed on solubilized cell surface proteins. Cultures (20 hr) of each strain were inactivated with formalin and mixed with 1:5 v/v **aluminum hydroxide** gel.
Female mice (5-wk-old) were inoculated s.c. with 0.5 ml vaccine diluted serially in 33% **aluminum hydroxide** gel and 3 wk later challenged with virulent strain Fujisawa (6.5 x 10 power 3 CFU/ml). All strains except for strain 82-150 were in the logarithmic phase by 4 hr of incubation while stationary phase cultures were only detected in TPB (vs. Feist) by 23 hr. Western blots revealed no quantitative or qualitative differences between strains. Protein of 66 to 64 kDa were dominant while 76, 74, 56, 45 and 38 kDa proteins were also identified. In mice, the most effective strain was Tama-96 (PD50 12 ul) followed by Shizuoka-63 (PD50 32 ul), 82-510 and 82-527 (both 45 ul) and strain 44 (117 ul). Tama-96 vaccine prepared from brain heart infusion (BHI) with 10% horse serum was more immunogenic than vaccines prepared in BHI plus Tween 80 or Feist medium.

L11 ANSWER 9 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1995-63559 VETU

TITLE: Protective activity and antigenic analysis of fractions of culture filtrates of **Erysipelothrix rhusiopathiae**.
AUTHOR: Sato H; Hirose K; Saito H
CORPORATE SOURCE: Univ.Kitasato
LOCATION: Aomori, Jap.
SOURCE: Vet.Microbiol. (43, No. 2-3, 173-82, 1995) 4 Fig. 2 Tab. 10 Ref.
CODEN: VMICDQ
AVAIL. OF DOC.: Department of Veterinary Microbiology, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori 034, Japan.
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
AN 1995-63559 VETU
AB The protective activity and antigenic analysis of fractions of culture filtrates of 11 **Erysipelothrix rhusiopathiae** strains are reported. In SPF mice, protection was achieved using the first (P-1) fraction obtained by Sephadex G-200 gel filtration of culture filtrate. In active and passive immunization trials, s.c. strain Agata, Fujisawa, Koganei 65-0.15 and SE-9 P-1 fractions were protective while in active immunization trials, strain Schizuoka-63 P-1 was also effective. Growth agglutination (GA) titers of protective antisera ranged from 80 to 320. Electrophoresis showed over 20 bands in each strain and Western blot analysis showed that protective antisera reacted with the 64 and 43 kDa proteins.
ABEX Culture filtrate from 11 strains of **E. rhusiopathiae** was fractionated and fractions concentrated by ultrafiltration. SPF female mice (4-wk-old) were injected s.c. with 250 ug strain Koganei 65-0.15 P-1 or P-2 fraction in **aluminum phosphate** gel and challenged s.c. 3 wk later with strain Fujisawa (1 x 10 power 3 CFU). In active immunization ED50 trials, mice were injected s.c. with 100, 20 or 4 ug P-1 of 1 of the 11 strains in **aluminum phosphate** gel and challenged as above. Antisera against P-1 fraction was raised in mice given 200 ug P-1 in Freund's complete adjuvant twice over 2 wk. In passive immunization ED50 trials, 1:1, 1:10, 1:100, 1:1000 and 1:10,000 diluted antisera was injected s.c. 4 hr before challenge. Only fractions P-1 and P-2 were eluted from culture filtrates and only fraction P-1 protected mice against challenge. The P-1 protein content was highest for strain Shizuoka-63 (7.1 ug) and was 2.2 to 4.6 mg for the other strains. In active immunization trials, PD50 was low at 2 ug or less for strains Agata, Fujisawa, Shizuoka-63, Koganei-65-0.15 and SE-9. In passive immunization trials, PD50 was highest for strains Agata and SE-9 while all strains except for 2179 and 2553 showed protective activity. GA titers of protective antisera ranged from 80 to 320. Electrophoresis of sonicated antigens showed over 20 bands in each strain and bands of 76 to 26 kDa. Western blot analysis showed that protective antisera reacted with the 64 and 43 kDa proteins.

L11 ANSWER 10 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1995-61995 VETU
TITLE: Prevention of clinical outbreak of erysipelas caused by **E. rhusiopathiae** type 10.

AUTHOR: Riising H J; Horslund Pedersen E
CORPORATE SOURCE: Intervet
LOCATION: Copenhagen; Logstrup, Den.
SOURCE: Int.Pig Vet.Soc.Congress (13 Meet., 228, 1994) 2 Tab. 2 Ref.
AVAIL. OF DOC.: Intervet Scandinavia AS, Copenhagen, Denmark.
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
AN 1995-61995 VETU
AB In a pig herd with a clinical outbreak of erysipelas despite routine vaccination with a conventional vaccine, subsequent vaccination with Combinord, a formalin inactivated vaccine containing **Erysipelothrix rhusiopathiae** types 2 and 10 and Haemophilus parasuis antigens and Alhydrogel ( **aluminum hydroxide**) adjuvant, allowed no further outbreaks. Vaccination with a conventional vaccine containing only type 2 cells allowed further infections. Combinord induced antibodies against both serotypes, while type 2 or type 10 vaccines showed higher responses to the homologous antigen. There were no side effects. (conference abstract).
ABEX Sows vaccinated with a conventional vaccine yrly developed occasional outbreaks of erysipelas caused by serotypes 10 and/or 11. 12, 7, 2 And 7 pigs were vaccinated with Combinord, type 2 or type 10 vaccine or unvaccinated, respectively. ELISA titers to type 2 were 10, 38.8, 6.9 and 1.9, respectively, and to type 10 were 13, 16.9, 21.3 and 1.8, respectively. 135 Sows were then vaccinated with Combinord and 138 with the conventional type 2 vaccine. They had 1393 vs. 1430 live piglets. Clinical erysipelas developed in 0 and 3 cases, respectively, all showing type 10 or type 10/11 antigens.

L11 ANSWER 11 OF 23 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1993-182249 [22] WPIDS
CROSS REFERENCE: 1992-024125 [03]
DOC. NO. CPI: C1993-080684
TITLE: Pasteurella multocida typed strain 4677 bacterin vaccine - contain bordetella bronchiseptica and/or **erysipelothrix rhusiopathiae** bacterins used to inoculate animals against atropic rhinitis and erysipelas.
DERWENT CLASS: B04 C06 D16
INVENTOR(S): FRANTZ, J C; KEMMY, R J; ROBERTS, D S; SWEARINGIN, L A
PATENT ASSIGNEE(S): (PFIZ) PFIZER INC; (SMIK) SMITHKLINE BEECHAM CORP
COUNTRY COUNT: 20
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---|---|---|---|---|---|
| WO 9309809 | A1 | 19930527 | (199322)* | EN | 66 |
| RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE | | | | | |
| W: AU CA JP US | | | | | |
| AU 9331430 | A | 19930615 | (199340) | | |
| EP 614371 | A1 | 19940914 | (199435) | EN | |
| R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE | | | | | |
| JP 07501334 | W | 19950209 | (199515) | | |
| EP 614371 | A4 | 19950607 | (199616) | | |

AU 669681 B 19960620 (199632)
US 5695769 A 19971209 (199804) 14

APPLICATION DETAILS:

| PATENT NO | KIND | | APPLICATION | DATE |
|---|---|---|---|---|
| WO 9309809 | A1 | | WO 1992-US10008 | 19921113 |
| AU 9331430 | A | | AU 1993-31430 | 19921113 |
| EP 614371 | A1 | | EP 1992-925340 | 19921113 |
| | | | WO 1992-US10008 | 19921113 |
| JP 07501334 | W | | WO 1992-US10008 | 19921113 |
| | | | JP 1993-509531 | 19921113 |
| EP 614371 | A4 | | EP 1992-925340 | |
| AU 669681 | B | | AU 1993-31430 | 19921113 |
| US 5695769 | A | CIP of | US 1990-537454 | 19900613 |
| | | Cont of | US 1991-792490 | 19911115 |
| | | | WO 1992-US10008 | 19921113 |
| | | | US 1994-244052 | 19940711 |

FILING DETAILS:

| PATENT NO | KIND | | PATENT NO |
|---|---|---|---|
| AU 9331430 | A | Based on | WO 9309809 |
| EP 614371 | A1 | Based on | WO 9309809 |
| JP 07501334 | W | Based on | WO 9309809 |
| AU 669681 | B | Previous Publ. | AU 9331430 |
| | | Based on | WO 9309809 |
| US 5695769 | A | CIP of | US 5536496 |
| | | Based on | WO 9309809 |

PRIORITY APPLN. INFO: US 1991-792490 19911115; US 1990-537454 19900613; US 1994-244052 19940711

AN 1993-182249 [22] WPIDS
CR 1992-024125 [03]
AB WO 9309809 A UPAB: 19980316
Vaccine compsn. comprises a Pasteurella multocida type D strain 4677 bacterin with a cell-bound toxoid, which upon admin. neutralised antibody to the toxin.

Also claimed are: (1) a P.multocida type D strain 4677 bacterin with a cell-bound toxoid, which on admin. to an animal induced the prodn. of neutralising antitoxin; (2) a vaccine compsn. comprising the bacterin of (1) and a P.multocida soluble free toxoid; and (3) a vaccine compsn. comprising the components of (2) and a Bordetella bronchiseptica bacterin and an Arysipelothrix rhusiopathiae bacterin.

The vaccine is pref. produced by treating P. multocida in the exponential phase of growth with formaldehyde to inactivate the intracellular toxin. The vaccine dosage comprises 0.5-3 ml of a sterile suspension of an immunogenic amt. of the P. multocida bacterin with cell-bound toxoid, esp. 150 relative toxoid units/ml free toxoid. The vaccine also comprises an adjuvant, pref. **Al(OH)**4, a saponin, Mg(OH)2, **Al phosphate**, Mg phosphate or a Ca cpd..

USE/ADVANTAGE - The vaccines are used to vaccinate animals against atropic rhinitis and erysipelas. The vaccine is storage stable at 4 deg.C for at least 24 hours. Free and cell-bound toxoids

have been seen to act synergistically in a single prepn.. Other vaccine components include E. coli, pneumonic P. multocida, Streptococcus suis, Actinobacillus pleuropneumoniae, Clostridium perfringens C and D toxoids, pseudorabies virus (modified live and/or killed virus), rotavirus vaccine (modified live), coronavirus vaccine (modified live virus) and M. hyopneumoniae. Swine are pref. vaccinated at 1 week of age, with a booster dose at weaning age. Pregnant dams are given 2 doses, with the last given 2 weeks before farrowing. Booster doses are given prior to each subsequent farrowindy

Dwg.0/0

ABEQ US 5695769 A UPAB: 19980126

Vaccine compsn. comprises a Pasteurella multocida type D strain 4677 bacterin with a cell-bound toxoid, which upon admin. neutralised antibody to the toxin.

Also claimed are: (1) a P.multocida type D strain 4677 bacterin with a cell-bound toxoid, which on admin. to an animal induced the prodn. of neutralising antitoxin; (2) a vaccine compsn. comprising the bacterin of (1) and a P.multocida soluble free toxoid; and (3) a vaccine compsn. comprising the components of (2) and a Bordetella bronchiseptica bacterin and an Arysipelothrix rhusiopathiae bacterin.

The vaccine is pref. produced by treating P. multocida in the exponential phase of growth with formaldehyde to inactivate the intracellular toxin. The vaccine dosage comprises 0.5-3 ml of a sterile suspension of an immunogenic amt. of the P. multocida bacterin with cell-bound toxoid, esp. 150 relative toxoid units/ml free toxoid. The vaccine also comprises an adjuvant, pref. **Al(OH)**4, a saponin, Mg(OH)2, **Al phosphate**, Mg phosphate or a Ca cpd..

USE/ADVANTAGE - The vaccines are used to vaccinate animals against atropic rhinitis and erysipelas. The vaccine is storage stable at 4 deg.C for at least 24 hours. Free and cell-bound toxoids have been seen to act synergistically in a single prepn.. Other vaccine components include E. coli, pneumonic P. multocida, Streptococcus suis, Actinobacillus pleuropneumoniae, Clostridium perfringens C and D toxoids, pseudorabies virus (modified live and/or killed virus), rotavirus vaccine (modified live), coronavirus vaccine (modified live virus) and M. hyopneumoniae. Swine are pref. vaccinated at 1 week of age, with a booster dose at weaning age. Pregnant dams are given 2 doses, with the last given 2 weeks before farrowing. Booster doses are given prior to each subsequent farrowindy

Dwg.0/0

L11 ANSWER 12 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1992-61129 VETU
TITLE: Priming Defences Against the Challenge of Disease.
AUTHOR: Walkland C
LOCATION: U.K.
SOURCE: Pig Farming (40 No. 3, 36-37, 1992)
AVAIL. OF DOC.: No Reprint Address.
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT

AN 1992-61129 VETU

AB The production of a combined E. coli and erysipelas vaccine is described. The vaccine contains **Erysipelothrix**

**rhusiopathiae** serotypes 1 and 2, E. coli antigens K88ab, K88ac, K99 and 987P, labile toxin B fragment and 12 strains of inactivated whole E. coli bacteria. The total production time for manufacture of the vaccine is 12 wk from the beginning of antigen production to dispatch.

ABEX The first combined E. coli and erysipelas vaccine has recently been launched. It contains **E. rhusiopathiae** serotypes and 2 and selected E. coli antigens K88, K99, 987P and labile toxin B fragment (LTB). It also contains 12 strains of inactivated whole E. coli bacteria. The whole cells provide added protection against less common diseases such as septicemia and endotoxin-mediated edema disease. LTB is included because some E. coli strains contain a toxin which disrupts the ionic balance in the gut, resulting in diarrhea. Specific antibodies to sub unit B, produced in response to the LTB in the vaccine, inhibit the attachment of the toxin to the gut wall. The antigen K88 also inhibits initial bacterial colonization. There are 22 serotypes of **E. rhusiopathiae**, the most important being serotype 2. Vaccines containing serotype 2 will protect against most other serotypes, but an increased incidence of serotype 1 infection prompted the incorporation of serotype 1 antigens into the vaccine. Production of each antigen can take between 2 and 14 days. For E. coli antigens, the pili are stripped off the bacterial surface and centrifuged and then inactivated with formaldehyde. Several weeks of potency and sterility tests then take place; there are over 100 quality tests for each batch of vaccine. Each batch of vaccine is 1800 l in volume, equivalent to 36,000 bottles. The antigens are then blended with a preservative, thiomersal, and added to a base of **aluminum hydroxide** gel. Further potency tests, taking up to 5 wk, are carried out and sterility is again tested. Total production time from antigen production to distribution is 12 wk. (CLW)

L11 ANSWER 13 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1990-63448 VETU M
TITLE: Cloning and Expression in Escherichia coli of a Protective Antigen of **Erysipelothrix rhusiopathiae**.
AUTHOR: Galan J E; Timoney J F
LOCATION: Ithaca; Stony Brook, N.Y., USA
SOURCE: Infect.Immun. (58, No. 9, 3116-21, 1990) 5 Fig. 2 Tab. 34 Ref. (J35/VDM)
CODEN: INFIBR
AVAIL. OF DOC.: Department of Veterinary Microbiology, New York State College of Veterinary Medicine, Cornell University, Ithaca, New York 14853, U.S.A.
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
AN 1990-63448 VETU M
AB S.c. immunization of mice with either of 2 clones (lambda gt11/ersA and lambda gt11/ersB from a lambda gt11 library of **Erysipelothrix rhusiopathiae** gave partial protection against subsequent challenge. Antisera raised in guinea pigs against the recombinant clones reacted with polypeptides of 66, 64 and 43 kDa. These polypeptides were also the major bands detected by convalescent pig serum. Mice immunized with both recombinant clones had a higher survival rate, than those immunized

with the negative control (lambda gt11). Western and Southern blot analysis revealed that the cloned genes were present in all of the **E. rhusiopathiae** strains examined.

ABEX Inbred ICR female mice (8 wk-old) were immunized s.c. with recombinant proteins (500 ug) in **aluminium hydroxide** on 2 occasions 15 days apart. Mice were then challenged with 100 x 50% lethal dose of **E. rhusiopathiae** E1-6P. Antisera against recombinant proteins was produced by s.c. inoculation of guinea pigs with protein (500 ug) in Freunds complete adjuvant. Mice immunized with recombinant proteins had a significantly increased mean time to death (6.4 and 6.5 for the 2 clones) compared to controls (4.3 days). No survivors were seen in micer immunized with lambda gt11 alone although the survival rates for lambda gt11/ersB and lambda gt11/ersA were 14 and 17%, respectively. Agarose gel electrophoresis of EcoR1 digests of the 2 clones suggested that they were identical.

L11 ANSWER 14 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1990-61127 VETU M T
TITLE: Value and Limitations of Vaccines and of Vaccination of Pigs.
(Interet et Limites des Vaccins et de la Vaccination chez le Porc)
AUTHOR: Laval A
LOCATION: Maisons Alfort, Fr.
SOURCE: Recl.Med.Vet. (165, No. 8-9, 697-706, 1989) 2 Fig. 3 Tab. 82 Ref. (M25/JLC)
CODEN: RMVEAG
AVAIL. OF DOC.: Service de Pathologie Medicale du Betail et des Animoux de Bosse-Cour, Ecole Nationale Veterinaire d'Alfort, 94704 Maisons Alfort Cedex, France.
LANGUAGE: French
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
AN 1990-61127 VETU M T

AB The causes of vaccination failure in the pig are reviewed. The vaccine virus, vaccine type, protocol, rearing conditions, concomitant therapy (antibiotics), toxic factors (aflatoxin, T2 toxin or ochratoxin A), pollutants (polychlorobiphenyls or PCB, Pb, Cd and DDT) and nutritional factors (deficiency in vitamins A, D or E, Se, Cu, Zn, Fe or Co) are all implicated in vacine failure. Problems with Aujeszky disease, Treponema hyodysenteriae, edema disease (E. coli vaccine), Strept. suis type 2, Actinobact. parasuis or pleuropneumoniae, **Erysipelothrix rhusiopathiae**, TGE, FMD, swine fever, porcine parvovirus, influenza and atrophic rhinitis vaccines are discussed. Local intolerance is more common with oil-adjuvanted inactivated vaccines, but general intolerance may be unavoidable.

ABEX Only inactivated FMD or live swine fever vaccines afford full protection and prevent viral shedding. E. coli 0139 K82 Ent-K88 glutaraldehyde-inactivated vaccine (edema disease) almost eliminates mortality and reduces symptoms, but not viral replication. Oil-adjuvanted inactivated Treponema vaccine induces diarrhea. Inactivated **Al-hydroxide**-adjuvanted A. parasuis vaccine eliminates symptoms, mortality and bacteriosis. The only pathogen-related vaccinal failure concerns African swine fever. A. pleuropneumoniae vaccination is often ineffective due to

the abundance of field serotypes and **E. rhusiopathiae** type 2 does not protect against types 9 or 10. Live virus must be adaptable to antigenic variations. In inactivated vaccines, **Al-hydroxide** adjuvant is unsatisfactory in the pig, while oil-adjuvant can cause local intolerance, especially with hypersensitizing bacterial antigen (Actinobac.), intradermal injection avoids this problem. Animal-related failures include those due to poor physiological status, environment, concomitant therapy, toxic factors, pollutants or a deficiency in vitamins A, D or E, Se, Zn, Cu, Fe or Co. General intolerance must be balanced against the benefit of vaccination, but may be minimized by dietary adaptation. Vaccinal cell lines or immune sera may be contaminated by bovine viral diarrhea or Border disease and trypsin by porcine coronavirus. Live vaccines may themselves spread infection.

L11 ANSWER 15 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1989-61034 VETU M
TITLE: Use of a Live Oral Vaccine to Immunize Turkeys against Erysipelas.
AUTHOR: Bricker J M; Saif Y M
LOCATION: Wooster, Ohio, USA
SOURCE: Avian Dis. (32, No. 4, 668-73, 1988) Tab. 15 Ref. CODEN: AVDIAI
AVAIL. OF DOC.: Food Animal Health Research Program, and Department of Poultry Science, Ohio Agricultural Research and Development Center, Ohio State University, Wooster, Ohio 44691, U.S.A. (Y.M.S.).
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
AN 1989-61034 VETU M
AB Medium-bodied white (EL) and broad-breasted large white young SPF turkeys vaccinated p.o. with Hydrovac (live **Erysipelothrix rhusiopathiae** serotype 1a, Anchor) comprising 1 to 3 doses administered 2 to 3 wk apart or s.c. with the inactivated **aluminum-hydroxide** absorbed erysipelas bacteria Ersipelin (Am.Home-Products) were protected against challenge with **E. rhusiopathiae** serotype 1a (VS). The live bacterin-production strain of **E. rhusiopathiae** serotype 2 (EW-2, Franklin) was not effective as a vaccine. The results indicate the potential usefulness of a p.o. live vaccine in erysipelas control in turkeys.
ABEX EL and SPF turkeys (5 to 9 wk-old) received s.c. Ersipelin or various doses of Hydrovac (8.8 x 10 power 9, 7 or 5 CFU) or EW2 (2.2 x 10 power 9 or 2.5 x 10 power 7 CFU) p.o. in drinking water with skimmed milk (1.3 g/L). Birds were challenged with 1 ml s.c. VS either from broth culture or twice yolk passaged. 31-95% Unvaccinated challenged EL or SPF turkeys died with generalized septicemia 40-96 hr post challenge with VS. Vaccinees that died had similar clinical signs. **E. rhusiopathiae** was isolated from the liver, heart blood, lung and spleen of all birds that died after challenge. Only 1 bird (EL) given E did not survive. Hydrovac at 8.8 x 10 power 9 CFU did not protect EL birds from VS challenge (9.6 x 10 power 4 CFU) but 2 doses 3 wk apart did. Hydrovac at 8.8 x 10 power 9 CFU or EW-2 (2.2 x 10 power 9 CFU), or 2 doses EW-2 3 wk apart (2nd dose 2.5 x 10 power 7 CFU) did not protect SPF birds but 2 doses Hydrovac 3 wk apart did. EL

birds given 1, 2 or 3 p.o. doses Hydrovac (8.6 x 10 power 9 CFU) over 6 hr were not protected from VS (3.2 x 10 power 9 CFU) 3 wk later but a 2nd treatment with 2 or 3 doses was effective. 1 Treatment of 2 doses Hydrovac given over 48 hr was not effective whilst 2 treatments 3 wk apart were. 2 Treatments 3 wk apart of 2 doses Hydrovac (8.8 x 10 power 9 CFU) 3 hr apart protected EL birds against VS (1.4 x 10 power 9 CFU) after 2 wk. Birds given lower vaccine doses were not protected. SPF birds treated similarly but with 2 wk between treatments and 4.3 x 10 power 9 CFU Hydrovac/dose were protected following challenge.5

L11 ANSWER 16 OF 23 CABA COPYRIGHT 2001 CABI
ACCESSION NUMBER: 84:126993 CABA
DOCUMENT NUMBER: 842248940
TITLE: Swine erysipelas vaccine as a model of study of enhanced immunogenic activity owing to a double adjuvant
AUTHOR: Seimenis, A.; Skyrianos, G.; Menasse, I.; Stoforos, E.; F.M. Cancellotti [EDITOR]; D. Galassi [EDITOR]
CORPORATE SOURCE: Vet. Inst. Infectious Parasitic Dis., Min. Agric., Athens, Greece.
SOURCE: (1984) pp. 203-208. 8 ref.
Publisher: Commission of the European Communities.
Meeting Info.: Agriculture-adjuvants, interferon and non-specific immunity. A seminar in the CEC Programme of Coordination of Research on Animal Pathology, Venice, April 1983.
PUB. COUNTRY: Luxembourg
DOCUMENT TYPE: Miscellaneous
LANGUAGE: English
AB The immunogenicity of an inactivated **Erysipelothrix rhusiopathiae** vaccine was improved by adding 15% **aluminium hydroxide** gel, and an oil mixture (Bayol F 8.5 parts, Arlacel A 1.5 parts). Efficacy of the vaccine with and without the adjuvants was tested in mice and swine challenged with **E. rhusiopathiae** 21 days after vaccination. The vaccine caused no adverse effects.

L11 ANSWER 17 OF 23 VETU COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1984-62439 VETU M T
TITLE: Swine Erysipelas-a Review of Prevalence and Research.
AUTHOR: Wood r L
LOCATION: Ames, Iowa, USA
SOURCE: J.Am.Vet.Med.Assoc. (184, No. 8, 944-49, 1984) 4 Fig. 2 tab. 63 Ref
CODEN: JAVMA4
AVAIL. OF DOC.: National Animal Disease Center, Agricultural Research Service, USDA, PO Box 70, Ames, IA 50010, U.S.A.
LANGUAGE: English
DOCUMENT TYPE: Journal
FIELD AVAIL.: AB; LA; CT
AN 1984-62439 VETU M T
AB A review of swine erysipelas is presented with regard to incidence in USA, etiology, immunology, epizootiology, pathogenesis, and vaccine development.

ABEX Heat stable antigens consisting of fragments of the cell wall form he basis for division of the species into serotypes. the glycolipoprotein is an essential component of whole-culture bacterins. methods for attenuation of **Erysipelothrix rhusiopathiae** have included air-drying and passage in media containing acridine dyes. Avirulent vaccine is used in both parenteral and oral dosage forms. Aerosol vaccination is used in some parts of Europe and USSR. A bacterin consisting of formalin-killed whole culture adsorbed an **aluminum hydroxide** gel is usually made from selected strains of serotype 2. Most of the immunizing antigen is found in the culture filtrate. There have been no significant differences found in the efficacy of avirulent live vaccines and bacterins under experimental conditions. Inactivated cells of Corynebact. spp. given with **E. rhusiopathiae** bacterin raised the potency of the bacterin in mice 1.35 to 2.15 times.

L11 ANSWER 18 OF 23 BIOSIS COPYRIGHT 2001 BIOSIS
ACCESSION NUMBER: 1985:391670 BIOSIS
DOCUMENT NUMBER: BA80:61662
TITLE: THE INFLUENCE OF IMMUNOMODULANTS ON THE DEVELOPMENT OF SECONDARY-TYPE ANTIBACTERIAL ANTI **ERYSIPELOTHRIX-RHUSIOPATHIAE** IMMUNITY.
AUTHOR(S): KULCSAR A; PADANYI M; RETHY L A; RETHY L; BACSKAI L
CORPORATE SOURCE: PHYLAXIA, SZALLAS-U 5., H-1107 BUDAPEST, HUNGARY.
SOURCE: ANN IMMUNOL HUNG, (1984 (RECD 1985)) 24 (0), 171-176. CODEN: AIMHA3. ISSN: 0570-1708.
FILE SEGMENT: BA; OLD
LANGUAGE: English
AB The influence of Corynebacterium parvum (Propionibacterium acnes) and C. lymphophylum-originating immunomodulants on the development of the secondary type antibacterial immunity as investigated. As test antigen, E. **rhusiopathiae bacterium** was applied (3 .times. 109 inactivated bacterial cells, absorbed onto aluminium **hydroxide carrier**). The adjuvant-type immuno modulating activity of the immuno modulants was present if given mainly prior to, or together with the 1st immunization (priming) with the bacterium.

L11 ANSWER 19 OF 23 BIOSIS COPYRIGHT 2001 BIOSIS
ACCESSION NUMBER: 1984:267008 BIOSIS
DOCUMENT NUMBER: BA78:3488
TITLE: IMMUNO MODULATION WITH INACTIVATED BACTERIUM SUSPENSIONS OR DERIVATIVES 2. THE INFLUENCE OF CORYNEBACTERIUM SUSPENSIONS ON THE DEVELOPMENT OF PRIMARY TYPE ANTI TOXIC AND ANTI BACTERIAL IMMUNITY.
AUTHOR(S): SOLTENSZKY J; RAJHATHY B; GERESI M; ECSI R; PADANYI M; RETHY L A JR; KULCSAR A; GELENCSER F; HEGEDUS L; ET AL
CORPORATE SOURCE: HUMAN INST. SEROBACTERIOL. PRODUCTION RES., LAB. NO. 229., DEP. ACTIVE IMMUNIZATION, DEP. BIOL. CONTROL.
SOURCE: ANN IMMUNOL HUNG, (1980 (1983)) 20 (0), 97-108. CODEN: AIMHA3. ISSN: 0570-1708.
FILE SEGMENT: BA; OLD
LANGUAGE: English
AB Having investigated the influence of Corynebacterium suspensions on the development of primary type antitoxic and antibacterial immunity

[in mice] the results can be summarized as follows. The immunizations were carried out with the following vaccines: **aluminium-phosphate**-adsorbed tetanus toxoid, **aluminium-hydroxide** adsorbed perfringens epsilon toxoid and **aluminium-hydroxide** adsorbed **Erysipelothrix rhusiopathiae** vaccine. All the vaccines were tested in active immunization toxin virulent bacterium challenge model. The results concerning the effect of corynebacterial immunostimulants/modulators on the development of anti-tetanus (primary-type) antitoxic immunity unanimously show that the corynebacterial immunostimulants except 1 strain generally increase the degree of protection against tetanus in case of joint application with tetanus toxoid. Among the Corynebacterium strains investigated, only C. parvum RR-1 [Propionibacterium acnes] exhibited an adjuvant effect on the development of the primary antitoxin immunity against perfringens epsilon toxin. One of the 2 C. parvum strains suppressed both the development of tetanus and anti-perfringens primary immune responses. The C. parvum RR-1 potentiated while the unrelated C. parvum RR-1-2 suppressed the immune reactions. Results concerning the development of antibacterial immunity show that immunological adjuvanting effect could be demonstrated if the vaccine was administered simultaneously with the immunomodulator. The subsequent application suppressed the development of the primary anti-**E. rhusiopathiae** immunity.

L11 ANSWER 20 OF 23 CABA COPYRIGHT 2001 CABI
ACCESSION NUMBER: 80:123255 CABA
DOCUMENT NUMBER: 802257219
TITLE: Comparison of the efficacy of swine erysipelas vaccines
Sravnitel'naya effektivnost vaktsin protiv rozhi
AUTHOR: Konyaev, M. T.; Shcherbinin, V. K.
CORPORATE SOURCE: Vses. Inst. Nezaraznykh Boleznei Zhivotnykh, Voronezh, USSR.
SOURCE: Veterinariya, Moscow, USSR, (1980) No. 3, pp. 33-34.
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB Trials were conducted on 500 pigs aged 10-14 weeks with the classical "depot" vaccine of D.F. Konev (1899), live attenuated "VR-2" vaccine, and a concentrated **aluminium hydroxide** vaccine, all three in various doses, with a second dose being given 14, 30 or 46 days after the first. Challenge infection by i/m inoculation of 800 million **E. rhusiopathiae** was done 62 days after the first vaccination. Protection was best with the live vaccine in a dose of 0.5-1.0 ml, with a second dose given after 30 or 46 days.

L11 ANSWER 21 OF 23 VETB COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1981-62260 M T
TITLE: EFFECTS OF ANTIBIOTICS ON THE IMMUNE SYSTEM OF ANIMALS. I. MOUSE EXPERIMENTS WITH THE LOW-VIRULENCE VR2 STRAIN OF **ERYSIPELOTHRIX RHUSIOPATHIAE**. II. MOUSE EXPERIMENTS WITH AN INACTIVATED ADSORBED VACCINE AGAINST SWINE ERYSIPELAS. III. EXPERIMENTS IN PIGS IMMUNIZED WITH LIVE AND INACTIVATED SWINE

ERYSIPELAS VACCINES.
AUTHOR: TU T D
LOCATION: BUDAPEST,HUNG.
SOURCE: ACTA VET. ACAD.SCI.HUNG. (28, NO.3, 297-331, 1980)
LANGUAGE: English

L11 ANSWER 22 OF 23 VETB COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1981-62257 M
TITLE: THE DEVELOPMENT OF PRIMARY ANTIBACTERIAL IMMUNE PROTECTION AGAINST **ERYSIPELOTHRIX RHUSIOPATHIAE** AND THE EFFECT OF ANAEROBIC CORYNEBACTERIAL IMMUNOSTIMULANTS.
AUTHOR: PADÁNYI M
CORPORATE SOURCE: PHYLAXIA
LOCATION: BUDAPEST,HUNG.
SOURCE: ACTA VET.ACAD.SCI.HUNG. (28, NO.3, 273-75, 1980)
LANGUAGE: English

L11 ANSWER 23 OF 23 JAPIO COPYRIGHT 2001 JPO
ACCESSION NUMBER: 2000-219637 JAPIO
TITLE: **ERYSIPELOTHRIX RHUSIOPATHIAE** ANTIGEN COMPOSITION AND VACCINE PREPARATION
INVENTOR: DAVID STEWART ROBERTS; SWEARINGIN LEROY A; BRIAN THOMAS SUIITAA
PATENT ASSIGNEE(S): PFIZER PROD INC)
PATENT INFORMATION:

| PATENT NO | KIND | DATE | ERA | MAIN IPC |
|---|---|---|---|---|
| JP 2000219637A | | 20000808 | Heisei | A61K039-02 |

JP
APPLICATION INFORMATION
ST19N FORMAT: JP2000-017930 20000124
ORIGINAL: JP2000017930 Heisei
PRIORITY APPLN. INFO.: US1999 117704 19990129
SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 2000

AN 2000-219637 JAPIO
AB PROBLEM TO BE SOLVED: To obtain the subject vaccine composition that is useful as a vaccine for vaccinating animals, preferably mammalians or birds by using a fluid fraction originating from a specific culture mixture and stabilizers.
SOLUTION: This vaccine composition comprises (A) a fluid fraction originating from the culture mixture of **Erysipelothrix rhusiopathiae** (swine erysipelas) and (B) a stabilizer. The component B is selected from **metal hydroxides, metal phosphates, aluminum hydroxide** gel, **aluminum phosphate** gel, **calcium phosphate** gel, **zinc hydroxide/calcium hydroxide** gel or **alum**. In the component B, the culture mixture is deactivated with formalin or β-propiolactone and the fraction is preferably concentrated in 3-30 times. For example, the **aluminum hydroxide** gel is added on the concentrate of the culture mixture so that the final concentration may reach about 10-40 vol.%.

(FILE 'CAPLUS' ENTERED AT 12:33:02 ON 17 OCT 2001)

L1 7 SEA FILE=REGISTRY ABB=ON PLU=ON ("ALUMINUM HYDROXIDE"/CN OR "ALUMINUM HYDROXIDE (AL(18OH)3)"/CN OR "ALUMINUM HYDROXIDE (AL(OD))"/CN OR "ALUMINUM HYDROXIDE (AL(OD)2)"/CN OR "ALUMINUM HYDROXIDE (AL(OD)3)"/CN OR "ALUMINUM HYDROXIDE (AL(OH))"/CN OR "ALUMINUM HYDROXIDE (AL(OH)2)"/CN OR "ALUMINUM HYDROXIDE (AL(OH)3)"/CN)

L2 6 SEA FILE=REGISTRY ABB=ON PLU=ON ("CALCIUM HYDROXIDE"/CN OR "CALCIUM HYDROXIDE (40CA(OH))"/CN OR "CALCIUM HYDROXIDE (CA(OD))"/CN OR "CALCIUM HYDROXIDE (CA(OD)2)"/CN OR "CALCIUM HYDROXIDE (CA(OH)(OT))"/CN OR "CALCIUM HYDROXIDE (CA(OH))"/CN OR "CALCIUM HYDROXIDE (CA(OH)2)"/CN)

L3 4 SEA FILE=REGISTRY ABB=ON PLU=ON ("ZINC HYDROXIDE"/CN OR "ZINC HYDROXIDE (65ZN(OH)2)"/CN OR "ZINC HYDROXIDE (ZN(OD))"/CN) OR "ZINC HYDROXIDE (ZNOH)"/CN

L4 13 SEA FILE=REGISTRY ABB=ON PLU=ON ("ALUMINUM PHOSPHATE"/CN OR "ALUMINUM PHOSPHATE (1:1)"/CN) OR ("ALUMINUM PHOSPHATE (AL(PO4))"/CN OR "ALUMINUM PHOSPHATE (AL0.5(PO4)0.5)"/CN OR "ALUMINUM PHOSPHATE (AL2(HPO4)3)"/CN OR "ALUMINUM PHOSPHATE (AL2(OH)3(PO4))"/CN OR "ALUMINUM PHOSPHATE (AL2O3(P2O5)5)"/CN OR "ALUMINUM PHOSPHATE (AL2P6O18)"/CN OR "ALUMINUM PHOSPHATE (AL3(OH)3(PO4)2)"/CN OR "ALUMINUM PHOSPHATE (AL3(PO4)(OH)6)"/CN OR "ALUMINUM PHOSPHATE (AL4(P4O12)3)"/CN OR "ALUMINUM PHOSPHATE (AL4P10O31)"/CN OR "ALUMINUM PHOSPHATE (ALH2P3O10)"/CN) OR "ALUMINUM PHOSPHATE (ALP3O9)"/CN

L5 6 SEA FILE=REGISTRY ABB=ON PLU=ON ("CALCIUM PHOSPHATE"/CN OR "CALCIUM PHOSPHATE (1:1)"/CN OR "CALCIUM PHOSPHATE (1:2)"/CN OR "CALCIUM PHOSPHATE (3:2)"/CN OR "CALCIUM PHOSPHATE (CA(H2PO4)2)"/CN) OR "CALCIUM PHOSPHATE (CA(PO3)2)"/CN OR "CALCIUM PHOSPHATE (CA2P2O7)"/CN

L6 2 SEA FILE=REGISTRY ABB=ON PLU=ON ALUM/CN

L7 38 SEA FILE=REGISTRY ABB=ON PLU=ON L1 OR L2 OR L3 OR L4 OR L5 OR L6

L12 462119 SEA FILE=CAPLUS ABB=ON PLU=ON L7 OR STABILIS? OR STABILIZ? OR (METAL OR AL OR ALUMIN? OR CALCIUM OR CA OR ZINC OR ZN)(W)(OH OR HYDROXIDE) OR CAOH OR ALOH OR ZNOH OR (METAL OR ALUMIN? OR CALCIUM OR AL OR CA)(W)(PO# OR PHOSPHATE) OR ALPO# OR CAPO# OR ALUM

L13 3 SEA FILE=CAPLUS ABB=ON PLU=ON L12 AND (ERYSIPEL? OR E)(W)RHUSIOPATH?

=> s l13 not l9

L14 1 L13 NOT L9

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2001:403420 CAPLUS

DOCUMENT NUMBER: 135:24648

TITLE: Ether-type surfactant-free oil adjuvants and animal vaccines containing the adjuvants

INVENTOR(S): Hashimoto, Satoru; Ogiya, Toshiaki; Katayama, Shigeji; Oda, Kenji

PATENT ASSIGNEE(S): Nihon Surfactants Industry Co., Ltd., Japan; Microbiochemical Research Foundation; Nikko Chemicals Co., Ltd.

SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 2001151699 | A2 | 20010605 | JP 1999-337421 | 19991129 |

AB Oil adjuvants, which have good emulsion stability and do not cause necrosis, induration, pain, etc., at the inoculation sites, comprise O/W emulsion contg. animal fats and/or vegetable oils, polyhydric alc. fatty acid esters having no polyoxyalkylene structure as emulsifiers, and sugar or sugar alc. fatty acid esters as immunostimulants. Animal vaccines contg. the oil adjuvants and .gtoreq.1 antigens are also claimed. An O/W emulsion was prepd. from squalane 50.0, dl-.alpha.-tocopherol 0.02, mannitol oleate 2.5, sorbitan monolaurate 1.0, hexaglycerin monolaurate 2.0, decaglycerin monolaurate 2.0, glucose 20.0, and H2O 22.48%. Time course of neutralizing antibody titer, pyrogenicity, and behavioral change in a cat inoculated with felid herpesvirus and the adjuvant were examd.

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, JICST-EPLUS, JAPIO, CABA, AGRICOLA, VETU, VETB, PHIC, PHIN, TOXLIT, TOXLINE' ENTERED AT 12:34:26 ON 17 OCT 2001)
L15 28 S L13
L16 5 S L15 NOT L10
L17 5 DUP REM L16 (0 DUPLICATES REMOVED)

L17 ANSWER 1 OF 5 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 2000-516029 [47] WPIDS
DOC. NO. CPI: C2000-154021
TITLE: Vaccine containing lecithin, oil and surfactant as adjuvant, useful for protection against bacterial or viral pathogens, particularly in pigs, does not cause significant local reactions.
DERWENT CLASS: B04 C06 D16
INVENTOR(S): DEARWESTER, D A; ROBERTS, D S; SWEARINGIN, L A
PATENT ASSIGNEE(S): (PFIZ) PFIZER PROD INC
COUNTRY COUNT: 32
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---|---|---|---|---|---|
| EP 1023904 | A2 | 20000802 | (200047)* | EN | 12 |
| R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI | | | | | |
| AU 9965372 | A | 20000803 | (200047) | | |
| CA 2296244 | A1 | 20000729 | (200051) | EN | |
| JP 2000219636 | A | 20000808 | (200052) | | 11 |
| CN 1270838 | A | 20001025 | (200104) | | |
| BR 2000000126 | A | 20010502 | (200129) | | |
| NZ 502341 | A | 20010831 | (200157) | | |
| ZA 2000000142 | A | 20010829 | (200157) | | 22 |

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|---|---|---|---|

| | | | |
|---|---|---|---|
| EP 1023904 | A2 | EP 1999-310514 | 19991223 |
| AU 9965372 | A | AU 1999-65372 | 19991221 |
| CA 2296244 | A1 | CA 2000-2296244 | 20000119 |
| JP 2000219636 | A | JP 2000-17032 | 20000126 |
| CN 1270838 | A | CN 2000-101175 | 20000128 |
| BR 2000000126 | A | BR 2000-126 | 20000119 |
| NZ 502341 | A | NZ 2000-502341 | 20000114 |
| ZA 2000000142 | A | ZA 2000-142 | 20000114 |

FILING DETAILS:

| PATENT NO | KIND | | PATENT NO |
|---|---|---|---|
| NZ 502341 | A | Div in | NZ 513202 |

PRIORITY APPLN. INFO: US 1999-121760 19990226; US 1999-117705 19990129

AN 2000-516029 [47] WPIDS

AB EP 1023904 A UPAB: 20000925

NOVELTY - Vaccine composition (A) comprises (by volume) 0.25-12.5% lecithin (I); 1-23% oil (II); 1.5-3.5% at least one amphipathic surfactant (III) plus an antigen (Ag).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) adjuvant composition (B) containing (I)-(III) in the above proportions;

(2) preparation of vaccines by adding (B) to a composition containing Ag;

(3) antigen composition (C) comprising a Bordetella bronchiseptica culture that has been inactivated by adding formalin and then glutaraldehyde;

(4) vaccine composition (D) containing (C) plus an adjuvant;

(5) method for inactivating a B. bronchiseptica culture by adding formalin and then glutaraldehyde;

(6) composition containing B. bronchiseptica, formalin and glutaraldehyde;

(7) vaccine for protection against B. bronchiseptica infection comprising cells from a culture inactivated by method (5) plus a carrier; and

(8) method for protecting a piglet against atrophic rhinitis.

ACTIVITY - Antibacterial; antiviral.

**Erysipelothrix rhusiopathiae** cells were killed by treating with formalin and then glutaraldehyde, clarified, concentrated 10-fold and **stabilized** by adding aluminum gel at 30%. The product was mixed with 25 %volume of an adjuvant containing 20% mineral oil/lecithin and 16% Tween 80 plus Span 80, also containing thiomerosal and ethylenediamine tetraacetic acid as preservatives. Pigs were immunized with 2 ml doses of the product at 3 and 6 weeks of age, then challenged (at 9 weeks or 6 months of age) with virulent **E. rhusiopathiae**. Protection was 100% at 9 weeks and 75% at 6 months.

MECHANISM OF ACTION - Induction of a specific immune response.

USE - (A) can be formulated with Ag from any bacterial or viral pathogen, especially for protection of animals, specifically piglets against Bordetella bronchiseptica and/or Pasteurella multocida.

ADVANTAGE - (I)-(III) form a stable oil-in-water emulsion vaccine that induces minimal local reactions (irritation or inflammation) after vaccination (contrast other adjuvants containing

mineral oil).
Dwg.0/1

L17 ANSWER 2 OF 5 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1999-388474 [33] WPIDS
DOC. NO. CPI: C1999-114642
TITLE: New capsule-deleted mutant of **Erysipelothrix rhusiopathiae** YS-1 - has low pathogenicity and is genetically stable.
DERWENT CLASS: B04 D16
PATENT ASSIGNEE(S): (ARAI-I) ARAI K; (MORI-I) MORI Y; (NORQ) NORINSUISANSHO KACHIKU EISEI; (SEKI-I) SEKIZAKI T; (SHIM-I) SHIMOCHI Y
COUNTRY COUNT: 1
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---|---|---|---|---|---|
| JP 11151084 | A | 19990608 | (199933)* | | 12 |
| JP 2992980 | B2 | 19991220 | (200005) | | 11 |

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|---|---|---|---|
| JP 11151084 | A | JP 1997-333767 | 19971119 |
| JP 2992980 | B2 | JP 1997-333767 | 19971119 |

FILING DETAILS:

| PATENT NO | KIND | PATENT NO |
|---|---|---|
| JP 2992980 | B2 Previous Publ. | JP 11151084 |

PRIORITY APPLN. INFO: JP 1997-333767 19971119
AN 1999-388474 [33] WPIDS
AB JP 11151084 A UPAB: 19990819
NOVELTY - A capsule-deleted mutant of **Erysipelothrix rhusiopathiae** YS-1 ( FERM P-16446 ) which is derived from a transposon mutant of a virulant **Erysipelothrix rhusiopathiae** Fujisawa-SmR and shows tetracycline sensitivity, is new. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for the application of the above capsule-deleted mutant of **Erysipelothrix rhusiopathiae** YS-1 ( FERM P-16446 ) as a live vaccine for the infectious disease of **Erysipelothrix rhusiopathiae**.
USE - The capsule deleted mutant is useful in the form of a vaccine.
ADVANTAGE - The mutant is low in pathogenicity and has no danger of restoring pathogenicity and is genetically stable.
Dwg.0/2

L17 ANSWER 3 OF 5 BIOSIS COPYRIGHT 2001 BIOSIS
ACCESSION NUMBER: 1994:175853 BIOSIS
DOCUMENT NUMBER: PREV199497188853
TITLE: Development of the technology of the production of dried live vaccines against avian Pasteurella

infection and porcine erysipelas.
AUTHOR(S): Yartsev, M. Ya. (1); Basnak'yan, I. A.; Raevskii, A. A.; Sapegina, E. P.; Shishov, V. P.; Rogozhin, S. P.; Tokarik, E. F.; Maslak, A. A.
CORPORATE SOURCE: (1) Res. Technol. Inst. Biol. Ind., Moscow Russia
SOURCE: Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, (1993) Vol. 0, No. 3, pp. 63-70.
ISSN: 0372-9311.
DOCUMENT TYPE: Article
LANGUAGE: Russian
SUMMARY LANGUAGE: English
AB The technology of the production of dried live vaccine against Pasteurella infection of fowl from Pasteur's 2nd avirulent strain, strains AB and K, has been developed. This technology includes the process of batch cultivation of Pasteurella cells, controlled in such parameters as eH, pO-2 and glucose concentration, in fermenters in optimized culture medium, based on Hottinger hydrolysate and fermentative casein yeast hydrolysate, and preservation in improved saccharosegelatin medium prepared in potassium sulfate buffer solution. The new technology makes it possible to increase the yield of preparations with stable biological activity 5- to 13-fold in comparison with the traditional technology. Furthermore, the technology of the production of live dried vaccine against swine erysipelas from Erysipelothrix incidiosa strain BP-2 has been developed. This technology is based on maintaining the optimum conditions of the batch cultivation of E. incidiosa in meat medium based on Hottinger hydrolysate and media obtained from hydrolysate of pancreatic fermentation products of microbial biomass; the preparation thus obtained is **stabilized** in peptone-saccharose-gelatin medium prepared in potassium phosphate buffer solution. This increases the yield of the vaccine 8-fold in comparison with the traditional technology, while ensuring the stability of bacteria after drying and during prolonged storage.

L17 ANSWER 4 OF 5 CABA COPYRIGHT 2001 CABI
ACCESSION NUMBER: 90:137171 CABA
DOCUMENT NUMBER: 902224377
TITLE: Principles for the use of synchronous aerosol immunization of pigs against swine fever, erysipelas and salmonellosis
Anwendungsgrundsatze fur die synchrone aerogene Immunisierung gegen Schweinepest, Rotlauf und Salmonellose
AUTHOR: Kaden, V.
CORPORATE SOURCE: Friedrich-Loeffler-Inst., DDR-2201 Insel Riems, German Democratic Republic.
SOURCE: Monatshefte fur Veterinarmedizin, (1990) Vol. 45, No. 8, pp. 272-274. 8 ref.
DOCUMENT TYPE: Journal
LANGUAGE: German
SUMMARY LANGUAGE: English; Russian
AB Various refinements of the aerosol immunization technique, in use since 1982, were specified, included precise measurements for the enclosed space (or air lock) for holding the pigs. The dosage of vaccine mixture used is related to the space in the air lock irrespective of the number of animals. The immunization should be replaced by injection whenever the air temperature exceeded 25 deg C. Dried skimmed milk or spray-dried milk was added to the vaccine

mixture at 5% as a **stabilizer**.

L17 ANSWER 5 OF 5 CABA COPYRIGHT 2001 CABI
ACCESSION NUMBER: 83:113345 CABA
DOCUMENT NUMBER: 822211601
TITLE: Activity of vaccines against swine fever, Aujeszky's disease and swine erysipelas, combined and in aerosol form
AUTHOR: Khasanov, Ch. G.
CORPORATE SOURCE: Vet. Inst., Kazan, USSR.
SOURCE: Nauchnye Trudy Kazanskogo Gosudarstvennogo Veterinarnogo Instituta, (1981) Vol. 138, pp. 42-46. 2 ref.
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB Efficacy of the aerosol immunization method depends on the stability of the vaccine micro-organisms in the aerosol state. Dry defatted milk (5%) and glycerine (5%) were used to **stabilize** swine fever virus (Chinese strain), Aujeszky's virus strain BUK-628 and swine erysipelas (strains VR2 and Konev) vaccines. The swine erysipelas vaccine, immediately after mixing with the other vaccines, plus antibiotics, lost 50% of its activity, but in a mixture without antibiotics only 9%. After 1, 3 and 6 hours its activity in a mixture containing antibiotics was 62, 35 and 46%, but without antibiotics 94, 147 and 144%, either in the triple vaccine or in a monovaccine. The **stabilizers** made little difference initially, but after 3 and especially 6 hours the quantity of **Erysipelothrix rhusiopathiae** was less in triple vaccine without **stabilizers** than with them, and the same applied to swine erysipelas monovaccine. Similar results were recorded for the activity of swine erysipelas depot vaccine. Aujeszky's virus in the triple vaccine during storage at 37 deg C lost 5% activity after 1 hour, 8% after 3 and 16% after 6 hours relative to its activity in monovaccine, which remained unchanged. In an aerosol the swine erysipelas vaccine activity fell from 21 and 44% in the mixture of vaccines (strains VR-2 and Konev respectively) to 20 and 27%, 9 and 15%, 9 and 4%, 6 and 2% and 3 and 0% at 15, 30, 45, 60 and 120 min after spraying. Aujeszky's disease vaccine activity, similarly, after 25 min remained at 79% of the original level, and at 56, 51, 44 and 33% after 30, 45, 60 and 120 min. In the triple vaccine aerosol swine fever vaccine activity was 45% after 15 min, 63% after 30 min and 74% after 1 hour. Viability of swine fever vaccine virus in the triple vaccine remained adequate in the aerosol state.

FILE 'REGISTRY' ENTERED AT 12:38:01 ON 17 OCT 2001
E LECITHIN/CN
E LECITHINS/CN
L18 1 SEA ABB=ON PLU=ON LECITHINS/CN
E MINERAL OIL/CN
L19 4 SEA ABB=ON PLU=ON "MINERAL OIL"/CN OR "MINERAL OILS"/CN
E TWEEN 80/CN
L20 1 SEA ABB=ON PLU=ON "TWEEN 80"/CN
E SPAN 80/CN
L21 1 SEA ABB=ON PLU=ON "SPAN 80"/CN
L22 2 SEA ABB=ON PLU=ON L20 OR L21

FILE 'CAPLUS' ENTERED AT 12:39:08 ON 17 OCT 2001

L23 5027 SEA ABB=ON PLU=ON (L18 OR LECITHIN) AND (L19 OR OIL)

L24 294 SEA ABB=ON PLU=ON L23 AND (L22 OR (SPAN OR TWEEN)(W)80 OR AMPHIPHIL?(3A)(SURFACTANT OR SURFACE ACTIVE))

L25 2 SEA ABB=ON PLU=ON L24 AND (ERYSIPEL? OR E)(W)RHUSIOPATH

L26 51 SEA ABB=ON PLU=ON L24 AND L12

L27 18 SEA ABB=ON PLU=ON L26 AND (ANTIGEN OR FILTRATE OR SUPERNATANT OR PROTEIN OR PEPTIDE OR POLYPROTEIN OR POLYPEPTIDE OR CARBOHYDRATE OR POLYSACCHARIDE OR POLY SACCHARIDE OR GLYCOPROTEIN OR (GLYCO OR LIPO)(W)PROTEIN OR LIPOPROTEIN OR LIPID)

L28 19 SEA ABB=ON PLU=ON L25 OR L27

L29 18 SEA ABB=ON PLU=ON L28 NOT (L9 OR L14)

L29 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2001:136991 CAPLUS

DOCUMENT NUMBER: 134:198075

TITLE: Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents

INVENTOR(S): Patel, Mahesh V.; Chen, Feng-Jing

PATENT ASSIGNEE(S): Lipocine, Inc., USA

SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001012155 | A1 | 20010222 | WO 2000-US18807 | 20000710 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2001024658 | A1 | 20010927 | US 2000-751968 | 20001229 |

PRIORITY APPLN. INFO.: US 1999-375636 A 19990817
WO 2000-US18807 A 20000710

AB The present invention relates to triglyceride-free pharmaceutical compns., pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. The compns. and systems include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the compn., or can be co-administered with the compn. as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compns. and systems. For example, when a compn. contg. Cremophor RH40 0.30, Arlacel 186 0.20, Na taurocholate 0.18, and propylene glycol 0.32 g, resp., was used, the relative absorption of PEG 4000 as a model macromol. drug was enhanced by 991%.

IT **1338-43-8, Span 80 9005-65-6,**
Polysorbate 80 **21645-51-2, Aluminum hydroxide,** biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
REFERENCE COUNT: 1
REFERENCE(S): (1) Cho; US 5858398 A 1999 CAPLUS

L29 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:824063 CAPLUS
DOCUMENT NUMBER: 133:362141
TITLE: Use of additives to modify the taste characteristics of N-neohexyl-.alpha.-aspartyl-L-phenylalanine methyl ester
INVENTOR(S): Gerlat, Paula A.; Walters, Gale C.; Bishay, Ihab; Prakash, Indra; Jarrett, Tammy C.; Desai, Nitin; Sawyer, Harold; Bechert, Claire-Lise
PATENT ASSIGNEE(S): The Nutrasweet Company, USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000069283 | A1 | 20001123 | WO 2000-US12584 | 20000510 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-134064 P 19990513
AB This invention relates to the use of at least one taste modifying ingredient to modify at least one taste characteristic imparted by N-[N-(3,3-dimethylbutyl)-L-.alpha.-aspartyl]-L-phenylalanine 1-Me ester, or neotame, compns. contg. the same, and use of modified forms of neotame that possess an improved taste, wherein at least one taste characteristic imparted by neotame is pos. affected by the modification of neotame.
IT **9005-65-6,** Polysorbate 80 **10103-46-5, Calcium phosphate**
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(use of additives to modify the taste characteristics of N-neohexyl-.alpha.-aspartyl-L-phenylalanine Me ester)
REFERENCE COUNT: 6
REFERENCE(S): (1) Ajinomoto Kk; WO 9930574 A 1999 CAPLUS
(2) Bishay, I; WO 0015049 A 2000 CAPLUS
(3) Kurtz, R; US 5631295 A 1997 CAPLUS
(4) Nutrasweet Co; WO 9912954 A 1999 CAPLUS
(5) Nutrasweet Co; WO 9912956 A 1999 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:822526 CAPLUS
DOCUMENT NUMBER: 134:9337
TITLE: Adjuvant optimized for stability and biocompatibility for enhancing humoral and cellular immune responses
INVENTOR(S): Mueller, Rainer Helmut; Grubhofer, Nikolaus; Olbrich, Carsten
PATENT ASSIGNEE(S): Gerbu G.m.b.H., Germany; Pharmasol G.m.b.H.
SOURCE: Ger. Offen., 26 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| DE 10024788 | A1 | 20001123 | DE 2000-10024788 | 20000519 |
| WO 2000071154 | A2 | 20001130 | WO 2000-EP4565 | 20000519 |
| WO 2000071154 | A3 | 20010628 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| WO 2000071077 | A2 | 20001130 | WO 2000-EP4644 | 20000522 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2000058091 | A5 | 20001212 | AU 2000-58091 | 20000522 |

PRIORITY APPLN. INFO.: DE 1999-19923256 A1 19990520
WO 2000-EP4644 W 20000522

AB A title adjuvant is disclosed for injection in combination with an **antigen.** The adjuvant consists of solid **lipid** particles or solid **lipid** mixts. It can be used for manuf. of efficient and biocompatible vaccines for immunization of human and other animals as well as for the prodn. of antibodies. By selection of the particle size, particle charge, and particle surface properties the strength of the immune response can be modulated. The optimized adjuvant can be used in combination with other adjuvants such as mol. adjuvants like GMDP.

IT **21645-51-2, Aluminum hydroxide,**
biological studies
RL: BAC (Biological activity or effector, except adverse); PEP

(Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(adjuvant optimized for stability and biocompatibility for enhancing humoral and cellular immune responses)

IT **9005-65-6, Tween 80**
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(adjuvant optimized for stability and biocompatibility for enhancing humoral and cellular immune responses)

L29 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:814284 CAPLUS
DOCUMENT NUMBER: 133:366419
TITLE: **Lipid** particles on the basis of mixtures of liquid and solid **lipids** and method for producing same for drug delivery
INVENTOR(S): Muller, Rainer Helmut; Jenning, Volkhard; Mader, Karsten; Lippacher, Andreas
PATENT ASSIGNEE(S): Pharmasol G.m.b.H., Germany
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000067728 | A2 | 20001116 | WO 2000-EP4112 | 20000508 |
| WO 2000067728 | A3 | 20010809 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| DE 19938371 | A1 | 20010222 | DE 1999-19938371 | 19990809 |
| DE 19945203 | A1 | 20001221 | DE 1999-19945203 | 19990921 |

PRIORITY APPLN. INFO.:
DE 1999-19921034 A 19990507
DE 1999-19938371 A 19990809
DE 1999-19945203 A 19990921
DE 2000-10016357 A 20000331

AB The invention relates to **lipid** particles which do or do not carry active agents and comprise a mixed matrix consisting of solid and liq. **lipid** (so-called solid/liq. particles). The inventive particles are provided with a disordered structure (semicryst., mostly non-cryst. to amorphous) in the semisolid to solid condition. The invention also relates to a method for producing said dispersions and esp. a method for producing highly concd. **lipid** particle dispersions with a **lipid** content of 30 % to 95 % or a solids content of 30 % to 95 % ( **lipid** and **stabilizer**). Said dispersions are integral particles unlike the biamphiphilic creams and/or the highly concd. particle dispersions result in free-flowing particle

dispersions when dild. with the outer phase.

IT **9005-65-6, Tween 80**
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(**lipid** particles on the basis of mixts. of liq. and solid **lipids** and method for producing same for drug delivery)

L29 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:553455 CAPLUS
DOCUMENT NUMBER: 133:155507
TITLE: Implant comprising calcium cement and hydrophobic liquid
INVENTOR(S): Bohner, Marc
PATENT ASSIGNEE(S): Mathys Robert Stiftung, Switz.; Stratec Medical A.-G.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000045867 | A1 | 20000810 | WO 1999-EP684 | 19990202 |
| W: AU, CA, CN, JP, KR, US | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| AU 9929241 | A1 | 20000825 | AU 1999-29241 | 19990202 |

PRIORITY APPLN. INFO.: WO 1999-EP684 A 19990202

AB The compn. comprises a hydraulic cement for implantation in the human or animal body, said hydraulic cement comprising a first component comprising a calcium source and a second component comprising water, which hardens after mixing of the components. The compn. further comprises a third component with a hydrophobic liq. The compn. allows to obtain a cement with open macroporosity enabling a rapid bone ingrowth. A mixt. of .alpha.-tri-**calcium phosphate** 8, pptd. tricalcium phosphate 0.8, calcium cement 0.5 g, Cremophor EL 0.001, and Tegosoft M 8.0 mL were stirred for 4 min. The mixt. was then poured into a syringe and injected into a cavity. After hardening, the cavity was filled with an open macroporous **calcium phosphate** structure.

IT **1305-62-0**, Calciumhydroxide, biological studies
**1338-43-8**, Sorbitan monooleate **7757-93-9**, Dicalcium phosphate **7758-23-8**, Monocalcium phosphate **7758-87-4**, .alpha.-Tricalcium phosphate **9005-65-6**, Polysorbate 80 **10103-46-5**, **Calcium phosphate**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(implant comprising calcium cement and hydrophobic liq.)

REFERENCE COUNT: 14
REFERENCE(S):
(1) Advance Kk; JP 01268560 A 1989 CAPLUS
(5) Iino, S; US 4959104 A 1990 CAPLUS
(6) Mattei, F; US 4439420 A 1984 CAPLUS
(7) Ngk Spark Plug Co Ltd; JP 02198560 A 1990

CAPLUS
(8) Nitta Gelatin Kk; EP 0538913 A 1993 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:534822 CAPLUS
DOCUMENT NUMBER: 133:140192
TITLE: Adjuvants for use in vaccines
INVENTOR(S): Dearwester, Don Alan; Swearingin, Leroy Allen; Roberts, David Stewart
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 1023904 | A2 | 20000802 | EP 1999-310514 | 19991223 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| AU 9965372 | A1 | 20000803 | AU 1999-65372 | 19991221 |
| BR 2000000126 | A | 20010502 | BR 2000-126 | 20000119 |
| JP 2000219636 | A2 | 20000808 | JP 2000-17032 | 20000126 |
| CN 1270838 | A | 20001025 | CN 2000-101175 | 20000128 |
| PRIORITY APPLN. INFO.: | | | US 1999-117705 P | 19990129 |
| | | | US 1999-121760 P | 19990226 |

AB The invention relates to adjuvants that contain a **lecithin**, an **oil** and an **amphiphilic surfactant** and that are capable of forming a stable **oil**-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.

L29 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1999:722884 CAPLUS
DOCUMENT NUMBER: 131:327566
TITLE: Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality, and greater stability, and method for its production
INVENTOR(S): Penkler, Lawrence John; Mueller, Rainer Helmut; Runge, Stephan Anton; Ravelli, Vittorino
PATENT ASSIGNEE(S): Pharmatec International, Italy
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9956733 | A1 | 19991111 | WO 1999-EP2892 | 19990429 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, | | | | |

MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| DE 19819273 | A1 | 19991111 | DE 1998-19819273 | 19980430 |
| AU 9940351 | A1 | 19991123 | AU 1999-40351 | 19990429 |
| EP 1073426 | A1 | 20010207 | EP 1999-923490 | 19990429 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI

PRIORITY APPLN. INFO.: DE 1998-19819273 A 19980430
WO 1999-EP2892 W 19990429

AB Solid, particulate **lipid**-based excipients are provided which are loaded with cyclosporin. Said excipients have improved biopharmaceutical properties for cyclosporins in vivo, are of a better quality (in terms of fineness, homogeneity of the particles, and inclusion of the medicament), and are more phys. stable in the particulate formulation (no aggregation or gel formation). These cyclosporin formulations produce an av. blood level concn. in the steady state range of 300->1000 ng/mL which is maintained for .gtoreq.5 h in the absence of high initial blood level concns. >1200 ng/mL. Cyclosporin is dispersed in the **lipid** by either hot homogenization in a **lipid** melt, or cold homogenization with **lipid** microparticles in an emulsifier soln. Thus, a soln. of cyclosporin A 2 and Tagat S 2.5 in Imwitor 900 8 wt. parts at 85.degree. was dispersed in a soln. of Na cholate 0.5 in distd. water 87 wt. parts and homogenized at 500 bar and 85.degree.. After administration of this formulation to pigs (16 mg/kg by gavage), the mean blood level was 600-700 ng/mL at 1-6 h after treatment.

IT **1338-43-8, Span 80 9005-65-6,** Polysorbate 80
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, phys. quality, and stability)

REFERENCE COUNT: 2
REFERENCE(S): (1) Rudnic, E; US 5430021 A 1995 CAPLUS
(2) Shire Laboratories; WO 9913864 A 1999 CAPLUS

L29 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1998:458416 CAPLUS
DOCUMENT NUMBER: 129:153131
TITLE: Influence of stearylamine and dicetyl phosphate on the physical properties of submicron O/W emulsions
AUTHOR(S): Mbela, N.; Verschueren, E.; Ludwig, A.
CORPORATE SOURCE: Dep. Pharmaceutics and Drug Analysis, Fac. Pharmaceutical Sciences, Univ. Kinshasa, Kinshasa, Congo
SOURCE: J. Pharm. Belg. (1998), 53(2), 81-86
CODEN: JPBEAJ; ISSN: 0047-2166
PUBLISHER: Association Pharmaceutique Belge, Service Scientifique
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Stearylamine and dicetyl phosphate were added to glycerol or sorbitol isotonic sunflower **oil**, soybean **oil** and medium chain triglyceride (MCT) **oil**-in-water submicron

emulsions **stabilized** using egg yolk and soybean **lecithins**, and blends of polysorbate/sorbate with the aim to induce pos. and neg. elec. charges. Glycerol isotonic emulsions contg. 0.3% (wt./wt.) stearylamine could only be obtained when **lecithins** dosing up to 80% phosphatidylcholine (PC) were employed, but they did not resist to long term storage up to 90 days. Sorbitol isotonic stearylamine emulsions were achieved only with **lecithins** having a PC content superior to 90% without more resistance to storage. Stearylamine did not influence the stability of emulsions prepd. with nonionic emulsifiers. So, the destabilizing effect of stearylamine on emulsions prepd. with **lecithins** could be due to interaction of its cationic group with anionic **lipids** and was not related to the nature of the **oil**. Dicetyl phosphate did not markedly affect emulsions supporting further the hypothesis of interaction of stearylamine with **lecithin** phospholipids.

IT **9005-65-6**, PolySorbate 80
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stearylamine and dicetyl phosphate effect on phys. properties of submicron O/W emulsions)

L29 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1997:532205 CAPLUS
DOCUMENT NUMBER: 127:189892
TITLE: Food and vitamin preparations containing the natural isomer of reduced folates
INVENTOR(S): Bailey, Steven W.; Ayling, June E.
PATENT ASSIGNEE(S): South Alabama Medical Science Foundation, USA; Bailey, Steven W.; Ayling, June E.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9727764 | A1 | 19970807 | WO 1997-US1870 | 19970131 |
| W: AU, CA, CN, JP, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| CA 2243981 | AA | 19970807 | CA 1997-2243981 | 19970131 |
| AU 9722602 | A1 | 19970822 | AU 1997-22602 | 19970131 |
| AU 722050 | B2 | 20000720 | | |
| EP 877563 | A1 | 19981118 | EP 1997-905791 | 19970131 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| CN 1209729 | A | 19990303 | CN 1997-191951 | 19970131 |
| JP 2000505286 | T2 | 20000509 | JP 1997-527939 | 19970131 |
| US 5997915 | A | 19991207 | US 1998-117586 | 19980731 |
| US 6254904 | B1 | 20010703 | US 1999-418649 | 19991015 |

PRIORITY APPLN. INFO.:
US 1996-10898 P 19960131
WO 1997-US1870 W 19970131
US 1998-117586 A1 19980731

AB A compn. for human or animal consumption for supplying folate which includes a natural isomer of reduced folate, such as (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid,

5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid, and their polyglutamyl derivs. is disclosed. Such compns. include multivitamin prepns. (with or without minerals and other nutrients); breakfast foods such as prepd. cereals, toaster pastries and breakfast bars; infant formulas; dietary supplements and complete diet and wt.-loss formulas and bars; animal feed (for example pet foods) and animal feed supplements (such as for poultry feed). The amt. of the natural isomer of a reduced folate in a compn. for human consumption can range between about 5 % and about 200 % of the daily requirement for folic acid per serving or dose.

IT **7758-87-4, Calcium phosphate**
**9005-65-6,** Polysorbate 80
RL: BOC (Biological occurrence); FFD (Food or feed use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(food and vitamin prepns. contg. the natural isomer of reduced folates)

L29 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1995:329144 CAPLUS
DOCUMENT NUMBER: 122:114761
TITLE: Structures of nanoparticles prepared from **oil**-in-water emulsions
AUTHOR(S): Sjoestroem, Brita; Kaplun, Alon; Talmon, Yeshayahu; Cabane, Bernard
CORPORATE SOURCE: Department Chemical Engineering, Technion, Haifa, 32000, Israel
SOURCE: Pharm. Res. (1995), 12(1), 39-48
CODEN: PHREEB; ISSN: 0724-8741
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Hydrophobic substances were dissolved in an org. solvent and emulsified with an aq. soln. at very high shear. Droplets of very small sizes (50-100 nm) were obtained by using surfactants which were combinations of **lecithins** and bile salts. After emulsification, the org. solvent was removed by evapn., yielding stable dispersions of solid particles. The sizes, shapes, and structures of the particles were examd. through quasi-elastic light scattering, small-angle neutron scattering and cryotransmission electron microscopy. Cholesteryl acetate particles **stabilized** by **lecithin** and bile salts were found to be platelets of 10-20 nm thickness and 80 nm diam. Cholesteryl acetate particles **stabilized** with POE-(20)-sorbitan monolaurate were dense spherical globules of diam. 100 nm. Particles with a compn. similar to the endogenously occurring **lipoprotein**, LDL, were large spherical globules studded with small vesicles. The subsequent evolution of the cholesteryl acetate dispersion upon aging was examd. There was no transfer of cholesteryl acetate between particles nor to large crystals. However, some aggregation of the particles was obsd. when the vol. fraction of the particles in the aq. dispersion exceeded 0.05. Thus, the structure of the nanoparticles obtained through deswelling of emulsion droplets changes according to the nature of the emulsifiers and to the compn. of the hydrophobic substances which they contain.

IT **9005-65-6, Tween 80**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(emulsifier; structure of nanoparticles prepd. by deswelling of **oil**-in-water emulsion droplets)

L29 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1992:79378 CAPLUS
DOCUMENT NUMBER: 116:79378
TITLE: Effect of preparation conditions of enzyme-encapsulating W/O/W emulsion on enzymic NAD+-recycling in the emulsion
AUTHOR(S): Kato, Keiichi; Yamasaki, Nobuyuki; Ii, Norikazu
CORPORATE SOURCE: Dep. Appl. Chem., Ehime Univ., Matsuyama, 790, Japan
SOURCE: J. Chem. Eng. Jpn. (1991), 24(6), 709-14
CODEN: JCEJAQ; ISSN: 0021-9592
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effects of the prepn. conditions of W/O/W emulsion on the NAD+-recycling reaction catalyzed by yeast alc. dehydrogenase (ADH) and malate dehydrogenase (MDH) encapsulated in W/O/W emulsion were exptl. studied. The main results were as follows. (1) The first-stage emulsifying agent, such as Span80, protects the enzyme from enzymic activity loss which is caused when the enzyme is subject to the shearing force of a homomixer or is in contact with an org. agent during prepn. of the emulsion. (2) Addn. of soybean **lecithin** or cholesterol to Span80 makes W/O/W emulsion rigid and stable. Moreover, the additives increase the reaction rate of enzymic NAD+-recycling. (3) Addn. of soybean **lecithin** increases the stability of the enzyme in the emulsion. (4) Apparent enzymic reaction rate in the emulsion depends on the solubilities of ethanol and acetaldehyde in the **oil** phase of the emulsion. It is suggested that enzymic activity is enhanced by the interaction between the phospholipid of **lecithin** and the enzyme which is in the **lipid** membrane of the W/O/W emulsion, and also by the localization of enzymes or substrates in the compartment of the microenvironment of the emulsion. It is also pointed out that the study of enzyme-contg. emulsion may be useful as a model of a membrane-bound enzyme or a multi-enzyme system in a living cell.

IT **1338-43-8**, Span80 **9005-65-6**, Tween80
RL: USES (Uses)
(NAD-recycling enzymes protection by, during encapsulation in water-in-**oil**-in-water emulsion)

L29 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1988:629160 CAPLUS
DOCUMENT NUMBER: 109:229160
TITLE: Aseptic fluid coffee whitener with increased shelf-stability at room temperature and process for preparing same
INVENTOR(S): McKenna, Ronald J.; Keller, David J.; Streiff, Paul J.
PATENT ASSIGNEE(S): Borden, Inc., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 4748028 | A | 19880531 | US 1987-16131 | 19870218 |
| ZA 8704607 | A | 19880330 | ZA 1987-4607 | 19870625 |
| CA 1329336 | A1 | 19940510 | CA 1988-555875 | 19880105 |

PRIORITY APPLN. INFO.: US 1987-16131 19870218

AB An aseptically packages, liq. non-dairy coffee whitener which is shelf-stable for several mos. at room temp. comprises water 75-91, vegetable fat (e.g. partially or wholly hydrogenated soybean **oil**) 5-15, edible emulsifier system (e.g. polysorbate 80) 0.07-0.3, and milk **protein** 0.2-2.6 wt.%. The whitener optionally contains a vegetable gum **stabilizer** such as carrageenan, flavoring agents, and/or salts such as Na tripolyphosphate. Browning of the whitener after opening is avoided by eliminating aldoses which have a dextrose equiv. >1 DE.

IT **9005-65-6**, Polysorbate 80
RL: BIOL (Biological study)
(in shelf-stable non-dairy coffee creamer)

L29 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1986:7512 CAPLUS
DOCUMENT NUMBER: 104:7512
TITLE: Some trials in **stabilizing** W/O/W emulsions under the presence of electrolytes
AUTHOR(S): Matsumoto, Sachio; Kitayama, Tetsushi; Koh, Yumyoung
CORPORATE SOURCE: Coll. Agric., Univ. Osaka Prefect., Osaka, Japan
SOURCE: Yukagaku (1985), 34(9), 688-95
CODEN: YKGKAM; ISSN: 0513-398X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Studies were carried out to det. relevant conditions for obtaining a stable water-**oil**-water (W/O/W) emulsion in the presence of electrolytes such as HOAc [64-19-7], ascorbic acid [10504-35-5], NaCl, and Na citrate [994-36-5] which cause the **oil** layer of this type of emulsion to be unstable. Two types of expts. were carried out,i.e., an examn. of the **stabilizing** function of **proteins** as protective hydrophilic colloids or polar **lipids** to reinforce the **oil** layer, and detn. of adequate condition of hydrophilic and hydrophobic emulsifiers to form a stable W/O/W emulsion during phase inversion in the presence of electrolytes. Although the addn. of lysozyme [9001-63-2] to the aq. phase or stearylamine [124-30-1] and oleic acid [112-80-1] to the foil phase effectively increased the stability of the **oil** layer, these additives were inadequate to bring about the complete **stabilization** of such an emulsion. However, a stable W/O/W emulsion may be obtainable by the phase inversion technique using an appropriate emulsifier compn.

IT **1338-43-8**
RL: USES (Uses)
(emulsifying agents, contg. hydrophobic colloids or polar **lipids**)

L29 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1984:489266 CAPLUS
DOCUMENT NUMBER: 101:89266
TITLE: Oleaginous compositions
INVENTOR(S): Roberts, Bruce A.

PATENT ASSIGNEE(S): Procter and Gamble Co., USA
SOURCE: U.S., 12 pp. Cont. of U.S. Ser. No. 46,886, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 4446165 | A | 19840501 | US 1981-313063 | 19811019 |

PRIORITY APPLN. INFO.: US 1979-46886 19790608

AB An emulsion-type compn. suitable for use as food, drug delivery vehicles, and cosmetic ointments comprises (I) an **oil** phase **stabilized** as a water-in-**oil** (W/O) emulsion, (II) an aq. phase, and (III) a component which destablizes the W/O emulsion and converts it to an **oil**-in-water (O/W), pseudomelting emulsion on use. Thus, margarine was manufd. by mixing 3 components. Component I comprising 58.0% Crisco **oil**, 36.0% hardened coconut **oil**, 5.0% fully hardened erucic rape **oil**, 0.8% monoolein [25496-72-4], and 0.2% **lecithin** was heated to 66.degree., then blended with a W/O **stabilizer** (1 part Ca stearate [1592-23-0] and 2 parts fatty acid heated to 71.degree.) to a 98:2 ratio and butter flavor was added. Component II, an aq. phase Ca alginate [9005-35-0] gel, was mixed with Component I at a 70:30-40:6 ratio and cream and salt were added. This mixt. was homogenized at 27-32.degree. and Component III, an immobilized W/O emulsion destabilizing agent (35 parts 10% gelatin soln., 30 parts Tween 60 [9005-67-8] in **oil** (50:50), 35 parts 10% colloidal soln. of gum arabic [9000-01-5] to yield **Tween 80**-**oil** encoated beads of 0.1-3 .mu. diam.) was added. The final mixt. was homogenized at 27-32.degree. to yield a margarine with butter-like melting properties.

L29 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1981:531084 CAPLUS
DOCUMENT NUMBER: 95:131084
TITLE: Microencapsulation of cheese ripening systems: formation of microcapsules
AUTHOR(S): Magee, E. L., Jr.; Olson, N. F.
CORPORATE SOURCE: Cheese Res. Inst., Univ. Wisconsin, Madison, WI, 53706, USA
SOURCE: J. Dairy Sci. (1981), 64(4), 600-10
CODEN: JDSCAE; ISSN: 0022-0302
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Microcapsules were formed that consisted of a milk fat coat contg. aq. **protein** or glucose carrier vacuoles **stabilized** by sorbitan esters of stearate or oleate. Microencapsulation was accomplished by extruding a water-**oil** emulsion, consisting of an aq. soln. (carrier) dispersed in a molten mixt. of milk fat and emulsifier, under high pressure through an orifice submerged in a chilled dispersion fluid (water or milk). The extent of encapsulation was dependent on process variables, such as emulsifier type, concns. and proportions of emulsifier, dispersion fluid temp., ratio of aq. carrier soln. to milk fat, and concn. of solids in the

aq. vacuoles. Max. encapsulation efficiency was 80-90%.
IT **1338-43-8**
RL: BIOL (Biological study)
(emulsifier, in encapsulation of cheese ripening system with milk fat)

L29 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1979:404090 CAPLUS
DOCUMENT NUMBER: 91:4090
TITLE: Formulation, storage possibilities, and chemical composition of ready-to-eat honey-tahena paste
AUTHOR(S): El-Shahaly, A. A.; Mohamed, M. S.; El-Zalaki, Estmat M.; Mohasseb, Zeinab S.
CORPORATE SOURCE: Fac. Agric., Univ. Alexandria, Alexandria, Egypt
SOURCE: Libyan J. Agric. (1978), 7, 65-72
CODEN: LJAGD3
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The formulation of ready-to-eat spreadable paste of honey (62.5%) and sesame seed butter tahena (37.4%) along with artificial honey flavor (0.1%) and various additives is described. The system is a multiphase with a predominant **oil** dispersed in a continuous polar phase. Sorbitol [50-70-4] (3%) decreased desiccation of the paste, and **lecithin** (2%) improved its texture and spreadability. Changes occurred in moisture, free fatty acids, peroxide value, **oil** sepn., and organoleptic properties of the paste upon storage up to 100 days at 25 and 6.degree.. Storage at 6.degree. was recommended for storing Al tubes contg. the paste (30 g each). Moisture, **protein**, fat, **carbohydrates**, ash, Fe, P, and Ca contents of the paste were 8.00, 11.76, 23.10, 55.00, 2.00, 0.024, 0.501, and 0.114%, resp. The essential amino acids were quant. estd.
IT **9005-65-6**
RL: BIOL (Biological study)
(**stabilizer**, for honey-tahena paste)

L29 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1979:404053 CAPLUS
DOCUMENT NUMBER: 91:4053
TITLE: Formulation, storage possibilities, and chemical composition of ready-to-eat fish-tahena paste
AUTHOR(S): El-Shahaly, A. A.; Mohamed, M. S.; El-Zalaki, Esmat M.; Mohasseb, Zeinab S.
CORPORATE SOURCE: Fac. Agric., Univ. Alexandria, Alexandria, Egypt
SOURCE: Libyan J. Agric. (1978), 7, 59-64
CODEN: LJAGD3
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The formulation of ready-to-eat spreadable smoked-fish-tahena paste (1:1) along with various additives is described. The system was multiphase with a predominant **oil** dispersed in a continuous polar phase. **Tween 80** [**9005-65-6**] and glycerol monostearate [31566-31-1] at 2% each had a high **stabilizing** effect. Sorbitol [50-70-4] (3%) slowed drying of the paste, while **lecithin** (2%) improved its texture and spreadability. Changes occurred in moisture, free fatty acids, peroxide value, **oil** sepn., and organoleptic properties of the paste, upon storage up to 100 days at

25.degree. and 6.degree.. Storage at 6.degree. was more suitable for storage of Al tubes contg. the paste. Moisture, **protein**, fat, **carbohydrate**, ash, Fe, P, and Ca contents of the paste were 30, 29.5, 35, 3.7, 1.8, 0.0012, 0.76, and 0.619%, resp., (dry wt. basis). The essential amino acids were quant. estd.

IT **9005-65-6**
RL: BIOL (Biological study)
(**stabilizer**, in fish-tahena paste)

L29 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1972:518162 CAPLUS
DOCUMENT NUMBER: 77:118162
TITLE: Integrated **stabilizers** of fatty emulsions
AUTHOR(S): Minina, S. A.; Abramova, N. V.; Abramzon, A. A.
CORPORATE SOURCE: Leningr. Khim.-Farm. Inst., Leningrad, USSR
SOURCE: Khim.-Farm. Zh. (1972), 6(6), 38-41
CODEN: KHFZAN
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB The effect of emulsifiers and their concn. on the formation of stable fatemulsions was detd. They were prepd. ultrasonically from soybean, olive and cotton-seed **oils** with addn. of the resp. emulsifiers. The highest stability was achieved with addn. of integrated emulsifier systems composed of low-mol. wt., surface active compds. and high-mol. compds., e.g. **proteins**-**lecithin**-serum blood etc.

IT **9005-65-6**
RL: BIOL (Biological study)
(**stabilizer**, for fatty emulsions)

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, JICST-EPLUS, JAPIO, CABA, AGRICOLA, VETU, VETB, PHIC, PHIN, TOXLIT, TOXLINE' ENTERED AT 12:45:29 ON 17 OCT 2001)

L30 2 S L25
L31 17 S L27
L32 15 S (L30 OR L31) NOT (L10 OR L16)
L33 12 DUP REM L32 (3 DUPLICATES REMOVED)

L33 ANSWER 1 OF 12 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 2000-224123 [19] WPIDS
DOC. NO. CPI: C2000-068311
TITLE: Non-stick chewing gum composition contains plasticized proteinaceous material containing **protein** and plasticizer components in combination with chewing gum base ingredients.
DERWENT CLASS: A97 D13
INVENTOR(S): ABDEL-MALLIK, M M; ORAMA, A M; VISHWANATHAN, A; ABDEL-MALIK, M M
PATENT ASSIGNEE(S): (WARN) WARNER LAMBERT CO
COUNTRY COUNT: 76
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---|---|---|---|---|---|
| WO 2000008944 | A2 | 20000224 | (200019)* | EN | 39 |

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW

W: AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS
JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL
TR TT UA UZ VN YU ZA
AU 9950923 A 20000306 (200030)
BR 9912890 A 20010508 (200129)

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|---|---|---|---|
| WO 2000008944 | A2 | WO 1999-US15388 | 19990708 |
| AU 9950923 | A | AU 1999-50923 | 19990708 |
| BR 9912890 | A | BR 1999-12890 | 19990708 |
| | | WO 1999-US15388 | 19990708 |

FILING DETAILS:

| PATENT NO | KIND | | PATENT NO |
|---|---|---|---|
| AU 9950923 | A | Based on | WO 200008944 |
| BR 9912890 | A | Based on | WO 200008944 |

PRIORITY APPLN. INFO: US 1998-131771 19980811
AN 2000-224123 [19] WPIDS
AB WO 200008944 A UPAB: 20000419
NOVELTY - A non-stick chewing gum composition comprises 2-25 wt.% plasticized proteinaceous material containing **protein** and plasticizer components in combination with chewing gum base ingredients sufficient to impart non-stick characteristics to the composition on porous and non-porous surfaces in the absence of an elastomer solvent and wax.
DETAILED DESCRIPTION - The chewing gum composition comprises:
(a) 2-25 wt.% plasticized proteinaceous material containing **protein** and plasticizer components; and
(b) chewing gum base ingredients sufficient to impart non-stick characteristics to the composition on porous and non-porous surfaces in the absence of an elastomer solvent and wax. The solid state blend of the **protein** and plasticizer components are heated under controlled shear conditions at 20-140 deg. C.
USE - None given.
ADVANTAGE - The chewing gums possess high flavor properties similar to conventional chewing gums. It also has unique non-stick properties on a wide variety of substrate including porous and non-porous substrates like leather and rubber.
Dwg.0/0

L33 ANSWER 2 OF 12 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 2000-160548 [14] WPIDS
DOC. NO. CPI: C2000-050062
TITLE: New injectable pharmaceutical formulation for treating pathologies sensitive to the action of the partricin derivative.
DERWENT CLASS: A96 B02
INVENTOR(S): BRUZZESE, T; FERRARI, V M
PATENT ASSIGNEE(S): (QUAT-N) QUATEX NV; (BRUZ-I) BRUZZESE T; (FERR-I) FERRARI V M
COUNTRY COUNT: 22
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---|---|---|---|---|---|
| WO 9966902 | A1 | 19991229 | (200014)* | EN | 25 |
| RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE | | | | | |
| W: JP KR US | | | | | |
| EP 1089710 | A1 | 20010411 | (200121) | EN | |
| R: AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE | | | | | |

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|---|---|---|---|
| WO 9966902 | A1 | WO 1999-EP1571 | 19990311 |
| EP 1089710 | A1 | EP 1999-914507 | 19990311 |
| | | WO 1999-EP1571 | 19990311 |

FILING DETAILS:

| PATENT NO | KIND | | PATENT NO |
|---|---|---|---|
| EP 1089710 | A1 | Based on | WO 9966902 |

PRIORITY APPLN. INFO: IT 1998-MI1457 19980625
AN 2000-160548 [14] WPIDS
AB WO 9966902 A UPAB: 20000320
NOVELTY - A new injectable pharmaceutical formulation comprises at least one derivative, in the form of a free base, or its water-soluble salts, with pharmaceutically and pharmacologically acceptable acids, in a solubilizing/dispersing medium of a **lipid** and/or phospholipid emulsion in water, such that the resulting emulsion is iso-osmotic.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of preparing the formulation comprising (a) sterilization, preferably by sterilizing filtration of the solution, (b) miscellar pseudo-solution or suspension of sub-micronized particles of the partricin derivative, and (c) subsequent inclusion in the **lipid** and/or phospholipid emulsion.

USE - The injectable formulation is used for the preparation of drug for the clinical treatment of pathologies sensitive to the action of the partricin derivative (claimed). Five male New Zealand rabbits was daily injected intravenously, over a time of 2 min, 2 ml in total (1 mg of SPA-S-843) of both **lipid** and glucose solution into the marginal veins of the left and right ear, respectively. The treatment was repeated for 3 or more days. Mostly on left ears had no damaged or mild inflammation, while most of the right ear had inflammation/necrosis. The partricin derivative **lipid** formulation was better than the formulation in glucose solution and its tolerance by the vasal endothelium was good.

ADVANTAGE - Side effects involving the vascular system, brought by intravenous injections of known formulation of the partricin derivatives, can be considerably limited, or even avoided, by the use of this new formulation.

Dwg.0/0

L33 ANSWER 3 OF 12 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1999-326901 [27] WPIDS
DOC. NO. CPI: C1999-096671

TITLE: Topical composition for application to mucosal tissue, comprising active agent and micelle forming **lipid** carrier providing controlled and prolonged release.
DERWENT CLASS: A96 B05 D21 D22
INVENTOR(S): LURIYA, E; LURIYA, L
PATENT ASSIGNEE(S): (LURI-N) LURIDENT LTD
COUNTRY COUNT: 83
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---|---|---|---|---|---|
| WO 9922703 | A1 | 19990514 | (199927)* | EN | 35 |
| RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW | | | | | |
| W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW | | | | | |
| AU 9895587 | A | 19990524 | (199940) | | |
| IL 122084 | A | 19990922 | (200002) | | |
| EP 1027029 | A1 | 20000816 | (200040) | EN | |
| R: AT DE FR GB IT NL | | | | | |
| CN 1283983 | A | 20010214 | (200130) | | |

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|---|---|---|---|
| WO 9922703 | A1 | WO 1998-IL504 | 19981018 |
| AU 9895587 | A | AU 1998-95587 | 19981018 |
| IL 122084 | A | IL 1997-122084 | 19971031 |
| EP 1027029 | A1 | EP 1998-949227 | 19981018 |
| | | WO 1998-IL504 | 19981018 |
| CN 1283983 | A | CN 1998-811388 | 19981018 |

FILING DETAILS:

| PATENT NO | KIND | | PATENT NO |
|---|---|---|---|
| AU 9895587 | A | Based on | WO 9922703 |
| EP 1027029 | A1 | Based on | WO 9922703 |

PRIORITY APPLN. INFO: IL 1997-122084 19971031
AN 1999-326901 [27] WPIDS
AB WO 9922703 A UPAB: 19990714
NOVELTY - A formulation for topical application to mucosal tissue contains an active agent (A) and a **lipid** carrier (B) in the form of a colloidal micellar dispersion.

DETAILED DESCRIPTION - A formulation for topical application to nasal, ophthalmic, oral, gastrointestinal, respiratory, vaginal or rectal mucosal tissue comprises:

(A) an active agent consisting of an antibiotic, antiviral or antifungal agent, disinfectant, nutrient, antiinflammatory, local anesthetic or essential **oil**; and

(B) a **lipid** carrier including at least one **lipid** selected from amphiphilic phospholipids, yolk **lecithin**, soya **lecithin** and phosphatidyl glycerol.

The **lipid** is in the form of a colloidal micellar dispersion with a particle size less than 200 nm, such that the carrier adheres strongly to mucosal tissue. The ratio of (A) to **lipid** is 1:10 to 10:1 (preferably 1:3 to 3:1) and the two form mixed micelles so that (A) is released in a sustained and prolonged manner.

An INDEPENDENT CLAIM is included for a method of topically administering the formulation to mucosal tissue.

USE - The formulations are personal care and hygiene formulations. They are useful for the treatment of gum disease, caries, dry mouth, malodorous breath, microbial infection, inflammation, irritation or dryness. The formulation is especially a mouthwash (claimed).

ADVANTAGE - The carrier (B) shows good adhesion to mucosa (e.g. the gums, tongue and palate), has a high load capacity for (A) and can specifically target a relatively large amount of (A) to the mucosa to ensure controlled and sustained release at the surface. Typically an antimicrobial formulation for oral hygiene applications can be effective for a long as 24 hours (i.e. suitable for once a day use). The formulations have wide range of applications.

Dwg.0/1

L33 ANSWER 4 OF 12 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 1

ACCESSION NUMBER: 1999088423 EMBASE

TITLE: Preparation of gadolinium-containing emulsions **stabilized** with phosphatidylcholine-surfactant mixtures for neutron-capture therapy.

AUTHOR: Miyamoto M.; Hirano K.; Ichikawa H.; Fukumori Y.; Akine Y.; Tokuuye K.

CORPORATE SOURCE: M. Miyamoto, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, 518 Arise, Ikawadani-cho, Nishi-ku, Kobe 651-2180, Japan

SOURCE: Chemical and Pharmaceutical Bulletin, (1999) 47/2 (203-208).
Refs: 13
ISSN: 0009-2363 CODEN: CPBTAL

COUNTRY: Japan

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 023 Nuclear Medicine
037 Drug Literature Index
039 Pharmacy

LANGUAGE: English

SUMMARY LANGUAGE: English

AB Gadolinium-containing **lipid** emulsions for neutron-capture therapy were designed to fulfill the following requirements: particle size smaller than 100 nm; gadolinium content as high as possible; surface of the emulsions modified with hydrophilic moieties to provide prolonged circulation in the blood. Emulsions containing soybean **oil**, water, Gd-diethylenetriaminepentaacetic acid-distearylamide (Gd-DTPA-SA), as an amphiphilic drug, and hydrogenated egg yolk phosphatidylcholine (HEPC), as an emulsifier, in a weight ratio of 7.36:92:1:2 were prepared without co- surfactants by the thin-layer hydration method using a bath-type sonicator. The mean particle size of the emulsions was 280.7 nm. In order to make the droplet size of the emulsions smaller than 100 nm, as well as to modify the emulsion surfaces, a co-surfactant, Tween.RTM. 80, HCO.RTM.-60, Pluronic.RTM. F68, polyoxyethylene alkyl ether (Brij.RTM.) or polyoxyethylene alkyl

ester (Myrj.RTM.), was introduced into the standard system. **Tween 80**, HCO-60, Brij 76, 78 and 700 were effective in reducing the particle size to below 100 nm when the co-surfactant weight ratio (CWR), defined as co-surfactant/(HEPC+Gd-DTPA-SA) (w/w), was larger than 0.67; the particle size with **Tween 80** and HCO-60 was reduced to 52.7 and 74.7 nm, respectively, at a CWR of 1.0 (w/w). In order to increase the gadolinium content, the weight ratio of Gd-DTPA-SA to HEPC was increased from 1:2 of the standard-Gd formulation to 2:1 of the high-Gd formulation. The measured particle size of the HCO-60 high-Gd emulsions was 78.7nm when the CWR was 1.0 (w/w). In this case, the calculated gadolinium content reached 3.0 mg Gd/ml. These results indicate that HCO-60 is an effective co-surfactant not only in terms of particle size reduction but also with respect to gadolinium enrichment.

L33 ANSWER 5 OF 12 TOXLIT
ACCESSION NUMBER: 1998:106365 TOXLIT
DOCUMENT NUMBER: CA-129-153131A
TITLE: Influence of stearylamine and dicetyl phosphate on the physical properties of submicron O/W emulsions.
AUTHOR: Mbela N; Verschueren E; Ludwig A
CORPORATE SOURCE: Dep. Pharmaceutics and Drug Analysis, Fac. Pharmaceutical Sciences, Univ. Kinshasa, Kinshasa
SOURCE: J. Pharm. Belg., (1998). Vol. 53, No. 2, pp. 81-86. CODEN: JPBEAJ. ISSN. 0047-2166.
PUB. COUNTRY: CONGO
DOCUMENT TYPE: Journal; Journal Article
FILE SEGMENT: CA
LANGUAGE: English
OTHER SOURCE: CA 129:153131
ENTRY MONTH: 199809
AB Stearylamine and dicetyl phosphate were added to glycerol or sorbitol isotonic sunflower **oil**, soybean **oil** and medium chain triglyceride (MCT) **oil**-in-water submicron emulsions **stabilized** using egg yolk and soybean **lecithins**, and blends of polysorbate/sorbate with the aim to induce pos. and neg. elec. charges. Glycerol isotonic emulsions contg. 0.3% (wt./wt.) stearylamine could only be obtained when **lecithins** dosing up to 80% phosphatidylcholine (PC) were employed, but they did not resist to long term storage up to 90 days. Sorbitol isotonic stearylamine emulsions were achieved only with **lecithins** having a PC content superior to 90% without more resistance to storage. Stearylamine did not influence the stability of emulsions prepd. with nonionic emulsifiers. So, the destabilizing effect of stearylamine on emulsions prepd. with **lecithins** could be due to interaction of its cationic group with anionic **lipids** and was not related to the nature of the **oil**. Dicetyl phosphate did not markedly affect emulsions supporting further the hypothesis of interaction of stearylamine with **lecithin** phospholipids.

L33 ANSWER 6 OF 12 JICST-EPlus COPYRIGHT 2001 JST
ACCESSION NUMBER: 960069225 JICST-EPlus
TITLE: Absorption of Insulin Using Water-in-**Oil**-in-Water Emulsion from an Enteral Loop in Rats.
AUTHOR: MATSUZAWA A; MORISHITA M; TAKAYAMA K; NAGAI T
CORPORATE SOURCE: Hoshi Univ., Tokyo, JPN

SOURCE: Biol Pharm Bull, (1995) vol. 18, no. 12, pp. 1718-1723. Journal Code: S0989A (Fig. 6, Tbl. 2, Ref. 41)
ISSN: 0918-6158
PUB. COUNTRY: Japan
DOCUMENT TYPE: Journal; Article
LANGUAGE: English
STATUS: New

AB The present work was undertaken to prepare water-in-**oil**-in-water(W/O/W) emulsions as a carrier for insulin via the enteral route. The emulsions were prepared by a two-step procedure using a homogenizer. To avoid insulin escape from the inner aqueous phase, 3, 5 or 10% gelatin was added in the inner phase. The oily phase was composed of 5% **lecithin**, 20% **Span 80** and 75% soybean **oil**. The purified water containing 3% **Tween 80** was used for the outer aqueous phase. In addition, these emulsions were filtered with a membrane filter (0.45.MU.m) to obtain smaller emulsion particles. The stability of the emulsions was evaluated by a turbidity measurement method and photomicrographic observation. By the addition of gelatin to the inner aqueous phase and storage at 4.DEG.C., the stability of the emulsions could be improved. The hypoglycemic effects of insulin after administration of emulsion to the stomach, the duodenum, the jejunum, the ileum and the colon were examined using an in situ loop method in rats. A significant hypoglycemic effect was observed at the ileum and colon loops after administration of the filtered emulsions containing 5% gelatin in the inner phase. These findings suggest that the W/O/W multiple emulsions **stabilized** by gelatin can improve ileal and colonic absorption of insulin. (author abst.)

L33 ANSWER 7 OF 12 TOXLIT DUPLICATE 2

ACCESSION NUMBER: 1995:37509 TOXLIT
DOCUMENT NUMBER: CA-122-114761S
TITLE: Structures of nanoparticles prepared from **oil**-in-water emulsions.
AUTHOR: Sjoestroem B; Kaplun A; Talmon Y; Cabane B
CORPORATE SOURCE: Department Chemical Engineering, Technion, Haifa
SOURCE: Pharm. Res, (1995). Vol. 12, No. 1, pp. 39-48.
CODEN: PHREE. ISSN. 0724-8741.
PUB. COUNTRY: Israel
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
FILE SEGMENT: CA
LANGUAGE: English
OTHER SOURCE: CA 122:114761
ENTRY MONTH: 199503

AB Hydrophobic substances were dissolved in an org. solvent and emulsified with an aq. soln. at very high shear. Droplets of very small sizes (50-100 nm) were obtained by using surfactants which were combinations of **lecithins** and bile salts. After emulsification, the org. solvent was removed by evapn., yielding stable dispersions of solid particles. The sizes, shapes, and structures of the particles were examd. through quasi-elastic light scattering, small-angle neutron scattering and cryotransmission electron microscopy. Cholesteryl acetate particles **stabilized** by **lecithin** and bile salts were found to be platelets of 10-20 nm thickness and 80 nm diam. Cholesteryl acetate particles **stabilized** with POE-(20)-sorbitan

monolaurate were dense spherical globules of diam. 100 nm. Particles with a compn. similar to the endogenously occurring **lipoprotein**, LDL, were large spherical globules studded with small vesicles. The subsequent evolution of the cholesteryl acetate dispersion upon aging was examd. There was no transfer of cholesteryl acetate between particles nor to large crystals. However, some aggregation of the particles was obsd. when the vol. fraction of the particles in the aq. dispersion exceeded 0.05. Thus, the structure of the nanoparticles obtained through deswelling of emulsion droplets changes according to the nature of the emulsifiers and to the compn. of the hydrophobic substances which they contain.

L33 ANSWER 8 OF 12 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 3
ACCESSION NUMBER: 94230381 EMBASE
DOCUMENT NUMBER: 1994230381
TITLE: Preparation of drug-carrier emulsions **stabilized** with phosphatidylcholine-surfactant mixtures.
AUTHOR: Lundberg B.
CORPORATE SOURCE: Department of Biochemistry/Pharmacy, Abo Akademi University, BioCity P. O. Box 66,Abo 20521, Finland
SOURCE: Journal of Pharmaceutical Sciences, (1994) 83/1 (72-75).
ISSN: 0022-3549 CODEN: JPMSAE
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 027 Biophysics, Bioengineering and Medical Instrumentation
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
AB A method has been developed to produce **lipid** emulsion particles for parenteral use as drug carriers. The technique uses a mixture of a triacylglycerol **oil** and purified egg yolk phosphatidylcholine (EPC) as the basic system and sonication under mild conditions to produce the emulsion. A large number of mild 'biological' surfactants were tested for their ability to improve the dispersing and stability properties of the basic system. The results showed a preference for polysorbate 80, and a suitable combination of **oil** and emulsifiers was found to be castor **oil**:EPC:polysorbate 80 (1:0.4:0.12, weight ratios). Repeated preparation of this emulsion system in phosphate-buffered saline (PBS) gave particles with a mean diameter near 50 nm, in a reproducible way and with a low polydispersity. The stability of the emulsion was very good (>3 months), both in PBS and in 2.5% glycerol. The method was also tested with two lipophilic anticancer drugs, which were solubilized in castor **oil**, with satisfactory results. The **lipid** emulsion particles described in this study also have a potential use as targetable carriers for site-specific drug delivery.

L33 ANSWER 9 OF 12 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1990-009141 [02] WPIDS
DOC. NO. CPI: C1990-003911
TITLE: Transparent compsn. with excellent stability and safety - comprises **amphiphilic** substance,

**surfactant**, oily component and water.

DERWENT CLASS: B07 D21
INVENTOR(S): KAKOKI, H; KUMANO, Y; NISHIYAMA, S; YAMAGUCHI,
PATENT ASSIGNEE(S): (SHIS) SHISEIDO CO LTD
COUNTRY COUNT: 13
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---|---|---|---|---|---|
| EP 349150 | A | 19900103 | (199002)* | EN | 11 |
| R: CH DE ES FR GB IT LI NL SE | | | | | |
| AU 8936676 | A | 19891221 | (199016) | | |
| JP 02078432 | A | 19900319 | (199017) | | |
| US 5162377 | A | 19921110 | (199248) | | 7 |
| EP 349150 | B1 | 19940817 | (199432) | EN | 11 |
| R: CH DE ES FR GB IT LI NL SE | | | | | |
| DE 68917544 | E | 19940922 | (199437) | | |
| CA 1339029 | C | 19970401 | (199725) | | |

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|---|---|---|---|
| EP 349150 | A | EP 1989-305991 | 19890613 |
| JP 02078432 | A | JP 1989-149959 | 19890613 |
| US 5162377 | A | US 1989-366569 | 19890615 |
| EP 349150 | B1 | EP 1989-305991 | 19890613 |
| DE 68917544 | E | DE 1989-617544 | 19890613 |
| | | EP 1989-305991 | 19890613 |
| CA 1339029 | C | CA 1989-602693 | 19890613 |

FILING DETAILS:

| PATENT NO | KIND | | PATENT NO |
|---|---|---|---|
| DE 68917544 | E | Based on | EP 349150 |

PRIORITY APPLN. INFO: JP 1988-150195 19880620
AN 1990-009141 [02] WPIDS
AB EP 349150 A UPAB: 19930928
Transparent compsn. comprises an **amphiphilic** substance, a **surfactant**, an oily component and water.

Pref. 10 pts. by wt. or less of a surfactant is contained per 1 pt. by wt. of an oily component. The **amphiphilic** **surfactant** is e.g. **lecithin**, a quat. ammonium salt type synthetic **lipid** such as dialkyl dimethylammonium chloride and a mixt. of a quat. ammonium salt with a higher alcohol. The surfactant is any nonionic or ionic surfactant partic. sugar or sugar alcohol fatty acid esters such as sucrose fatty acid ester and maltitol fatty esters etc. The oily component may be any liq. **oil**, solid **oil** or semi-solid **oil** components, or substances not easily solubilised in water.

USE/ADVANTAGE - The compsn. has an excellent transparency, stability with a lapse of time, and safety. The irritation which occurs when a large amt. of surfactant is added is avoided, and thus the compsn. has an excellent safety factor.

0/0
ABEQ US 5162377 A UPAB: 19930928

Carrier compsn. comprises a dispersion of a pharmaceutical or cosmetic **oil** component 1 pts. wt.), a nonionic and/or cationic surfactant (up to 10 pts. wt.), a phospholipid (0.001-100 pts. wt. per pt. wt. surfactant), and water. Prodn. of these carriers comprises mixing the components under strong sharing forces.

USE - The prods. are stable, transparent carriers for pharmaceutical or cosmetic compsns.

0/0

ABEQ EP 349150 B UPAB: 19940928

A transparent composition comprising (a) a phospholipid, (b) a nonionic surfactant, (c) an oily component and (d) water, wherein a mixture of (a) phospholipid, (b) a nonionic surfactant, (c) an oily component and (d) water is subjected to a strong shearing force treatment which comprises operating a high pressure homogeniser under a pressure of at least 3447 KPa (500 psi), a colloid mill at least 1000 rpm, or an ultrasonication emulsifier and wherein 10 parts by weight or less of the nonionic surfactant is contained per 1 part by weight of the oily component, and 0.002 to 100 parts by weight of the nonionic surfactant is contained per 1 part by weight of the phospholipid.

Dwg.0/0

L33 ANSWER 10 OF 12 BIOSIS COPYRIGHT 2001 BIOSIS

ACCESSION NUMBER: 1979:244820 BIOSIS

DOCUMENT NUMBER: BA68:47324

TITLE: FORMULATION STORAGE POSSIBILITIES AND CHEMICAL COMPOSITION OF READY TO EAT HONEY TAHENA PASTE.

AUTHOR(S): EL-SHAHALY A A; MOHAMED M S; EL-ZALAKI E M; MOHASSEB Z S

CORPORATE SOURCE: FOOD SCI. TECHNOL. DEP., FAC. AGRIC., ALEXANDRIA UNIV., ALEXANDRIA, EGYPT.

SOURCE: LIBYAN J AGRIC, (1978 (RECD 1979)) 7, 65-72. CODEN: LJAGD3.

FILE SEGMENT: BA; OLD

LANGUAGE: English

AB The formulation of ready-to-eat spreadable paste of honey (62.5%) and sesame seed butter tahena (37.4%) along with artificial honey flavor (0.1%) and various additives is described. The system is a multiphase with a predominant **oil**, dispersed in a continuous polar phase. **Tween 80** and glycerol mono-stearate at 1% each gave the best **stabilizing** effect. Sorbitol (3%) decreases the desiccation of the paste and **lecithin** (2%) improved its texture and spreadability. Changes occurred in moisture, free fatty acids, peroxide value, **oil** separation and organoleptic properties of the paste upon storage up to 100 days at 25 and 6.degree. C. Storage at 6.degree. C was recommended for storing the Al tubes containing the paste (30 grams per each). Moisture, **protein**, fat, **carbohydrates**, ash, Fe, P and Ca contents of the paste were 8.00, 11.76, 23.10, 55.00, 2.00, 0.024, 0.501 and 0.114%, respectively. The essential amino acids were quantitatively estimated.

L33 ANSWER 11 OF 12 BIOSIS COPYRIGHT 2001 BIOSIS

ACCESSION NUMBER: 1979:244821 BIOSIS

DOCUMENT NUMBER: BA68:47325

TITLE: FORMULATION STORAGE POSSIBILITIES AND CHEMICAL

COMPOSITION OF READY TO EAT FISH TAHENA PASTE.
AUTHOR(S): EL-SHAHALY A A; MOHAMED M S; EL-ZALAKI E M; MOHASSEB Z S
CORPORATE SOURCE: FOOD SCI. TECHNOL. DEP., FAC. AGRIC., UNIV. ALEXANDRIA, ALEXANDRIA, EGYPT.
SOURCE: LIBYAN J AGRIC, (1978 (RECD 1979)) 7, 59-64.
CODEN: LJAGD3.
FILE SEGMENT: BA; OLD
LANGUAGE: English
AB The formulation of ready-to-eat spreadable smoked fish-tahena paste (1:1) along with various additives is described. The system is multiphase with a predominant **oil**-dispersed in a continuous polar phase. **Tween 80** and glycerol monostearate at 2% of each showed a high **stabilizing** effect. Sorbitol (3%) decreased the desiccation of the paste while **lecithin** (2%) improved its texture and spreadability. Changes occurred in moisture, free fatty acids, peroxide value, **oil** separation, and organoleptic properties of the paste, upon storage up to 100 days of storage at 25.degree. C and 6.degree. C. Storage at 6.degree. C was more suitable for storage of Al tubes containing the paste. Moisture, **protein**, fat, **carbohydrates**, ash, Fe, P and Ca contents of the paste were 30, 29.5, 35, 3.7, 1.8, 0.0012, 0.76 and 0.619%, respectively (results are based on dry weight basis). The essential amino acids were quantitatively estimated.

L33 ANSWER 12 OF 12 BIOSIS COPYRIGHT 2001 BIOSIS
ACCESSION NUMBER: 1978:144526 BIOSIS
DOCUMENT NUMBER: BA65:31526
TITLE: PREPARATION OF **LIPID** VESICLES ON THE BASIS OF A TECHNIQUE FOR PROVIDING WATER **OIL** WATER EMULSIONS.
AUTHOR(S): MATSUMOTO S; KOHDA M; MURATA S-I
CORPORATE SOURCE: DEP. AGRIC. CHEM., COLL. AGRIC., UNIV. OSAKA PREF., SAKAI, OSAKA 591, JPN.
SOURCE: J COLLOID INTERFACE SCI, (1977) 62 (1), 149-157.
CODEN: JCISA5. ISSN: 0021-9797.
FILE SEGMENT: BA; OLD
LANGUAGE: English
AB As one of the applications of a technique for providing W/O/W-type multiple-phase emulsions, an attempt was made to prepare an aqueous suspension of **lipid** vesicles as a model for 1-lamellar liposomes. The procedure tested was divided into 4 operations; preparation of a water-in-n-hexane emulsion **stabilized** by a mixture of soy **lecithin** and **Span-80**; removal of n-hexane from the emulsion under reduced pressure, thus obtaining a water-in-**lipid** mixture system; mixing of the above system with an aqueous solution of hydrophilic emulsifying agent so as to prepare an aqueous suspension of **lipid** vesicles composed of aqueous compartments 1-2 .mu.m in diameter, surrounded by the **lipid** layer; and dialysis of the **lipid** vesicle suspension against distilled water to remove the residue of the hydrophilic emulsifying agent from the aqueous suspending medium. The necessary weight fraction of soy **lecithin** to **Span-80** in the **lipid** mixture for attaining 90% or higher yields of the **lipid** vesicles ranges from 0.35-0.65 and that a relatively low concentration of the hydrophilic emulsifying agent is recommended to

provide the **lipid** vesicle suspension in a stable form.

(FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, JICST-EPLUS, JAPIO, CABA, AGRICOLA, VETU, VETB, PHIC, PHIN, TOXLIT, TOXLINE' ENTERED AT 12:52:51 ON 17 OCT 2001)

- Author(s)

```
L34      12815 S ROBERTS D?/AU
L35         20 S SWEARINGIN L?/AU
L36         25 S SUITER B?/AU
L37          3 S L34 AND L35 AND L36
L38         18 S L34 AND (L35 OR L36)
L39          3 S L35 AND L36
L40         12 S (L34 OR L35 OR L36) AND RHUSIOPATH?
L41         20 S L37 OR L38 OR L39 OR L40
L42         17 DUP REM L41 (3 DUPLICATES REMOVED)
```

L42 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 1

ACCESSION NUMBER: 2000:534822 CAPLUS
DOCUMENT NUMBER: 133:140192
TITLE: Adjuvants for use in vaccines
INVENTOR(S): Dearwester, Don Alan; **Swearingin, Leroy Allen; Roberts, David Stewart**
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 1023904 | A2 | 20000802 | EP 1999-310514 | 19991223 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| AU 9965372 | A1 | 20000803 | AU 1999-65372 | 19991221 |
| BR 2000000126 | A | 20010502 | BR 2000-126 | 20000119 |
| JP 2000219636 | A2 | 20000808 | JP 2000-17032 | 20000126 |
| CN 1270838 | A | 20001025 | CN 2000-101175 | 20000128 |
| PRIORITY APPLN. INFO.: | | | US 1999-117705 P | 19990129 |
| | | | US 1999-121760 P | 19990226 |

AB The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.

L42 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:544802 CAPLUS
DOCUMENT NUMBER: 133:155383
TITLE: Erysipelothrix **rhusiopathiae** antigen compositions and their vaccine compositions for prevention and treatment of swine erysipelas
INVENTOR(S): **Roberts, David Stewart; Swearingin, Leroy Alan; Suiter, Brian Thomas**
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 2000219637 | A2 | 20000808 | JP 2000-17930 | 20000124 |
| AU 9959445 | A1 | 20000803 | AU 1999-59445 | 19991116 |
| EP 1027895 | A2 | 20000816 | EP 1999-309202 | 19991118 |
| EP 1027895 | A3 | 20010718 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| CN 1262129 | A | 20000809 | CN 1999-126163 | 19991215 |
| BR 9905853 | A | 20001114 | BR 1999-5853 | 19991215 |

PRIORITY APPLN. INFO.: US 1999-117704 P 19990129

AB The antigen compns. contain fluid fraction of cultured E. **rhusiopathiae**, and stabilizers, e.g. metal hydroxides or phosphates. Rehydragel [Al(OH)3 gel] prevented loss of activity of formalin- or .beta.-propiolactone-inactivated E. **rhusiopathiae** antigen.

L42 ANSWER 3 OF 17 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 2000-484844 [43] WPIDS
DOC. NO. CPI: C2000-145992
TITLE: Novel antigen comprising fluid function from an Erysipelothrix **rhusiopathiae** culture, useful as a vaccine.
DERWENT CLASS: B04 C06 D16
INVENTOR(S): **ROBERTS, D S; SUITER, B T;** SWEARINGEN, L A; **SWEARINGIN, L A**
PATENT ASSIGNEE(S): (PFIZ) PFIZER PROD INC
COUNTRY COUNT: 31
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---|---|---|---|---|---|
| EP 1027895 | A2 | 20000816 | (200043)* | EN | 13 |
| R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI | | | | | |
| JP 2000219637 | A | 20000808 | (200043) | | 12 |
| AU 9959445 | A | 20000803 | (200046) | | |
| CA 2290078 | A1 | 20000729 | (200051) | EN | |
| CN 1262129 | A | 20000809 | (200055) | | |
| BR 9905853 | A | 20001114 | (200064) | | |
| ZA 9907138 | A | 20010627 | (200140) | | 23 |

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|---|---|---|---|
| EP 1027895 | A2 | EP 1999-309202 | 19991118 |
| JP 2000219637 | A | JP 2000-17930 | 20000124 |
| AU 9959445 | A | AU 1999-59445 | 19991116 |
| CA 2290078 | A1 | CA 1999-2290078 | 19991116 |
| CN 1262129 | A | CN 1999-126163 | 19991215 |
| BR 9905853 | A | BR 1999-5853 | 19991215 |
| ZA 9907138 | A | ZA 1999-7138 | 19991116 |

PRIORITY APPLN. INFO: US 1999-117704 19990129
AN 2000-484844 [43] WPIDS
AB EP 1027895 A UPAB: 20000907
NOVELTY - Antigen (I) comprising a fluid function from an Erysipelothrix **rhusiopathiae** culture and a stabilizing agent, is new.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
(1) a vaccine comprising an antigen as in (I) and an adjuvant; and
(2) making an antigen comprising adding a stabilizing agent to a fluid fraction from an E. **rhusiopathiae** culture.
ACTIVITY - Antibacterial.
MECHANISM OF ACTION - Vaccine.
Pigs were vaccinated intramuscularly with two 2 ml doses of vaccine with Al gel (3 and 6 weeks). Immunity was tested at 9 weeks with intramuscular injections of E. **rhusiopathiae**. Protection due to vaccine was 100 %.
USE - The antigen composition of (I) and a vaccine comprising it are used to vaccinate an animal, especially a pig against E. **rhusiopathiae** infection and erysipelas (claimed).
ADVANTAGE - The vaccine provides long term protection from E. **rhusiopathiae**.
Dwg.0/0

L42 ANSWER 4 OF 17 TOXLIT
ACCESSION NUMBER: 2000:54719 TOXLIT
DOCUMENT NUMBER: CA-133-155383R
TITLE: Erysipelothrix **rhusiopathiae** antigen compositions and their vaccine compositions for prevention and treatment of swine erysipelas.
AUTHOR: **Roberts DS; Swearingin LA; Suiter BT**
SOURCE: (2000). Jpn. Kokai Tokkyo Koho PATENT NO. 2000219637 08/08/2000 (Pfizer Products Inc.). CODEN: JKXXAF.
PUB. COUNTRY: UNITED STATES
DOCUMENT TYPE: Patent
FILE SEGMENT: CA
LANGUAGE: Japanese
OTHER SOURCE: CA 133:155383
ENTRY MONTH: 200009
AB The antigen compns. contain fluid fraction of cultured E. **rhusiopathiae**, and stabilizers, e.g. metal hydroxides or phosphates. Rehydragel [Al(OH)3 gel] prevented loss of activity of formalin- or .beta.-propiolactone-inactivated E. **rhusiopathiae** antigen.

L42 ANSWER 5 OF 17 TOXLIT
ACCESSION NUMBER: 2000:52008 TOXLIT
DOCUMENT NUMBER: CA-133-140192D
TITLE: Adjuvants for use in vaccines.
AUTHOR: Dearwester DA; **Swearingin LA; Roberts DS**
SOURCE: (2000). Eur. Pat. Appl. PATENT NO. 1023904 08/02/2000 (Pfizer Products Inc.). CODEN: EPXXDW.

PUB. COUNTRY: UNITED STATES
DOCUMENT TYPE: Patent
FILE SEGMENT: CA
LANGUAGE: English
OTHER SOURCE: CA 133:140192
ENTRY MONTH: 200008

AB The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.

L42 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1997:262603 CAPLUS
DOCUMENT NUMBER: 126:308794
TITLE: Method of preparing Gram-negative bacterial vaccines
INVENTOR(S): **Roberts, David S.**; Dearwester, Donald A.; **Swearingin, Leroy A.**
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 6 pp., Cont.-in-part of U.S. Ser. No. 792,488, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 5616328 | A | 19970401 | US 1994-240649 | 19940711 |
| WO 9310216 | A1 | 19930527 | WO 1992-US9944 | 19921113 |

W: AU, CA, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE

PRIORITY APPLN. INFO.: US 1991-792488 B2 19911115
WO 1992-US9944 W 19921113

AB There is provided by this invention a novel method of prepg. Gram-neg. bacterial vaccines. The method comprises providing a concd. Gram-neg. bacterial antigenic prepn., adsorbing the prepn. with a mineral carrier capable of binding free endotoxin in the antigenic prepn. in an amt. effective to produce optimal binding of endotoxin and antigen, and dilg. the adsorbed prepn. for use in a vaccine. Also provided by this invention is a vaccine produced by the method of this invention. A concn. of mineral carrier in the vaccine is less than 5.0 % by vol. Also provided by this invention is a method of vaccinating an animal against Gram-neg. bacterial infections comprising administering to the animal an effective amt. of a vaccine of this invention. Actinobacillus pleuropneumoniae, serotype 1, 5, and 7 were prepd. and cultured in a liq. medium. At the end of exponential growth, each culture was chilled to arrest growth; the chilled culture was centrifuged and the sediment collected as a very dense suspension of bacteria. The suspension was centrifuged and the supernatant fluid (ext.) collected, treated with preservatives, and filtered. The pH and total vol. were adjusted, Rehydragel carrier was added, followed by Amphigen adjuvant. The final concn. of Rehydragel carrier was 0.98% by vol. a very desirable value for the avoidance of tissue reactions at the injection site.

L42 ANSWER 7 OF 17 TOXLIT
ACCESSION NUMBER: 1997:79428 TOXLIT
DOCUMENT NUMBER: CA-126-308794H
TITLE: Method of preparing Gram-negative bacterial vaccines.
AUTHOR: **Roberts DS**; Dearwester DA; **Swearingin LA**
SOURCE: (1997). U.S. PATENT NO. 5616328 04/01/97 (Pfizer Inc.).
PUB. COUNTRY: United States
DOCUMENT TYPE: Patent
FILE SEGMENT: CA
LANGUAGE: English
OTHER SOURCE: CA 126:308794
ENTRY MONTH: 199707

AB There is provided by this invention a novel method of prepg. Gram-neg. bacterial vaccines. The method comprises providing a concd. Gram-neg. bacterial antigenic prepn., adsorbing the prepn. with a mineral carrier capable of binding free endotoxin in the antigenic prepn. in an amt. effective to produce optimal binding of endotoxin and antigen, and dilg. the adsorbed prepn. for use in a vaccine. Also provided by this invention is a vaccine produced by the method of this invention. A concn. of mineral carrier in the vaccine is less than 5.0 % by vol. Also provided by this invention is a method of vaccinating an animal against Gram-neg. bacterial infections comprising administering to the animal an effective amt. of a vaccine of this invention. Actinobacillus pleuropneumoniae, serotype 1, 5, and 7 were prepd. and cultured in a liq. medium. At the end of exponential growth, each culture was chilled to arrest growth; the chilled culture was centrifuged and the sediment collected as a very dense suspension of bacteria. The suspension was centrifuged and the supernatant fluid (ext.) collected, treated with preservatives, and filtered. The pH and total vol. were adjusted, Rehydragel carrier was added, followed by Amphigen adjuvant. The final concn. of Rehydragel carrier was 0.98% by vol. a very desirable value for the avoidance of tissue reactions at the injection site.

L42 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 2
ACCESSION NUMBER: 1993:456132 CAPLUS
DOCUMENT NUMBER: 119:56132
TITLE: Gram-negative bacterial vaccines
INVENTOR(S): Dearwester, Donald A.; **Roberts, David S.**; **Swearingin, Leroy A.**
PATENT ASSIGNEE(S): SmithKline Beecham Corp., USA
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9310216 | A1 | 19930527 | WO 1992-US9944 | 19921113 |
| W: AU, CA, JP, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE | | | | |
| AU 9331413 | A1 | 19930615 | AU 1993-31413 | 19921113 |
| AU 667858 | B2 | 19960418 | | |

| | | | | |
|---|---|---|---|---|
| EP 669971 | A1 | 19950906 | EP 1992-925307 | 19921113 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE | | | | |
| JP 3043809 | B2 | 20000522 | JP 1993-509495 | 19921113 |
| US 5616328 | A | 19970401 | US 1994-240649 | 19940711 |
| PRIORITY APPLN. INFO.: | | | US 1991-792488 A2 | 19911115 |
| | | | WO 1992-US9944 A | 19921113 |

AB A novel method of prepg. Gram-neg. bacterial vaccines comprises providing a concd. Gram-neg. bacterial antigenic prepn., adsorbing the prepn. with a mineral carrier capable of binding free-endotoxin in the antigenic prepn. in an amt. (<5%) effective to produce optimal binding of endotoxin and antigen, and dilg. the adsorbed prepn. for use in a vaccine. Exts. of cultured Actinobacillus pleuropneumoniae was treated with a 25% soln. of glutaraldehyde, neutralized with lysine and stored at 4.degree. overnight. Al(OH)3 gel and Amphigen were added to the ext. at pH 6.5 and the vol. was adjusted with buffer to obtain final concn. of Al(OH)3 0.98 and Amphigen 5%vol./vol. in the vaccine. Efficacy of the vaccine was tested in pigs.

L42 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 3

| | |
|---|---|
| ACCESSION NUMBER: | 1993:456130 CAPLUS |
| DOCUMENT NUMBER: | 119:56130 |
| TITLE: | Pasteurella multocida toxoid vaccines |
| INVENTOR(S): | Frantz, Joseph C.; Kemmy, Richard J.; **Roberts, David S.; Swearingin, Leroy A.** |
| PATENT ASSIGNEE(S): | Smithkline Beecham Corp., USA |
| SOURCE: | PCT Int. Appl., 65 pp.<br>CODEN: PIXXD2 |
| DOCUMENT TYPE: | Patent |
| LANGUAGE: | English |
| FAMILY ACC. NUM. COUNT: | 1 |

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9309809 | A1 | 19930527 | WO 1992-US10008 | 19921113 |
| W: AU, CA, JP, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE | | | | |
| WO 9119419 | A1 | 19911226 | WO 1991-US4092 | 19910610 |
| W: AU, CA, JP, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE | | | | |
| AU 9181953 | A1 | 19920107 | AU 1991-81953 | 19910610 |
| JP 05508407 | T2 | 19931125 | JP 1991-512282 | 19910610 |
| JP 3178720 | B2 | 20010625 | | |
| EP 651609 | A1 | 19950510 | EP 1991-913518 | 19910610 |
| EP 651609 | B1 | 19990811 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| AT 183202 | E | 19990815 | AT 1991-913518 | 19910610 |
| ES 2136064 | T3 | 19991116 | ES 1991-913518 | 19910610 |
| AU 9331430 | A1 | 19930615 | AU 1993-31430 | 19921113 |
| AU 669681 | B2 | 19960620 | | |
| EP 614371 | A1 | 19940914 | EP 1992-925340 | 19921113 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE | | | | |
| JP 07501334 | T2 | 19950209 | JP 1992-509531 | 19921113 |
| US 5695769 | A | 19971209 | US 1994-244052 | 19940711 |

| | | | | | |
|---|---|---|---|---|---|
| AU 685659 | B2 | 19980122 | AU 1995-13628 | | 19950303 |
| AU 9513628 | A1 | 19950810 | | | |
| US 5536496 | A | 19960716 | US 1995-439714 | | 19950512 |
| PRIORITY APPLN. INFO.: | | | US 1990-537454 | A | 19900613 |
| | | | US 1991-792490 | A1 | 19911115 |
| | | | WO 1991-US4092 | A | 19910610 |
| | | | WO 1992-US10008 | A | 19921113 |
| | | | US 1993-87946 | B1 | 19930706 |

AB A vaccine is manufd. for the protection of animals against disease assocd. with P. multocida infection. The vaccine elicits antitoxin formation. The vaccine comprises whole P. multocida killed cells (bacterins) with cell-bound toxoid, optionally also comprising free, sol. toxoid. The sol., cell-free toxoid is produced by subjecting the toxin to varying pH and temp. regimens. In addn., the vaccine may also comprise Bordetella bronchiseptica bacterin, Erysipelothrix **rhusiopathiae** bacterin and/or Mycoplasma hyopheumoniae ext.

L42 ANSWER 10 OF 17 TOXLIT
ACCESSION NUMBER: 1993:80690 TOXLIT
DOCUMENT NUMBER: CA-119-056132N
TITLE: Gram-negative bacterial vaccines.
AUTHOR: Dearwester DA; **Roberts DS; Swearingin LA**
SOURCE: (1993). PCT Int. Appl. PATENT NO. 93 10216 05/27/93 (SmithKline Beecham Corp.).
PUB. COUNTRY: United States
DOCUMENT TYPE: Patent
FILE SEGMENT: CA
LANGUAGE: English
OTHER SOURCE: CA 119:56132
ENTRY MONTH: 199309

AB A novel method of prepg. Gram-neg. bacterial vaccines comprises providing a concd. Gram-neg. bacterial antigenic prepn., adsorbing the prepn. with a mineral carrier capable of binding free-endotoxin in the antigenic prepn. in an amt. (<5%) effective to produce optimal binding of endotoxin and antigen, and dilg. the adsorbed prepn. for use in a vaccine. Exts. of cultured Actinobacillus pleuropneumoniae was treated with a 25% soln. of glutaraldehyde, neutralized with lysine and stored at 4.degree. overnight. Al(OH)3 gel and Amphigen were added to the ext. at pH 6.5 and the vol. was adjusted with buffer to obtain final concn. of Al(OH)3 0.98 and Amphigen 5%vol./vol. in the vaccine. Efficacy of the vaccine was tested in pigs.

L42 ANSWER 11 OF 17 TOXLIT
ACCESSION NUMBER: 1993:80688 TOXLIT
DOCUMENT NUMBER: CA-119-056130K
TITLE: Pasteurella multocida toxoid vaccines.
AUTHOR: Frantz JC; Kemmy RJ; **Roberts DS; Swearingin LA**
SOURCE: (1993). PCT Int. Appl. PATENT NO. 93 09809 05/27/93 (Smithkline Beecham Corp.).
PUB. COUNTRY: United States
DOCUMENT TYPE: Patent
FILE SEGMENT: CA
LANGUAGE: English
OTHER SOURCE: CA 119:56130
ENTRY MONTH: 199309

AB A vaccine is manufd. for the protection of animals against disease assocd. with P. multocida infection. The vaccine elicits antitoxin formation. The vaccine comprises whole P. multocida killed cells (bacterins) with cell-bound toxoid, optionally also comprising free, sol. toxoid. The sol., cell-free toxoid is produced by subjecting the toxin to varying pH and temp. regimens. In addn., the vaccine may also comprise Bordetella bronchiseptica bacterin, Erysipelothrix **rhusiopathiae** bacterin and/or Mycoplasma hyopheumoniae ext.

L42 ANSWER 12 OF 17 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1992-024125 [03] WPIDS
CROSS REFERENCE: 1993-182249 [22]
DOC. NO. CPI: C1992-010389
TITLE: Pasteurella multocida toxoid vaccines - used for protecting against e.g. atrophic rhinitis, pleuritic and pneumonic pasteurellosis and erysipelas particularly in pigs.
DERWENT CLASS: B04 C06 D16
INVENTOR(S): FRANTZ, J; KEMMY, R J; **ROBERTS, D S**; **SWEARINGIN, L A**; FRANTZ, J C
PATENT ASSIGNEE(S): (PFIZ) PFIZER INC; (SMIK) SMITHKLINE BEECHAM; (SMIK) SMITHKLINE BEECHAM CORP
COUNTRY COUNT: 18
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---|---|---|---|---|---|
| WO 9119419 | A | 19911226 | (199203)* | | 75 |
| RW: BE CH DE DK ES FR GB GR IT LU NL SE | | | | | |
| W: AU CA JP US | | | | | |
| AU 9181953 | A | 19920107 | (199217) | | |
| JP 05508407 | W | 19931125 | (199401) | | 18 |
| EP 651609 | A1 | 19950510 | (199523) | EN | |
| R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE | | | | | |
| AU 9513628 | A | 19950810 | (199540) | | |
| US 5536496 | A | 19960716 | (199634) | | 12 |
| AU 685569 | B | 19980122 | (199811) | | |
| EP 651609 | B1 | 19990811 | (199936) | EN | |
| R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE | | | | | |
| DE 69131525 | E | 19990916 | (199944) | | |
| ES 2136064 | T3 | 19991116 | (200001) | | |
| CA 2312296 | A1 | 19911214 | (200053) | EN | |
| JP 3178720 | B2 | 20010625 | (200138) | | 27 |

APPLICATION DETAILS:

| PATENT NO | KIND | | APPLICATION | DATE |
|---|---|---|---|---|
| JP 05508407 | W | | JP 1991-512282 | 19910610 |
| | | | WO 1991-US4092 | 19910610 |
| EP 651609 | A1 | | EP 1991-913518 | 19910610 |
| | | | WO 1991-US4092 | 19910610 |
| AU 9513628 | A | | AU 1995-13628 | 19950303 |
| | | Div ex | AU 1991-81953 | |
| US 5536496 | A | Cont of | US 1990-537454 | 19900613 |
| | | Cont of | US 1993-87946 | 19930706 |
| | | | US 1995-439714 | 19950512 |
| AU 685569 | B | | AU 1995-13628 | 19950303 |

| | | | | |
|---|---|---|---|---|
| | | Div ex | AU 1991-81953 | |
| EP 651609 | B1 | | EP 1991-913518 | 19910610 |
| | | | WO 1991-US4092 | 19910610 |
| DE 69131525 | E | | DE 1991-631525 | 19910610 |
| | | | EP 1991-913518 | 19910610 |
| | | | WO 1991-US4092 | 19910610 |
| ES 2136064 | T3 | | EP 1991-913518 | 19910610 |
| CA 2312296 | A1 | Div ex | CA 1991-2086258 | 19910610 |
| | | | CA 1991-2312296 | 19910610 |
| JP 3178720 | B2 | | JP 1991-512282 | 19910610 |
| | | | WO 1991-US4092 | 19910610 |

FILING DETAILS:

| PATENT NO | KIND | | PATENT NO |
|---|---|---|---|
| JP 05508407 | W | Based on | WO 9119419 |
| EP 651609 | A1 | Based on | WO 9119419 |
| AU 685569 | B | Previous Publ. | AU 9513628 |
| EP 651609 | B1 | Based on | WO 9119419 |
| DE 69131525 | E | Based on | EP 651609 |
| | | Based on | WO 9119419 |
| ES 2136064 | T3 | Based on | EP 651609 |
| JP 3178720 | B2 | Previous Publ. | JP 05508407 |
| | | Based on | WO 9119419 |

PRIORITY APPLN. INFO: US 1990-537454 19900613; US 1993-87946 19930706; US 1995-439714 19950512

AN 1992-024125 [03] WPIDS

CR 1993-182249 [22]

AB WO 9119419 A UPAB: 20010711

A vaccine compsn. for internal administration to an animal comprises an immunogenic amt. of a soluble free-toxoid of Pasteurella multocida (PM) and a carrier suitable for internal administration; the compsn. may further comprise one or more additional antigens, e.g. a Bordetella bronchiseptica bacteria, and Erysipelothrix **rhusiopathiae** bacteria or a PM tye A bacteria.

A PM toxoid prepd. by incubating a clarified lysate of PM whole cells at 12-19 deg.C at a pH greater than 9 fro at least 12 hrs., and a method for detoxifying PM necrotising toxin which comprises incubating the toxin at greater than pH 9 at 12-19 deg.C for at least 12 hrs also claimed. A method fro vaccinating an animal against PM which comprises internally adminsitering to the animal an fmmunogenic amt. of PM toxoid.

USE - Vaccines are used for preventing diseases resulting from infection with PM such as atrophic rhinitis, pleuritic and pneumonic pasteurcellosis and erysipelas, in animals such as pigs. The soluble toxoid can be elicit antibodies that can bind to the toxin and neutralise its toxicity. The toxoid is stable at 4 deg.C for at least 24 months.

Dwg.0/0

ABEQ US 5536496 A UPAB: 19960829

An alkaline-toxoided Pateurella multocida protein necrotizing toxin prepared by incubating a toxin extracted from a culture of a dermonecrotic necrotizing protein toxin producing strain of P. multocida whole cells at a temperature of between 12 and 19deg. C. under conditions of pH greater than about 10.5 for at least 12

hours, wherein said toxoid is capable of inducing production of an amount of antitoxin effective to neutralize the toxin.
Dwg.0/0

L42 ANSWER 13 OF 17 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1992-007209 [01] WPIDS
DOC. NO. CPI: C1992-003083
TITLE: Swine pneumonia vaccine - contains vaccine component of inactivated Mycoplasma hyopneumoniae and opt. other antigens.
DERWENT CLASS: B04 C06 D16
INVENTOR(S): DAYALU, K I; FRANTZ, J C; KEMMY, R J; PEETZ, R H; **ROBERTS, D S; SWEARINGIN, L A**
PATENT ASSIGNEE(S): (SMIK) SMITHKLINE BEECHAM CORP; (SMIK) SMITHKLINE BEECHAM; (SOLV) SOLVAY ANIMAL HEALTH INC; (AMCY) AMERICAN CYANAMID CO
COUNTRY COUNT: 17
PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|---|---|---|---|---|---|
| WO 9118627 | A | 19911212 | (199201)* | | |
| RW: AT BE CH DE DK ES FR GB GR IT LU NL SE | | | | | |
| W: AU CA JP | | | | | |
| AU 9179078 | A | 19911231 | (199215) | | |
| JP 05507484 | W | 19931028 | (199348) | | 37 |
| EP 597852 | A1 | 19940525 | (199421) | EN | |
| R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE | | | | | |
| AU 657907 | B | 19950330 | (199521) | | |
| AU 9517662 | A | 19951019 | (199549) | | |
| EP 597852 | B1 | 19971203 | (199802) | EN | 16 |
| R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE | | | | | |
| DE 69128361 | E | 19980115 | (199808) | | |
| ES 2112274 | T3 | 19980401 | (199819) | | |
| JP 3187419 | B2 | 20010711 | (200140) | | 11 |

APPLICATION DETAILS:

| PATENT NO | KIND | | APPLICATION | DATE |
|---|---|---|---|---|
| JP 05507484 | W | | JP 1991-510290 | 19910524 |
| | | | WO 1991-US3689 | 19910524 |
| EP 597852 | A1 | | EP 1991-911598 | 19910524 |
| | | | WO 1991-US3689 | 19910524 |
| AU 657907 | B | | AU 1991-79078 | 19910524 |
| AU 9517662 | A | Div ex | AU 1991-79078 | 19910524 |
| | | | AU 1995-17662 | 19950426 |
| EP 597852 | B1 | | EP 1991-911598 | 19910524 |
| | | | WO 1991-US3689 | 19910524 |
| DE 69128361 | E | | DE 1991-628361 | 19910524 |
| | | | EP 1991-911598 | 19910524 |
| | | | WO 1991-US3689 | 19910524 |
| ES 2112274 | T3 | | EP 1991-911598 | 19910524 |
| JP 3187419 | B2 | | JP 1991-510290 | 19910524 |
| | | | WO 1991-US3689 | 19910524 |

FILING DETAILS:

| PATENT NO | KIND | | PATENT NO |
|---|---|---|---|
| JP 05507484 | W | Based on | WO 9118627 |
| EP 597852 | A1 | Based on | WO 9118627 |
| AU 657907 | B | Previous Publ. | AU 9179078 |
| | | Based on | WO 9118627 |
| EP 597852 | B1 | Based on | WO 9118627 |
| DE 69128361 | E | Based on | EP 597852 |
| | | Based on | WO 9118627 |
| ES 2112274 | T3 | Based on | EP 597852 |
| JP 3187419 | B2 | Previous Publ. | JP 05507484 |
| | | Based on | WO 9118627 |

PRIORITY APPLN. INFO: US 1990-634237 19901226; US 1990-530669 19900529; US 1990-575921 19900831

AN 1992-007209 [01] WPIDS

AB WO 9118627 A UPAB: 19960405

Vaccine component comprises inactivated Mycoplasma hyopneumoniae (MH) at a dosage of at least 5 x 10 power (8) CCU, the component being capable of inducing an immunological response in vaccinated swine against MH;

Also claimed is a vaccine capable of inducing immunity to MH in a mammal without serious side effects comprising the component above and an adjuvant to elicit an immunoprotective response in a porcine animal, the component having immunogenic activity in at least an amt. sufficient to protect the animal against challenge by MH; the adjuvant may be e.g. lecithin and mineral oil, saponins or Al(OH)3.

Prepn. of vaccine for protecting mammals against MH comprises (a) pretreating a culture medium capable of sustaining MH with an anion exchange resin, (b) inoculating the medium with MH, (c) increasing the dissolved oxygen content of the culture to 20-40% of saturation, (d) culturing MH to a titre of at least 1 x 10 power (8) CCU and (e) inactivating culture by addn. of an inactivating agent, e.g. binary ethyleneimine (BEI).

USE/ADVANTAGE - The vaccine components and vaccines are used in pigs to prevent infection by MH. They confer protection against MH challenge with a wild-type strain as well as other known virulent strains. Vaccine compsns. contg. an additional antigen can reduce the morbidity and mortality from secondary respiratory pathogens such as Pasteurella multocida. @(37pp Dwg.No.0/0)

0/0

ABEQ JP 05507484 W UPAB: 19940120

Vaccine component comprises inactivated Mycoplasma hyopneumoniae (MH) at a dosage of at least 5 x 10 power (8) CCU and the component is capable of inducing an immunological response in vaccinated swine against MH.

Also new is a vaccine inducing immunity to MH in a mammal without serious side effects comprising the component above and adjuvant to elicit an immunogenic activity in at least an amt. sufficient to protect the animal against challenge by MH, and the adjuvant may be e.g. lecithin and mineral oil, saponins or Al(OH)3.

Prepn. of vaccine for protecting mammals against MH comprises (a) pretreating a culture medium sustaining MH with an anion exchange resin, (b) inoculating the medium with MH, (c) increasing the dissolved oxygen content of the culture to 20-40% of satn. (d) culturing MH to a titre of at least 1 x 10 power (8) CCU and (e) inactivating culture by addn. of an inactivating agent, e.g. binary ethyleneimine (BEI).

USE/ADVANTAGE - The vaccine components and vaccines are used in pigs to prevent infection by MH. They confer protection against MH challenge with a wild-type strain and other known virulent strains. Vaccine compsns. contg. an additional antigen may reduce the morbidity and mortality from sec. respiratory pathogens e.g. Pasteurella multocida.
Dwg.0/0
ABEQ EP 597852 B UPAB: 19980112
Vaccine component comprises inactivated Mycoplasma hyopneumoniae (MH) at a dosage of at least 5 x 10 power (8) CCU, the component being capable of inducing an immunological response in vaccinated swine against MH;

Also claimed is a vaccine capable of inducing immunity to MH in a mammal without serious side effects comprising the component above and an adjuvant to elicit an immunoprotective response in a porcine animal, the component having immunogenic activity in at least an amt. sufficient to protect the animal against challenge by MH; the adjuvant may be e.g. lecithin and mineral oil, saponins or Al(OH)3.

Prepn. of vaccine for protecting mammals against MH comprises (a) pretreating a culture medium capable of sustaining MH with an anion exchange resin, (b) inoculating the medium with MH, (c) increasing the dissolved oxygen content of the culture to 20-40% of saturation, (d) culturing MH to a titre of at least 1 x 10 power (8) CCU and (e) inactivating culture by addn. of an inactivating agent, e.g. binary ethyleneimine (BEI).

USE/ADVANTAGE - The vaccine components and vaccines are used in pigs to prevent infection by MH. They confer protection against MH challenge with a wild-type strain as well as other known virulent strains. Vaccine compsns. contg. an additional antigen can reduce the morbidity and mortality from secondary respiratory pathogens such as Pasteurella multocida.
Dwg.0/0

L42 ANSWER 14 OF 17 MEDLINE
ACCESSION NUMBER: 89191734 MEDLINE
DOCUMENT NUMBER: 89191734 PubMed ID: 3239853
TITLE: A standard antitoxin for Pasteurella multocida.
AUTHOR: **Roberts D S; Swearingin L A**
SOURCE: AMERICAN JOURNAL OF VETERINARY RESEARCH, (1988 Dec) 49 (12) 2168.
Journal code: 40C; 0375011. ISSN: 0002-9645.
PUB. COUNTRY: United States
Letter
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198905
ENTRY DATE: Entered STN: 19900306
Last Updated on STN: 19900306
Entered Medline: 19890502

L42 ANSWER 15 OF 17 VETB COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1971-61807 M
TITLE: A NOTE ON SPHEROPLASTS AND MYCOPLASMA IN SYNOVIAL FLUID.
AUTHOR: **ROBERTS D H**; LITTLE T W A
LOCATION: WEYBRIDGE,ENG.
SOURCE: BRIT.VET.J. (127, NO.3, 143-47, 1971)

L42 ANSWER 16 OF 17 JAPIO COPYRIGHT 2001 JPO
ACCESSION NUMBER: 2000-219636 JAPIO
TITLE: ADJUVANT TO BE USED IN VACCINE
INVENTOR: DON ALAN DIAUESUTAA; **ROBERTS DAVID STEWART; SWEARINGIN LEROY A**
PATENT ASSIGNEE(S): PFIZER PROD INC)
PATENT INFORMATION:

| PATENT NO | KIND | DATE | ERA | MAIN IPC |
|---|---|---|---|---|
| JP 2000219636A | | 20000808 | Heisei | A61K039-00 |

JP
APPLICATION INFORMATION
ST19N FORMAT: JP2000-017032 20000126
ORIGINAL: JP2000017032 Heisei
PRIORITY APPLN. INFO.: US1999 117705 19990129
PRIORITY APPLN. INFO.: US1999 121760 19990226
SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 2000

AN 2000-219636 JAPIO
AB PROBLEM TO BE SOLVED: To obtain the subject adjuvant composition that is useful for enhancing immune response of an animal to an antigen, can form an oil-in-water type emulsion in a vaccine composition and minimize inflammation or the like on the vaccination sites.
SOLUTION: This adjuvant composition comprises (A) about 0.25-12.5%(v/v) of lecithin, (B) about 1-23% of oil (suitably mineral oil), (C) about 1.5-3.5% of amphiphatic surfactant, (D) an antigen, preferably in addition, (E) an aqueous carrier. The component D is selected from the group consisting of Erysipetothrix **rhusiopathiae** antigen, Bordetella bronchiseptica antigen, Pasteurella multocida antigen and the like. As for the two kinds of amphiphatic surfactants, one kind of a hydrophilic surfactant and one kind of lipophilic surfactant can be used preferably.
COPYRIGHT: (C)2000,JPO

L42 ANSWER 17 OF 17 JAPIO COPYRIGHT 2001 JPO
ACCESSION NUMBER: 2000-219637 JAPIO
TITLE: ERYSIPELOTHRIX **RHUSIOPATHIAE** ANTIGEN COMPOSITION AND VACCINE PREPARATION
INVENTOR: DAVID STEWART ROBERTS; **SWEARINGIN LEROY A**; BRIAN THOMAS SUIITAA
PATENT ASSIGNEE(S): PFIZER PROD INC)
PATENT INFORMATION:

| PATENT NO | KIND | DATE | ERA | MAIN IPC |
|---|---|---|---|---|
| JP 2000219637A | | 20000808 | Heisei | A61K039-02 |

JP
APPLICATION INFORMATION
ST19N FORMAT: JP2000-017930 20000124
ORIGINAL: JP2000017930 Heisei
PRIORITY APPLN. INFO.: US1999 117704 19990129
SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 2000

AN 2000-219637 JAPIO

AB PROBLEM TO BE SOLVED: To obtain the subject vaccine composition that is useful as a vaccine for vaccinating animals, preferably mammalians or birds by using a fluid fraction originating from a specific culture mixture and stabilizers.
SOLUTION: This vaccine composition comprises (A) a fluid fraction originating from the culture mixture of Erysipelothrix **rhusiopathiae** (swine erysipelas) and (B) a stabilizer. The component B is selected from metal hydroxides, metal phosphates, aluminum hydroxide gel, aluminum phosphate gel, calcium phosphate gel, zinc hydroxide/calcium hydroxide gel or alum. In the component B, the culture mixture is deactivated with formalin or β-propiolactone and the fraction is preferably concentrated in 3-30 times. For example, the aluminum hydroxide gel is added on the concentrate of the culture mixture so that the final concentration may reach about 10-40 vol.%.


FILE 'HOME' ENTERED AT 12:55:08 ON 17 OCT 2001